var title_f5_17_5392="Untreated early ankylosis";
var content_f5_17_5392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Panoramic radiograph: ankylosis of second primary molar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This panoramic radiograph shows the result of untreated early ankylosis of the secondary primary molar that resulted in severe submergence of the primary teeth and displacement of the permanent premolar (see arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:975. Copyright WB Saunders 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5392=[""].join("\n");
var outline_f5_17_5392=null;
var title_f5_17_5393="Mesterolone: International drug information";
var content_f5_17_5393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mesterolone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mestoranum (DE, DK, NO);",
"     </li>",
"     <li>",
"      Proviron (AT, AU, BE, BR, CH, CL, CZ, DE, ES, FI, FR, GB, HR, HU, IT, LU, MX, NL, PT);",
"     </li>",
"     <li>",
"      Provironum (IN);",
"     </li>",
"     <li>",
"      Vistimon (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Androgen",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Male: Androgen replacement, hypogonadism, infertility",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Male: Oral: 50-100 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 25 mg, 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10415 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-85249D4AE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5393=[""].join("\n");
var outline_f5_17_5393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979521\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979516\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979519\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979515\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821124\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979518\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5394="Patient information: Brain aneurysm (The Basics)";
var content_f5_17_5394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16264\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/52/6979\">",
"         Brain aneurysm",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/34/22050\">",
"         Patient information: Hemorrhagic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/19/30002\">",
"         Patient information: Subarachnoid hemorrhage (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/63/8180\">",
"         Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Brain aneurysm (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/brain-aneurysm-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16589334\">",
"      <span class=\"h1\">",
"       What is a brain aneurysm?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A brain aneurysm is a swollen bulge or &ldquo;ballooning&rdquo; in the wall of a blood vessel in the brain (",
"      <a class=\"graphic graphic_figure graphicRef54428 \" href=\"UTD.htm?6/52/6979\">",
"       figure 1",
"      </a>",
"      ). A small aneurysm often causes no symptoms. But if it grows, an aneurysm can press on nerves inside your brain, causing pain and other symptoms. It can also leak blood or burst, causing a sudden, severe headache.",
"     </p>",
"     <p>",
"      A burst aneurysm is a very serious, life-threatening emergency that needs to be treated right away. It leads to a bleeding (hemorrhagic) stroke. A &ldquo;stroke&rdquo; is the term doctors use when a part of the brain is damaged because of a problem with the blood vessels in the brain. The stroke that happens after a brain aneurysm bursts is called a &ldquo;subarachnoid hemorrhage.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16589349\">",
"      <span class=\"h1\">",
"       What are the symptoms of a brain aneurysm?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most small brain aneurysms cause no symptoms. But a large aneurysm can cause symptoms that include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A bad headache",
"       </li>",
"       <li>",
"        Pain in the face &nbsp;",
"       </li>",
"       <li>",
"        Blurry or double vision &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the aneurysm bursts, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A sudden, severe headache &ndash; People often say the headache is the worst they have ever had.",
"       </li>",
"       <li>",
"        A stiff neck",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16589364\">",
"      <span class=\"h1\">",
"       Are there tests for a brain aneurysm?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of a brain aneurysm, your doctor might do several different tests, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Imaging tests &ndash; These tests include a CT scan and an MRI. Both show pictures of your brain. During these tests, you might also get an injection of a dye that makes it easier for doctors to see blood flow in the brain.",
"       </li>",
"       <li>",
"        Lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a needle into your lower back and takes out a small sample of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. If this fluid has more red blood cells than usual, you could have a subarachnoid hemorrhage. &nbsp;",
"       </li>",
"       <li>",
"        Cerebral angiogram &ndash; For this test, your doctor puts a thin, plastic tube into a large blood vessel, usually near the top of your thigh. Then he or she will advance the tube through your blood vessels past your heart to your brain. Your doctor then injects dye that shows up on an X-ray. This lets the doctor see the blood vessels in your brain and find the aneurysm.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16589379\">",
"      <span class=\"h1\">",
"       How is a brain aneurysm treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 2 main ways to treat a brain aneurysm:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgical clipping &ndash; In this surgery, your doctor puts a tiny metal clip on the base of the aneurysm to stop the blood flow to it.",
"       </li>",
"       <li>",
"        Endovascular coiling - The first part of this treatment is like a cerebral angiogram (see above). But instead of injecting dye into the tube, your doctor advances a soft wire up through your blood vessels into the aneurysm. The wire coils up inside the aneurysm and seals it off from the blood vessel.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your aneurysm is leaking or bursts, your doctor will do one of these treatments right away. If it has not burst, you might not be treated. The decision depends on the size of the aneurysm, your age, and whether you have other health problems. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16589394\">",
"      <span class=\"h1\">",
"       Are there things that make people more likely to have a brain aneurysm?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Having a parent, brother, or sister who had an aneurysm makes you more likely to have one. Other things that can raise your chances include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having high blood pressure",
"       </li>",
"       <li>",
"        Smoking cigarettes",
"       </li>",
"       <li>",
"        Drinking too much alcohol",
"       </li>",
"       <li>",
"        Using illegal drugs, such as cocaine or amphetamines",
"       </li>",
"       <li>",
"        Taking diet pills",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Avoiding these things might help lower your chance of getting an aneurysm.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16589411\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       Patient information: Hemorrhagic stroke (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/19/30002?source=see_link\">",
"       Patient information: Subarachnoid hemorrhage (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"       Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/17/5394?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16264 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-983B24DA49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5394=[""].join("\n");
var outline_f5_17_5394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589334\">",
"      What is a brain aneurysm?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589349\">",
"      What are the symptoms of a brain aneurysm?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589364\">",
"      Are there tests for a brain aneurysm?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589379\">",
"      How is a brain aneurysm treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589394\">",
"      Are there things that make people more likely to have a brain aneurysm?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16589411\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/52/6979\">",
"      Brain aneurysm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/19/30002?source=related_link\">",
"      Patient information: Subarachnoid hemorrhage (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5395="Surface anatomy anterior knee";
var content_f5_17_5395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Surface anatomy of anterior knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 397px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGNAiYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOC+OUUdx8OLqGeNJYZL7TkdHUMrKb6AEEHqDXlC+EvDY/5l/R/wDwCj/+Jr1r42HHw9nP/UQ07/0ugrzxSSM0rAZY8J+Gsc+HtH/8Aov/AImuS+KOmeHdE8IXklvoekx3coEcTJZxqyk9wQM13t5cC2tZpmOFjUufoBmvl7xt4ou/EurSTSyMLZGIhjzwo9frRZXsZzfQ5zYm3Gxc+uKQxqT91fyp3ehjiqIu2NKIBnav5VEwUnAUflTmcklRSKuDSK2HBFHRATTZAiJjA3fSlZ9vTrTUTcfmoC76jAoxyKeigg/KCfpTpV2halsF3XKD3pPRGkNTqtE0y1FvEJ7eGRj1LoDW/DpOnEYFjafjCp/pWXZZwpOML0rXt5VUYwfmOK8WrUk23c9qlCNkrDl0rTmB26fZj/tgv+FWl0jS/LJOnWRP/XBP8KW1eRw5CgRjrVpcEZXOKxdSVtzpVOKWqKh0nSsIBptlux/zwX/Cnx6Lpef+QbZY94F/wqcqu8M3YYqdmjFv8nLcZwajnl3L9nG+xVl0XRxtxp9iP+2C/wCFRvoekiRT9hs9o6/uF/wq/CHbrGAvvRcj51RMDPrRzy7lezj2M5NJ0kzORplnt6LmBP8ACoptG00Ef6BZ8+kC/wCFagjOCDjNQupOMHkGjnl3H7OPYz/7I01Rn+zrMk9P3C/4U5dF051/5Btnk+kC/wCFWihLZdic9hUm+ReRk9uKPaS7h7OPYoT6Hp6pxYWfbkQr/hVO80jTkC7LK1PriJf8K2WORg1DOiBT5bDPpR7SSe5Dpx7GBPplltYrZ2w4/wCeS/4VlXunW4jO23hH0QV1MkZUZxgYzWXPHuiG3r161rTqST3MqlKLWxg2tpbg7Xgib3KCprzT7Z4GCwRKT3VADUkQCuwbr2xVlskYr0adVvc8upTUdDiZojaXBSVQQParBEEsYMaqG/3aua7EDlu4rDRip4JFdkXdHJJa2LLxgdAv5VGVHoKsKdyA9u1IUB5NUTYgwB2FOULnkD8qc0fFR9KCVLQmVUz9wflQ6IRwoH4UxSTz2p5JwaBqXRlfAJ6CmD72KcPekA+egZJtGegqXYoH3R+VNi+9UtAxgRf7q/lSSKoTIUdfSpKhlYjIoAixz0r1X9l8Y+Onhnjvc/8ApLNXlqjIFeqfswn/AIvn4YHvc/8ApLNQB980UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwnxt5+Hlx/wBhDTv/AEugrz1fu4r0L42nHw8uD6ahp3/pdBXmZlJPpUt2AnlVHjZJRlGBVh6g9a+XfHugnw/4kurVeYmYyRH/AGTX02HOK+cvi5qE1z4yuYpFwltiNQfT1pR3Jkk9zj+nNRu3BPehnByfWo+p5qxW6IfEp6+tSkcURDCc07gU0RPQiWMA55zUwHGcUg461K33TQEddSvMfl4qTTCBdDPpmoZsdKXT3/05M9DxUVF7rNqMm5I7GJyYgqnsK1o23KB3HBrEtHycHGMda04JQFA6/SvDqntUtjat2jWMRtnHqKtRsBn0xxWXCX44+9+laEUbl/mOMnjPSsHKzsdhZEuWUAAjODkUGNTPu3qp7LTEB8wrnBUZyKklMDynywScfmaVrlolMv7naRlT+dRO2QcdMfrSuuIxhlbv8ueKbGeZC56jjigYsDY+8Bu9aRoiw2AEgmpAmzCnAJ55pYXJd0OMdyDSbS3AidWDBWCggYHPXFMU/vMHp6092D9MEA81HISChi6Z5oUkxpNiMN0rA5xmoo1AVwxyQT0qcI+WKjIHWkLDYcjH4UE2KBbOGHrVS7UfLt9Mc1oSjkfLgeoqB9rRjcoJx+VOJDXQ527jMUu9T7mpFAaNalvYi27gg46e1VrA/O6N17Z712UpdTirR7GRrwwj1y9dhr0eLeQ46jNchXqUZc0bnl1VZ2J4G+Ujv2qaLc0i5qrC2HGehq4px0rYyJnPaoHXB46VLnIphILdelAmrkYpJSQvFPKkVDOcLigmKaIqD1FIDxSGgotx/cFOqOInAFSUDGyN8uDUGCTzU8i5GahzzQA+Mcn6V6j+zGMfHXwyB63P/pLNXl8f3vwr1P8AZl/5Ll4Y+tz/AOks1AH3tRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHB/HD/knVz/1/wCnf+l0FeXBeea9S+N//JO7n/r/ANO/9LoK8vPHvUSAcCB1rwr44aaV1mPUYx8sqhX4/iHGfxr3Bjk1w/xTsxL4Yu5tgYxrn6e9JOwHzxnANKCCODz6UwnPtSqPmBrQRbwQMdqBxTl+768U6NAxwTTRlJaiAAjk4pAT0OalCBT8xFDID90j6UyW3sUp2+c+1RWzbbhG96W4bLFR681GnBB9Kh6m8Fy2OttHyoO6tm2UMqtniufsTlVUdx1rcsxwfbjFePWjqe1Rd0b9omdp4OTxmrdwxMwjQjDYrOtpPlKtkgYxVuEs8yblGR05rkdrHaWLhCJEVeVx8xHSn+YC2NuCvWnjO0s6d6SZTvAjIYAcgHpUDTIUaYsrklY8kYXinnOBswcdctSblR8FTux09KfGuwqCPvHBzTRY9M7SSOaVQoYk/e+vSpXUBGVWG/I6DOKDasMujqxznaaAGBE2jYVw3XmogkgcGPoDz9KniU5K7MnoMdKesEir87YPI4PNKyaC5EjkxtvGCAMk96gSYkZOD7Vb3LGCDjJGGOe1UyFYFkIYZ4FCVgGSpHMzHcV47cc1U28MoXnGBVqTOc8gelQvw24KRx+vrTTsTJGdcAbWU4J6VjTKbeTzAckenpXQTRxs+edxGTWTqEB28AEEVrTlZmNWN0VdcVZdLdhwcE8VwVdy/wA+mzwk8opx9K4dhhiPevXwrvFnjYpWkNPWrULbkHtxVYinROVb2NdRzFzp0NNIOeKAcgcU5etAmrgeo5/Cqk5zJ1zirD8A881Wc5Y0CimlqIKD0oApT0oAfE2Ksqwx0zVNODU8bY4oKHv901Bjmp2GRik2gD39aABBhenNeo/sy/8AJcvDH1uf/SWavLIySeTXqf7Mv/Jc/DH1uf8A0lmoA+9qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4P44f8k5uf+v/AE7/ANLoK8s3Y4Fep/HD/knNz/1/6d/6XQV5ai469aiQDgMis3WI45LOeGZQ8ciFWU9xWmCMVlaqrFxgEg+lID508SeH3sriV4FzFngelc8QUOD1r6I1jwxBqKMY22S4zjHBryrX/B+pxXrR29jPO2eDDGW3fkKUXKKtMTs9UcpAxKHNSqxXkV0Vp4C8VmEvL4f1K2jbkSXUBgQ/RnwDV6y8CapO3ltd6Mjjqi6nBM4+qRM7D8RWyZlKLvocexLHJqrPP1WM/jXqDfCXVTGHvdQ8iE55j028AP8AwKWKND+DH8+Ki/4V54as+dQ8Slj3U3FhF+i3Mr+nVB+XILlRh1Z5UOTTjXqg034a2I+fUFuWHUG9uJv0W0iH5SH8OhQ+IPh3Zf8AHpowmcdxprnP/ApryQH/AL9jp360jQ4nSHbyEPoa6rSbW6v5B9jtppmXqsSFz+lbVh8SNKQFNL0KWDaeqmzgH/kK1V/Xq5/AcVcl+JGoXf7s2qtGO09/ezj/AL5ecoPwUfnzXBXhG7cmehRnOysvxHw+FdfRBJcaPe20R6PcxGFT+L4FXLHQ5HnKtqWjB1GCkeoRTuPqkTMw/EVQg8Q3ex5oLbSLeQ9Gg0u3R8+7hNx/En0q4ninX7lVjl1jUHiUf6s3LhQc88ZxXD+5Xd/cdsXWfb8WdB/wiMzKGle88vnBi0y7UH/gUsaIfwY/nxSDw1p0LAyTXQJ6+ZdWUWf++biR/wA0H5c1zjXQnd5JgxZerNzURkU4YD5W6dqTqU1tD8SvZ1HvP7kdT9i0GAs7yWjsf79/POf++VtYx/4+fw6F51DQ4l3Rpbk4/wCWWluT/wB9S3Tg/wDfA/HrXKo32iP5JNikfexyKaFWPCDAxzij29tor7ilh7/FJ/ebuqXMVzIDbK6LgffjhTn2EUaDH1yffGAM/c6TDDKV24IxSWiEIZDk54Az0pWaQHG0E+nasZS5ndm8YqKshEmYAeSmB3OelStAyKJPMBcjcRntTkQRxg7YwhPQ9eaieJ2baGC8ZwBUlJXI/LSWL74znOB3pPs4zvGBvOQoqWWLYojjKuvUhu1RFpGXaMFiewxkUAV3lwSCAcHGfSoZf9Yynmp5UCyAlgOuVbgg1Bcj5PlwT70mSysy5UkDH1rOu13Qk9x0Nah+6uCNuO/rVS8VvLC4AyDgCriyJbHM3OY9zA/fUg1x0nMhPvXdahCDuBJJA5AriLuMxXDqeua9fBSumeRjY2syKmkelL3pwGK7TgJbaTsanJGcjrVE5VsirSNvXOKBkTk4JNQjmny9KYKAHc0Uc0lBIqrzTxxRGM9Kk2jI9KBiKxyBninyE8Ad6QID608DAxQMYilTzXqX7Mv/ACXPwx9bn/0lmrzCvT/2Zf8AkuXhj63P/pLNQB97UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcd4n8Y3On+LtN8MaHpceo6zeW0l4RPdG3hhhQ43M4RzktwAFP4VQ8L/ABV0HV7WzW/MmmarcS3kBsZEaUrJajdON6rjCrgjOMg8DPFX/HXgxtduIdY0XUZ9I8UWVvLDZX0QVlAcfckRlYMmcHpkdQa5fQPhFbnQtBTVXl0vWdLa5Y3Gl3n2j7QbhQs7OZof4+eNuVGMNQB0tx8TvCtvolprMl7ef2PcxiaO+XTLpoApcoN8gj2odwxhiD07EZwviL8VbTRJ7Wx8OTQX+pjU7Szu1a2mkhhSY85lXCCTHIUtnrwao337P/ha902ysZtQ1pre0svsMYd4JCE3l9y74m8t8n70e3IGDnJzrXvwe0O5vpZ11HWIIJr231CW1iki8p7iEAK5LRlxkDkBgOeg4wALqPxi8JqmoR6TqtpdX1hKsdzDcLcQrHmZYjllhc53MAABg+oHI6B/HvhxL7ULU3srHTzIt5cJaTNbWzIpZ1knCeWpAHQsDnA6kCspvhZojeEdR8Om61L7FfakdUkfzE8wSmRZMKdmNuVHBBOO/enN8MtKxrdtHf6nHo2tSzT32lK0Rt5JJVw7gmMyIc4b5XAyBxjigCQfFXwcbG6u21aSOG28jzBLZXEb4mOImCMgZlbswBHvUh+J3hIW/mHUpvM+2fYPsv2G4+0+fjOzyNnm5xz93FcR4i+B8Efg640nwreRR3MsltiS6tbWHakUgbmSC3V3bA/jLZPJ7muguvg9o13p+oW11qWpXEuo3TXl5c3ENnPJPIV2g4kgZE2jOPLVSM9emADv7fUbabTF1AtJBalPMLXUTW7IvqyyBWX/AIEBWDL8QvCEchjXxJpc8q9Y7a4Wdx9VTJrT0Dw/Y6H4as9BtlebT7WAW6rct5pZAMYYnr/L8K04o0hjCRIqIOiqMAfhQB5j8RvEOn+JPCk2n2MGtndc2svnHR7lI/3dzHJjfIiKSdhUYPUgVxpix0sL36z3NnCPyWd2/NR+XNejfHIE/Di6A6/btO/9LoK8q8tgOc0mD0Ljrj/llpkf+9fzzn/vlbdB+Tn+lRvKo4NxZrjtDpbZ/wC+pblwf++B+PWqxyOtQsaaRm5l37YqfdutTPtH9lgH/kK3VvzY/wBKqX195kbh455hg4+1aleTj/vlpig/BR+fNQk1XmYYIPemtCeZnh+s+NdZs9Uuo7ddLtCjkZt9KtY3/FxHuP4nuR04rGvfHPiu/Ty7nxJrDwjpF9skCD6KDgdPSrnxMtPsviKdlGFmwwrkx0pMuL0FlZpZC8rtI56sxyT+NNIpe1A60DGHOaTHNS45owO9AybTZNlyB/e4rqrb5SMdTzXHA7JFdf4Tmurs5PMRGU8bQa4sVHZnbhZ2ujoLV2AIJ+Q1rwoojVs9eawLNpDuVxgA8VrRSgGNuo9G7V5TVmetB9DSedZAEUAtjtUmzerO4LsTjJ9Kq6aoWaRiASOcGrwYrGdrEFv0pGhBJlgnlsPLC8cVYhQCOTdGSQM7j0qqzeRguRt6DA71Y85mQLtYgZJXpTsWiaAuycKdrdAPX1qICVc7ydoIzkZwfwpgcMY1DFSTyu7gD1pzDykPmSSGM/wr3/CoaGWY5WYh5QXQn5ckAn61LLLlj5UPIH3V5qtDMGQHYAey+g+tPkO5R8qhvR//AK1Ah6EwfvvKMecBiwyKk8zYDs2kNwcjn8KqOjDeGEbIRywyuKF82RhtYDaAcZzmnygyzdQrIi8qce3IqkFjQMpTHrj+HFIbxo7iRJiFz0YngU8bjtMYWRQM5z19s96TRPTUoS/MrF0yv8JHaqz7t2WXjsR2rRdz5bbMHB54qm7Pn5AB9OaIoW5i3kW4k475zXF65CVuN578V3V0CQ3Fc34giMluXXGR2rswk+WdjixUE4M5UDJpaBxR3r2TxhG6U63bDEGmnmm4wwoAvCwmlgM8aMYx3xVMrg17n8ONDivfCSJPGCJhnJPSuO8ceBp9Mkae2UNDntQZ8+p550pKldSrEMCCOOaaBzQWtSWNflBp56UwEgY7+lKr5IGKBdw3AZ9aFfJ5ppBz0NIODz60DtpYmr0/9mX/AJLl4Y+tz/6SzV5ivNenfsy/8ly8MfW5/wDSWagdz72ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhfjYM/D2ceuoad/6XQV5tKmBXpPxr/wCSfT/9hDTf/S6CvOJfm6Um7AyhKD2qq4NaLpnrVeSLFNO5m4FTHBzWdc5ZuK05FPaiG2BOWGaGrijpueS/FXRGuLe2u41/eL8v1FeXGAxkhxgj1r6m1nRoNV09reUY9GHavKPEfgC+twzW0YnTrlTyKhuUXtdFxaZ5bsGc4xUZUg8Vq6jZS2jlJYZExwdwxVBhzx0qlJPYGuqIwvc01uppWz3NNNMFd7iEZH1rf0KQyWu0H5lODWIgBJz0q7oU3lX2zOFcEfj2rKtHmgbUZWmjr7WQlSTwScfStOAF5Ao544zWNA+DtY4BrWgYbCcHPQH8K8apFHswd0X45EVyGGTxkjnNXEIUHbyOxrLt1IZe4q7FJvjUxfMpbBPpWSN4u5MZSrggBv8AZNSq2BvC8j5sen+NR7gTwvyjge/vTHdhzvwPbFMoemHc8ZbPX0HvT1UyXAhj5XPpnNVY7gIecAvzUsT+Y4C4Jb14Bx60Fpl0Rwg7HG7I/P6UQRCYbZF9cDOP1qKCQFWXIC5zhOc/QdxUsSwEYLCMdtoGT74/xNDdhjPL8qUh5VCqNo3HP60kkReAM0mQTwFI/pUkqweXuKyhjjHy9fWq7vAkgV1Kg9Mk5/LihuwDXBhBU9R0DjJz6VEuYlL/AHDnJCj+lWhGk8nlxNvZiTh1xz+NQTxtCdkiN0+tJO4mPVwFCuf3Z5OD1H1qs4UOQrEr2prhsfulOBzs9aiWQ7/mAIzyB1+lBBDcx7Ukyv4kda5/UoVaBwehHeumfbIjKcgEViXa7VYOhwOK0p6O5jUjdO55842uVweOKMVbv4yLt+MZOarDg8jNe7F3SZ4DVnYTafT9KbjJAHNTbt30q3oNhJqGqW8MalgXGfzqm7CPoPwFE1t4eso2zxGK6K7tIryBo5kDAjBBFR6ZaC2s4YsY2qBitBExRcwSPHPGHw5PmPcWAyDzjuK801HSbmxkKyxEAHGa+sGiVwQRxWBrXhq0vVYSQqc9wOaaaZWq2PmAcGgYBzivVvEXw4ZSz2WSOuK8+1PQ72wciWFsA4zihqwuZ9TLPNNcccCn7eeeCPWkPQikXHuxYz8gzXqX7M3/ACXHwx9bn/0lmryscACvUv2ZDn45eGB3zc/+ks1BK+LQ+9qKKKDUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDhfjX/AMk+n/7CGnf+l0FeebRXofxs/wCSez/9hDTv/S6CvOdxqJADKMVWlFTMxqvISelCYEDAA06M0eWxpyoQeRWiIkSA01wPSlwaUjjmtUZmLquj6dqMbLd2kbluN2Oa8/1n4XWUxaTT5mhY/wAJHFeqSLVd1p2T3RF2mfPOs+BtX00t+5M8f95BXMTWssDYmikQj+8K+pnXPXB+tZt9pVjdoVubWJweuVqXT7MftX1PmgcDio0YpIHBwykEfWvbdV+HOj3TFrcyWzEduQDXFa98PbqwjeS3uEmRe2MGocGaRmiK2kE8ayD+IBhWnaOWbAbPriuc8Pu8Ze2lGGiP6GuitysbZT7rDk149eNpM9yhLmimX0bGd+4DHGOKniMkTCONBtPU1SeVjsBxjHH0q7ECrKq8qeSc965nHsdBfjZzIDgkYOMD8KrzOnlOevfgdKmUF2CIQYsfN6tVO7ZYkbC+23uP/wBdJWvqaxasVDOx+XaApPLDrVhJsyeWFIA6sT0FVDuKEkEEmiJlVuocZ6dM+9Kdy1qaxZSQsZJU88c7vcmtKFZDCzIIwigFpJGAC/nWZbSMkLMinaePNZeh9l7/AFrSNsZZVkmZpC/IyOv4f/qqWWPjPAJnyp/igVv1P+FQ3trauCwmeM5yV2kY+ueavyQr5TExyOMDmUgc+vA4HtVZ4Vchsoir1/eAFvoMVHSwGWIVI/ct5zA8DkED6GnRTSRMUbcPRW6AnrUupWzx4dUKAchh1/OobXU0mJivMjHSULyo+lCQErybijoqiVTgjOcis6ZfNmLKhSUenAb/AOvV+5iKR7kZZIjyGQ5z+NVmeKdWV2dZCPvNzk+lVe5LVys+4vhe2DzVG+J+bpu6mrUm5l2ldpXjGetV5WL53Dtg01uYzXU47WosOr8Bj6d6zNhIrrjpcmpXf2eAYkxmt/Sfhy0hVrp8jute7hm5QR4WJtCo0efaXpV1qMojtomck44r2TwF4L/stRcXKgzEdCPu11Xh7w5babAqQQqvTJxya6aG1AHStnFdTn5m3oV4oyAKsItT+WBTgtS2hpEYT0pxQEYNSYwKTAxioKKr2ykcCsjUtBt7xSJYlbPqK6KggGqUrEOKPH/EPw1hnLSWg2MecV55rHgvUrDJ8pmUHqBX1CY1PaqV3p8U4IZQatTT3JcOx8lTWc8LFZI2B+lek/syqV+OfhjPXNz/AOks1ej6p4Uspixe2Rs0vwx8N2ukfF3wjdWybGa5uIz+NncH+lXZWuhK6Z9XUUUVBsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw3xr5+H83/YQ03/ANLoK8/WL1Feg/Gj/kQZf+wjpv8A6XQVxKqM1LVwKxtwaabUelaAUU4KMUWEzMFvTZIBjpWkVANQygVaMmZjRYqNlq1KQAelUppkHU1XMCTY11qCTaOvFMkuP7uTVWSR3PAp84nG25K+31qtLx05p6QySHvUy2Lt1zRzMVigAznAFRXemPcQupB5GCK3oLMJirohG3pTuxnz54h0c6ZqTPtID8Gq8DZZQp+terfELRln015lA3JzXlVupjcBlxkda8vFQad+56eCqKzRcICjcylgDgHParVu5DqRxjIxnpSwwma1ZQoL54zVRyYpnGCDjrXCejc2I5nETyBioHAZRn/PesuadWkb72QTmmGXy4pNrtgLmqMZIcu5yzfhQo9RpmkTkJyDnkg9qktk3vhFBYnhmHAFQWSGVwEBx69K6PTbUoy7sHHOcdaylY6YLRDrODyjkpvJGNx61pRI+MyYC9FJJGfyqWKBz8wwuauHaoGVDMemSag6ErFMDcrfZpDvXsq8n8SangW6lUeZNcoP4vMUfy5zU8AjL4VFBPoOtWvsqo4Y221cd1xn9KSv1FJaGLdWNv5bpFLuJOcHALVzt/ZFWY7MP6A/rXePZ+ZEcIq+gxWTqGmP5bHZlh0wKXMZ2tocdb3NxZuiA7rYn5kPQn3q1fW8N1D9ps5Arqf9W33gfcenvUF4j27ncOM8qRUcJMLB4GwGHyj27irTuTsRCUSK3mg+aOhqCd9xPCq3cAdTV+6RGBkRSDnDDPIJrPlQmXKDHqDzVxdmZT1LnhBlj8U2gfneSvPcEf44r2y2t0A4QCvBbNvI1mzlORtlQ/qK+g7Ng6g+tenhJPlaPGxsffVx8ceO1TbacFp+OK6rnIlYh20mOamIpmDmkMYRRszUgHrQaAIthoIIqWk2g0ARUfWnFPSm4IoAY6g8EZo8PQLH8RfBrgdb+cf+SN1T6k0T/koPgv8A7CE3/pDdVSYj3eiiirGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwvxrbb8PpmPbUNNP8A5PQV579uUY+b8xXonxoGfAMo9dR03/0ugrjViiYYdB+VJoVzPGpIOhzSrqAboKvGxtz/AAD8KFtIVPAA/CpswujNe6lf7ik1GftUnbFb6QIo6Cgxp/dFOwXRzxspn+8xoGmjq1dEqJ6CmzIpQ4FUJtIwvsKAYI/So2skXtWsVOajaPPNNGTdygtuq9BUgiHpVgpjtTWGK0VkBEYwB0pAMCnE80h6cUwKGqwCezljYZDCvDtXtha6m0B4AY49xXvkq5Ug15J8QLAQagLgA4OecVy4iN1fsdGHnyyMfTuQSwzyenaqFztM57DHHfNS2szoo2njqR61LeNvhjcIoK5yB37V49rHuXujNmPyjacHGcetQx5ZgAMsTUso/hXB3c89vanWkLLMpwcD1qnpEzUnzWOh0izKx5xj610NrG3BPC/3c9aqaVGGiUH/ACa37eOMxrvwDnqBzXNJ3PRhHoIkJjI+b8KtRwq77nJBHAIFJGwZ2CjPOKnjjc5zkAcYIqNjUdHaBZFKO3Jwcn/Cr6pHGoCDLdgAR/Nv6VJHFtG7GMd+vNW97MAfMJyOhXP9K0USZ7FBot6hgkvXBzzj86q3ERZtgU7uxxWuqEoWJVfm+6FIP8qjkwpLc7sYocUZHBeIbENE58shuma4uFgkjQscZ+6T2Neoaj8ytkZJOBXnmv24hug6jg9DUxV2JvQSKUxMu8ZGMMD1NZ774pGBCksOpq4GMqrIwG4DDf41FOgZc/xCqtZ2IequUJX2ukhB+Rgc/jX0HpDCW1ikXkMob8xXz/cL+7KnuDXuPg2587QrMkYbylz+WK9LCPdHk45e8mdEKMUCnV1nCNxSFafilAoAh2kGpMe1SAe1FAERWmHirBqMgGgCLFGPapMCloAYF9qdpQx4+8F/9hGb/wBIbqnDrS6aMePPBX/YRm/9IbqmtwPbqKKK0AKKKKACiquqajZaTYy3uq3ltZWUWPMuLmVY40yQBlmIAySB9TVoHIyOlABRVWTUbGLUYdPkvLZL+ZDJHbNKoldB1ZVzkgdyBVqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOI+M3/Ihyf9hLTf8A0vgrjWYIpNdh8ajj4fzH01HTf/S6CvP3dm60CauaML7/AKVIGUHpVO3bauKsA0BYmMnHFN30zNFBDgSBvekkYsMA8VETSEmmRZgR701iBTWOKhdjQArtUDvQxNM21aQADRuNGKciFmAUEk9hVAMY8GuG8e2YuLMsVyc9hXorabdLCZZbeWKEdZJF2IP+BHArn9SGlXKSQHWdJaYjBiju0nkH/AIyzfpWU1e6LhozxO3O27wRgY4HpVm9Y7CmCH/hNdlP4I2XBuZZrtY85Urps0QP/ArgQqfqDj0NQXGg6BDIhvb5iwGCZdSt4v8A0nF1+ma8uVCVz16WIXJrueevGIZdi43rwT71f0pCZFYA89cjFdgW8I2pACWcxHcQ3N2frlpbYfmp+h72rfxJpcBVbW0mVRwDFbWkH6tDLIPwcfU0SpJLWQ6dR891Fsj0qN5Ij9nhkmcDoiFm/SujOk6hbQq93avZowB33eIF/NyBVRPExuFCyQ3EkZ6LPqN1Iv4RiUR+n8FTaVOkdyZLex0y1Yjh7ewhjf6lwu4n6muXlox3bfyO6M63SKXqyTTLW0lJWLUrKd1blbKQ3pB9MW6yflW9HZsiti01eTnvZrbA/wDgVJDj8f8A61IL+/uEAuL26lUDAEkrMAPoTSqhCgHbkdzVJ0ltG/zK5a09XNL0X+ZJDGocmYeWR/DJMkhH4oSPwyavwKsjbQ659N2DVOzjxwZMEHPA61rQMdgZku5P9lQAB9cVK1d7Fu6Vm7leWJ0YCReM8EKG/XtWTfH5s9cjHpitm5n3qUjW5XJ4HOPzrH1EOCCEYsBnDHrRKOgkYWpxlgWzwB0rgPEK7ww6/wBK73U5tyNj5eOQOa4nV+Q2RyKzW4pbGFYcMRnIC42kdamKYdSePSq0eRLx9K71tU0KNsraRkH+7piD/wBDmf8ATFXGCk9XYylUcVZRucLdxbUZsZHXNeu+AiJfD1mynhV2fkcVzEniPS4hlLCZh0O2109eP+B2sn8iff16/wAGanFqmmLJbTaraJ5rIYopbWMDHf8AdWyY/DFehhlFPR3PNxblJJuNjpFWpo4nf7is2PQZpnkrzuvdabP/AFFZ4/8A0Wy/n196RrW1Y/ONRkPrNrV/Lj6bpzj8K7GeffzLa2F2x+W1nP0jJ/pUjaZfJHve0nSP+80ZVR+J4rJbSdKcAPpdpIB0E2+UfXDseffrTV0TREfenh7QBJ13nS7cv/30Uz+tToUX5vLg3Ce5tISBkiW5jTA9eTWdJq+jxMBPr+gQ56eZqtsufpl6uw29pAMQafp0Izn91ZxJz68L1q1BqF5EWMNzNED18timfrijQDLGq6NJjy9a02XPIEM3mn8kBOPfpUsd5Yvjy5ruXPTyNMvJs/TZCc/hmtJ767f793cN9ZCageWV875HbPXLZzRoBXMkRHy22tt/3BLxM/hJGp/PA96bvbPGm6yw/wCveKP/ANDlXP4ZqXA9BSkZFF0BF5kvGNG1Uf8AXS509R/47dMfzApLRrr/AISXw9Nb6Yv22C7ke2hn1KFRM5tplKnYHxhGduM/dp5Wo9LBHxA8F5P/ADEZv/SG6poD0b+0PG0mfL8O6BGOgM2ty5HvtW1IP5j8K2tEfV3t5DrsFhDPu+QWczyqVx3LKpBzntWjRVgfP3ifwL4o1342+Jr/AEK5m0mCaytbOW7mjcQ3FtJGVnWNgpBlXClfQjnFc74Xk+I/hj4aeD9J0Ww1DSbYxXxuJjYSSTQzmeUxCSMW87hMENxGN2cb1617he/EHStO8U6xpWp3NtZwaXYC/uJZvPRwhYLkKYgjJyACkjEtxtzmq918TtCaCJ9Nuonl+321jNDfRXNpJGZ87DsMJfLDlcqqn+8KAPHvitP4/wDEfhTWdJ1K11WWKTSrCS1g0vSJXhv5zIjTmRmh8yIqQSEPlngZB6HpL3UvFej3fiw2OjazD9o12KO3udN06KImEw/NJI32WZpUz/GI3bIAyOh9AHxU8JPO1vBqM0twZLiGNBZXAEssIJkjRvLwzjH3QSTkYByKtfCzxrH4+8H2muR2M9g824PBIrlVIYj5ZGRRIMDquQDkdQaAPL/hwfGOs+PfBmr+MNNv0u7fTtQtrm5ksmhXPm/u93yqFLKBjgZ64r36iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOG+NX/ACT+b/sI6b/6XQV5+wAr0L4ygHwI4PQ6lpv/AKXwVyQtoT/AKAucBf8Ajyw0+91KGez1DyNNkiiurpVjMURkxsON+4jnsproo/EOkLfSWbatp/2qLd5kP2hN6beTlc5GO9UIvh5pr+I9X1XUna8jvZoZktSzpHGY1wNyh9snPI3LxVGb4fXlx4qttYu/EE1yltetdwwyROSiEY8ofvNgA9QgPrnsAamgeNtA1nQF1dNQgsrUuY3W8mjjaNskAN8xAJxkc8jms7xH47h0m8vIra0jvoYNI/tZJ47gBZR5vl7BhSPfdk/Ss+L4Wyx6PpNiutEHSriWW0kEEkfyyEllk2SqxPPDKy9+Dmnt8LUFpNBDqENvHJpL6WEhtnKJunM28b5WbvjaWPrkdKBN2OqtfEOkSy21vLqVhDqE6Iws2uU80FlDAbc5PBHbmtuK3lnJEMbOVG47RnA9T6D3rz7Vfh3eanf20tx4ine1tpbeaG3eJysRiAGFAkCfNzyULDPXrnuruytLwKt9ZWd5Gjb1S6t0mVW6BgrgjPJ596BcyK15f6ZaTeVeaxpNvKekcl9EJDjrhN24/gKas1tMM266jdD1t9LuWT/v40ax/wDj1altLJZxGOyK2keMbLZBEv5LgVBMzytmRmc+rHNMi6KO2VhlNJvVHrd3drAPySSV/wA1B/qbbrBPl6NAOwM1xeH8QFgH5H8e5nZaYV5qoiv5DNk+Pm1R0J/589Oghx9PO88j9f60pjRhiW51ecHs+qTxKfqsDRqfoRj9KCMU0tVcqDmZV/s7SopRKmj6V5o6SyWcc0g/4HIGb9as3GrXaWxiS4mSLGAiMVUfRRxQF3U2SDK8ik12C7Z5B4zikF48jcmVicn8q5RgJJUKc7Rg+ua9P8d2ObUuqn5T1FeYbSu5ow2fvcda8zEQ9+56eGk+TlCFQLglyBgHg1oQLhVYnHeqaj5AGUBs5OKvwjcQvbFYS1Vjspbm5phMu0YxgV1enlNoAPOe3XFcno7Yfk44wM11NkAIlbIB9a5Glc707m7bYKjOQAcDPetW3hLpkBT9TWXYcDDvxn861I0+XKBip7g00gu9iSPfGceXGMcjcxH/AOuriPMBlY4Oe5bI+tVzCobLxEnGPnariwBTkRNjqACGAFdEY9iWQXIYJuKxueh2uKxLwFXJOfTFbd3MmANp47lcVhXpJJYkMD0AqJbAjC1RFCHBwcc1xuroWcgdD3FdjqGWRhnnpmuU1GJkcAtlQOuOBWOzuJ66HNyRFJuRwT2NaC/vF4HTvTrq2zHuGAFHB9KigYooHI4pydyYEdwu2MjOCe9d38KZi1te25JJjkVx/wACH/1q4eWPcCWNbvw6uzYeJVQn91coY+e7dR/Wt8LPlmjnxkOamz2FOnNSAU2L5lB9akwRXstHzoBaUjFKGx1FKcN0NQzSNhpHFRN14qwPfpSOgAyKViyED1pT0p23ABppoASinAUhGKQDTTNNH/Fe+C/+wjN/6Q3VSd6bp4/4r3wX/wBhKb/0guqa3A9sooorQDyTUfAtv4x+I/i1/EdzpbWdxpEWl/2fZXhkuUTzvNSaQFV8s5UFR8w46nHOq3wj0We5e8v9R1e91KS8tL2S9nkiErm2/wBUh2xhQnrhQT3NcJ8Q9L15PF3xAvdM0S4u/tA0YWzPpouo5dsmJCiujKxUEkkAlevFaEms/ElPEpmjOqSWA8Yf2aLRtMTym0xhnzt4i37VI/1m7HPOaAOvs/hPoNrLYOtzqT/YtUuNXQNImGlmGHVsIPk9AMH3Nb/gLwlbeCdAj0XTr6+udPhZjbpdmNjCrEsUUqikjJJ+bJ5615x8Ltd+I1/4ugj8Xh7a2dZ1urKSwmCRsCTGYZVtljAwAPmnk3ZyMH5a9qoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4n4yf8iK3/YS0z/0vt65YV1Hxm48Bv8A9hLTf/S+CuXjOQKBNXFORSZNOI5pMUEtiilHPFGKUCge43aKRh7VKBmjYaZm1Yrlc03YaslcU0igRVaPioXAHarjdcDk0ktrciEytbyLCOsjrtUfUniqiBnMKjCZNRyappQmMJ1jS2m7ww3STyD6pGWYflVhHUruis9ZuAehTTZIAfo1x5S/jnHvVXQ7MekWKeUyKbvvCBs0qOL3vdTjjx9RAk/6H8e9OZb8jm50i2HpFZTXLfgzyxr+aH6Ci4WOV8ZQNNZSgD5QDmvJtN07U9RJg0+1u7hC3It4WcnB6cCvcNUmlt4ZJJNR1KYqM7YltrZBx6pD5n/j/wD9fy7U/F9zcnbJZwToDtAvbi4vBj/dmldR9AoHtXFiLKzbOzCuTb5dTm57O4tJZLe8hkguYm2SRyqVZT6EHoasQowHIxjtRK7XVwZWSBM4ylvCkKKAMYCIAoH0AqxCpY9QT9MV582lc9WCeiZo2kXIbA6Zro7EswXpjrg1mWEBSAbOS3Vf7talvGQV2D5wASDWHK3qdcUadr5vng+chU/dDLyv5Vu2UwGRI5AH61j2uwgArgkdj1rStY1X5lOO/UH9KuC6lNmrBMkcm4zRsrDlWHP59qe0wY7lOPUI26qsKhzuE2AOCfLyf5VbFu2393JKSerAKvFboz0Kk8x3EKWOemV6fWsu4wy7lGGHrWndRzAhw7Ng4IOP5is2cS4Y7MKKxlsMwtQ4V8eorF1BFKAqB84PX1roLwAbmbrnkd+lc/dcOUYck7s5rFi3Mu4jIGQV2cZBqCSBVYMvIJ49q1ZYP3YOFODk5qFEUhflYCgUbLYypgxbJHfv0NKjtBPFcRrsMTiQemRVy4Rl644qpMcKfXtRF8ruhzs42Z7jp0y3FpDKn3ZEVx+Iq6EOK5vwFKZ/Dllnkxgx/gDgfpiurVeK+gi7pM+XqaSaICtNK+lSspzilVabVxJ9yHBpynIwakZKTbU2saJkRGOKjYYqdlzSbKTQJkGaCCelWFQE9KdtAHFCiwbsVgMmm2Ix488Ff9hKb/0guqsheagtBjx34K/7CU3/AKQXVNKwJ3PaKKKKoYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcrd+Lvs/xLsPCX2Ld9q06S/wDtfm427X27Nm3nPXOfwoA6qiuZ1fxzoOj6xBpmpzX1tdXEy28BfTrnyppWGQiS+XsdiOgDE5468Vzfg74vaNrfhZdZ1SC50ovetYxW5gnmaeTcwVYsRgyMQpJVASvQ0AelUVwc/wAXfA0Cac0uvIv9oZ+zA282XIk8sqRsyrBuNrYPfGOam1j4i6Pb/wBo2NrLcRa5DZXF1b219p9xbibykJJUyIodcj+E9KAO2ornvAWuTa/4E0PXNREEM97ZRXMwjysasygnGSSBz3JqO98eeFLObyZvEWlG4PSGO5SSQ/8AAFJb9KAM34yjPgRx/wBRLTf/AEvgrlEUr1rU8eeJNP8AEXhs2en2utyKbuzn8/8AsuaKM+VcxyYDzCNTnZt+91YVj/aL53xDociZxzf6hDD+fkifH+fpQJuxaXntS45quF1ZuHm0Sz+lvPeH6BjJCPxKn6Un2W5Zcz69qROc7LWC2t0P4+U0n5P/AEoIdi/FbySH92jufRQTUV/PbaXk6pd2lgByftlwkGP++yKpSaVYTgfaory+9Re6jc3Cn/gDSFB+CirOmWFjpjB9L0vTdPK4INpaRxH65UA5oBtEEWuaXMM2d3Jfen9nWk94D/wKJGXHuTj3qX7ZcupNvoWsOv8Afn+z2yf+RJQ//jh/x0ZLmeQkyTSNnrliaizkUybopltXfGLPRrUes19Lct/3wkSD/wAfP4VGYdQYZn1mGL2sNMRMfQzvNn64/DtV9lOPSoHU45BoC5QktVcET3+t3ORgh9Re3B+q23lD8MY9qrjSNJEol/sfTHmHSWe2W4kH/A5dzfrWqsWRnFNaPHaqikF2It1cpEIo55I4h0jQ7VH/AAEcVXbJ65NSsvtTWqwI8c0jnApT+dROGNAjK1kbrWQHpgmvEGBE7FuQBkDtXuWpr/o8m44+U/yrxV4xvIxgdP1rz8X0O7A/ExkUQO0xngcke9aNgh3kqAB2FO0vS7u+JWytp7g9MRRl8H3xW1/wj9/p+f7Qji08KOTfzx2v/oxlrgcJPZHqxnFPVk9hGzBDnb6GteS2+RcOS2PSotJ09ZvL8q8juB2FhBPe549YI3H45x71vx2gRubLVJCDxvW3tV/8jTI//jhpwoT6ov6zTT0ZkQRzKoEZ5HXg1atJZI5SZSuc5yDzitZLduv2LTUHrcajJK3/AHxHb7f/ACJ/jU0SSLtX7fYwnqVs9KbP/fc00gP/AHwPoav2Vt5IpYi+0W/w/MihuRKfkYknsXxn8RV+J0Bw/lj2GTTIo2cc3t7dqOCk5gVB7hIoYxn3OTVpYXhP7zz4mHcLxj3pv+67jU21eSsU53wo3AFfRQaz71yACnGDnHpWjcEbmPmDA56YrOvSjRnBB9TWElcbVzEv1MgbBBJ96w3jElySy5wMA10N0sYjZmwcc/WszyQIy6n5cbvxqHEzb1KScb8qM44PtSSquMISVwKnEewgkn8R1pZkUldpwG9O1SOLdzEnUeaw55PcVQuiUcg45xWpeBhlzncOnv6VnSoC5Zz8x9qkuex6X8Mj/wASFvad/wCh/rXcIK4f4Zf8gFwf+fh/5LXdKK+gp/Cj5uv/ABGMcZbik2N6VL3oq7GJHtbHNNK1NTXFItPQixTcVMV4phWgLiU0mnbTTWXFMhsSoLUf8V14K/7CU3/pBd1MDjrUFo2fHfgof9RKb/0guqRcWez0UUUGgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcj4h8Dw6v4ts/ElvrOq6XqtraNZI9n5DKY2bccrLE4znvXXUUAeZX3wZ0K/8AFUXiC81HVp9QjvrfUA0hgJMsOMDf5W9UJGTGrBc9AMDCT/Bbw5PoY0ia61GWxhv21G0jl8iQWsjFiwUNEQ6Nu5WQOOBXp1fOvhvWfFVtBrcOlvcjT4vGd5Z6jqWmaTBJdrAqJiTyooSsjs33n8tj+lAHqHhz4ZaPoOu6bq1pcXJubCCa3jRYba3iZZSCxZIYkXPHBAHvmsPS/gb4b07VTqEd/q8lx5d1FuleAsVuEKPukEQd8BjtLs2PpxXFxal8R5lstTvdIuP7Wi0HVDDd/wBjxmcyrn7PuPlkxu2AfKGA3de1Zvj2D4i+IvA+u6PfpreoxXGg6dqIjbTY0b7X5kZmgBSJc45bZ98FQM9QQD6E0Lw7YaP4VsvDyIbrTrW2W0C3QVzJGq7fnGADkdeMVo2Vla2MPlWVtBbRf3IYwi/kKqeG3MmhWLm4vrkmMfvb638idv8Afj2JtPttH0rSoA4r4xf8iOf+wnpn/pfb1zo+ldF8YuPA5P8A1E9M/wDS+3ry74leJbvwzpulT2b2UJu9Shs5ZrxS0cMbhsuQGXpjPJAxmmjOW51rcmlVPWvOdO+Ixt9CutR1u3jmhivJreG5tJIoY7mNACJEWaUEg5IAUt0p9r8SPtXiq3hgs3Ph+XRjqjXLKokjAchnb5/uAAggAtnoCOaCbHpCgL0oJryDxL8WrO/8J6w/hiWe01W3t4rqJ5FhkBjadIycBnAPzfdYBhkHFbdh40nsL/xa+rubizsdSS1gUSW8HlKY88tI8YPPqxPP5AWZ6GOtLjNcBafFTRr0aWLDT9Zu5NRRnjjt7ZZGQK+xtwDcYPORkY713s84gjDfZry5JOAlrEHb8ckADjqSB0oCzHZ45FNIz2yKhFzqTH9x4euEHY399bw5/CJpiPxGfb0Ty9bcHJ0Cy544uL7A/ODP6UBYnxtHAqMq8hwqsT2Apn2G9cHz9fvEA/hsrK2hB/GRJWH4EH3qN9JtpARdT6tdgjlbjVbjZ/37R1Q/iv8AWrQ7Iku7eS1i8y7AtYuvmTkRL+bYFY6azpDuUj1ewuGU4K2cv2tgfQrCHOfar0Oi6PaS+ZaaJpMMv/PVbKMyH6uQWP4mtD7ZdHCtPNsAwF3nAH07U9Q0MtZtx/c6Xrs49rD7KP8AyaaH9acXvipKaPbQj1vdUVSPwgjmz9Nw+oq6Tu61HcKCvFFmJNdDIvPtJjJmuNJiUD5hBYzXDdOzvMg/Eofwrz6XxDa2zD7NBdZOcGJbS3HX/Yg8z/yIf5k9/rSiPTZypwdhx+VeKR/NEck7lHA9eea5cS3BKx2YSKm2mdPc+JpLpR59sJl6Yu7q6uh9NssrIPwUCobHWrm1wLBLTTyPu/YbOK2x+MaisYpkoARjqamG9ZFIXEY53e/pXmTqzfU9SnRguh1Sahfagu69vLidvvFpZGbP5mrkFxuRAoBYnnuaw9NYoVKk8npW5aHL7ARkE5OKxi2dSVtjchd2ZM+Yc4+7jir8cSGQsXdWzgZBz+lVrRFK8hyw4yDjFXoUcv8AI7jHQ7q1SuVcs20a7SvDc4wJNrfhmkuWKKqo0qDpgyb6sRSKYdskyKM5/wBQDn/gXWoLkQjbzET6qpFa6IzVmZk43N8+T6ZrK1JFbhGKgHnArRuXCswFZtzIhz5hIBPT1rCWxbVjPdV2n5sjuW71BgCEqRgdKWaTad4ywB+UU9WO4jgGktVqYPcZKvlCIlDkDkgVUmTcDLyp6fWr5kB4UEe5qtMBtIbkdcVDKjpuYE/J2u3tzWfLgHLc54HFad1FumILD6iqEoBA+XBGaIocpXPRvhgudEJ7ec/9K7xRXE/DEY0QADgyMR+f/wBau3B4r3afwo+crO82G2jaKQsBSbxVmQ7aKTHpSbs0ZoAMUmBS7qazUABqJyKGY1GeaAEYVXsx/wAV34K/7CU3/pBdVaC5qC2Qr468FE/9BKb/ANILqgcdz2WiiikbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMmijmheKZFkikUq6OMhgeCCO4rhPiRqUfwy+F2q6n4T0vS7U2RiaK1W3EcGXmRGJSMrzhieCOcV31YPjnwvZeM/C17oGqS3MVnd7N727Ksg2OrjBYEdVHbpQBht8S9DtNWv7DVLqKKWDUBpsKWsdxcSSylN4UqIRhiOylx/tZ4qU/FHwedKstQj1dpre883yFgtJ5ZW8r/WkxKhdQvUkqMCq0vwr0STxIdba61L7WdWTWdgkTZ5ypsC42Z2Y7ZznvWVP8DfC0trZRtJetNaXFxcRzTJbzn982XVkliaNlz0ymR60AekaTqNnq+mWuo6ZcJc2V1GssMqHh1IyDVus/w/pUOh6NaabanMFsmxD5UcWR/uxqqD6KoHtWhQBxXxi/5Ec/9hPTP/S+3rjdX0ax1hbMalB5wtLlLuD52XZKmdrcEZxk8Hiuy+MP/IkH/sJ6Z/6X29c/igzmc7qej6B4ou0kuDHdXWnO8W+2umSSBmGHRjGwIyOCp7dqZb+CfD9vLZPBYFDZ25tIts8mPJJJMbjd865J4bIrgZ/CHiqwfxcNBivILi9vhcQXAvspNASu5ADICsv+0QpwCA44rQ0zwv4xkbSIbm51o2Q1KSS6El0IHjt2jGFDJcyO6humXLD9aYreZ0uoeEPDNh4cv4b2K7GipAWmge+uXiSNCJPlTeQuCgPygHt0OKfD4W8L67bx6rDatIt9KmpJcJNNE5cp8sikMGT5SOBj6VwknhXx9caBa2Wrpqd4n9n3tu0Meoor+ezMImmbzF8xNpXjLe4qRvCnju3022tbUXyTR6bYwWLW9+sUNlKgUTCZA48zODggOMcUBbzPQ9I8H6Do93bXWnWHkz2yyJE/nSNtEjbn+8xzk88/hXRJyeteW3fhnxudYubyGbUCV12CSILqGImstv7392X27c4+UjPp3r1cWzg0WExykY60pPpR5LDrS7KBERJwajKmp5BiojVRAjPFRkFjmpcUBasGQGMio5BnirTVEy5NAkrGPrke/T5l/wCmbH9K8RsxmJ3YBgUIwex45r3PWQBZTg4JKEY/CvEUiWOa4jU5AOFI6HNceLV0juwbs2SRRArweTzip1i83bCc7k5OPWnRIwU7Rlj1qYwkfMvyY54ryL81z2or8C3ZRneoGNwOTXSwwYkyGGSMjJrmLMlpUzjcDk11enqMDeAQTxSgaJ3NizI2AE7mPOPStW0KqwZG2HoflJNZVrGMYWMEkVejLxrtRGyeysRk1ukBeebaMM4Y45xxVG8mBbhmLEckkH+VWnkaRQHtp+3SU1jak5RsHzFx2zzTlsJaFe6fBKgcjrxWVesG+82MnAGOtSzuZHwAQAc5Peo9g5O4E55AzWe4pS6FVs/d25K8jFPdS53FRj0XrVwwhT13VG8eJAH6Ec1MjNJszyrDBODmo5VBRiDyTitOaIICu0BAvBrLeRQ4DHgHnioLa0MmaLyic9f51TuAQc/iD71dunR7hgHXcpwR3qnckcjPINVAiWh6X8OEUaFEI+Fy38zXYbDiuU+HkHk6FBjIVgWAJ9TmuwB4r3aa9xHztX42VipzTdpHarDLSBeaZBEOlIam2UhX2oAgFOxT9gPal2E9KAIGGaYRVi7RbO3+0X0kdpbj/ltcusSf99MQKzItX064G7T5bjVB2Om2styh/wC2qr5Q/FxQOzLqdRUaDHjfwSf+onN/6QXdMEupSKfs+jxW3o2pX6Kfr5cAlz9C6/0qIQX0/iHw9a3mrLBLd3kkUMml2McbW7C2ncsHnMxJKoyEgIcOelIpLU9nJwMnpVayv7O/Epsbq3uRE/lyeTIH2NgHacHg4IOPeubHw90CfnV4rvWmzk/2rdyXSH/tm7GMfQKK6TT7Cz063Fvp9pb2kA6RwRiNR+AGKDQ8H+LHxV17QfiSsGgNO/h3QRbtrix2RmVzK4yplCHy8RnIJZcnI5xiuk1X4yPY6zqkMehR3Gl6fqlppst2l/8AO4uF3LIkfl4IHpvHbn064Xng973xZpUVhaz3VsI5tbtYdMaRpvNQshdVQ+cWUHgbj2NUfDUvg7XNc8Q6BYeGrWKTSWspboTadFGkjPFvgIUjduRRj5lUr0FAHBaV8Wtd0XTPF1/4ks4tSS18Ty6NYxwSndG2RtiISHJjUZIkwzsTjb0rYufi/rccei28HgK/bWNUvLqzisri5a03+SiuJEaaJCUYN1ZVI2ngniu+tdE8MatJq8w8PWbSXErW9891pXlNdFSD8xkQGVM4w3zKccE4rLtY/CGkeONO8L2HhuxtdRW1l1a2lt7GFIoeVicqRgq7DaCQOQOTxigDktP+Kl8uv3Oix6ZLd6tc65cadbx317HFBCIoVkYebHBkAbsKpDsTn5qXS/jPea5ceG7bw/4RmvrnWLeWdo2v0h8jypvLk5ZcOowSCCCeBjrj0u88LeH76C4gvdC0q4huZ/tM0ctnG6yzYx5jAjDPjjceasW+h6TbXFrcW+l2MU9rEYLeSO3RWhjPVEIGVU+g4oA0aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPi8M+CgD31TTP/S+3rJEYB4Fa3xd/wCRMX/sKaX/AOl9vWeF96uKM5jUj9qmAwKTPFLk+hqyBaMA0mfajPOe9AxwGKWmUuKAEcZHFQsCDU2KRl4pNXEV2XJ5qLbzirLDHNRsORQkBFtpCKkpppgRMuTTSlS4oIwKARj6rAXtpM9NpNeFxsrTytxhRkemegr3jWJMWc+BkhGP6V8/WrHcdw+ZuSK5MVsjqw27sbVg7LIOAwzyav6hHvA2BtpHWq2mxhsN0GeAR1q9O4ClSM7e1eKnY9+LTKNmwEmGDA8AYrrdMy6j5WwPU1yccZ81SrYOfSuq0okFAJAT3FOL1LVjobZA3+r9gcVeWBwBhz9Kp2WSQCBj1ArR3LHGu5Tg8ZBPNdEQe5WdGj5kRyTz8rVm3beYpw7D8Oa055UKlNsmelZ0hbpzRLYErmTL+7kZn3t0IAFS24MjgHdzwApwPxp88hST/Vsf9rcKQy7FyqqAOMgc1mZT3FlhMWcA8dBVbdliZcZ7Z71Z3FyCxO319BVWXY25SCSvbNRJ3COiYy9baHCsXOcfSsSYAln5B9DWjPIUOGYhivHasmaUZZc5K9eetQy76XM6S08ueadSMyHcT6Yqldybei/MVILeprQvpTsBQ4HAI9akstF1G+ME62M32IMpa4ZNsQGe7nCj863ox5tEctadkepeFY9mnwIudqoAM/SuiU1zuj6ppSwLHa3n9oTKMFNMhkvsEdQWhVlH/AiK1Fu9Rl/49NCkjHZ9TvYrcfXbF5z/AIFVP0617kdFY8Fpt3L+3NPjieRtsaM59FGazhBrEp/0jVrO0X+5p9gGcf8AbSdnU/8AfoUx9Dsp1xqD6jqYP8N9eyPH/wB+VKxf+OUWCyJr/VtM02fyL/U7G2ue0DzqZj9IwS5/AVCNTaYA2Ok6zdgjId7YWcf1zctGxHuqt9Kv2EMGmwGHTLa2sIenl2cKQL+SACpOc571NhaGav8AbUv/ACz0bTlPTc8t+4+oHkqD/wACYfXpQNNmkH+na3q1wO8dvIlin0HkKsn5yGtAnFI/SgOYzrbR9ItLj7RbaXZLcn/l4kiEs3/f19z/APj1aEs0szbppHkPq7E1EAc07pQDdxapqf8Ait/BP/YTm/8ASC7q1n0qov8AyO/gr/sJzf8ApBd0BHc9eooopGx4z4g+FN9deJ/iFqFhbaE0fibThb208paOazm8lkfgRtlZGILEMDxyDXP3fwV8RXGqag4k0JFu20po9SE0hurH7JCqSGJfK5LkH+NeAM+29cfETxFo3jX4o/bbe1vtF8OWttcwWouBG8YaEthSIstvIy24/J0G4VgfFH4qX2o6JfafpENxpdzbxaVfreW96wZ1uHQmP5VBAAbBOTkdqANLWPhP4kurTVbSJ/Ds9rqHiK+1WRbmNXkWCZUCeW8kEgjkBU7sIeCMMK1/hn8N9e8Na14XvdYvbG4Gl6HNpcxilkdmdrjzFK7kGVCYHODkdO9Qah8bTY3Nzpsvh9pNai1c6SIre4kngZgobdvSFpDxxtEROfzqxb/FrW7rUfDum2vgO/Gq6rbyXEtpd3QtXthHLsYkSINy7fmB4J4GPQA9doryDS/jPJfy6bJH4amks9WN+mnCC68y6le1BJWSHYBGX24HztjIzgc1Tk+Ll1fWFsZrF9J1GPVtPs7iwhuHFzCLgt8s63FooAwB9zOecOvUgHtdFeEeEfip4jsPAtx4g8VWFtqFhFrrWFxdQXIV7WEyFC7IIVUqh2AHOW3c7e/qXw88TSeMPDEOttp5sbe5kk+yo0u9pIQxVJD8o27gM7ecAjk0AdLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxnxd/wCRLH/YU0v/ANL7es8GtD4vf8iWP+wppn/pfb1m5q4GcxxY0oBzzTU68mpMjsasgMUUtKuDQAgODzT6ZIwHHelDetAxTQOmKQmloAYwyCKicVN3pjigRCaYRU2KQpnmgCLrQBkc1IEANKRwaQGB4l+TS7pwcYjP8q8Dtpt91lBiJOAR2r3D4i3C2vhK/kJwWAQH3JxXgkW6Nsg7eMYrkxTd0jtwkW02jqtPdcAL1QksPXPSpmcKcY9+tY1nMxi3Kcc8+9Xw/mwu6H5VYflXlVY2Z61Jvl1J04cGuh0nkocgMe5rnkG4r9a6LTYt4AXG7OayW50ROjs3cyKI2AA9e9af79goLKw68AVm2UQjCs2QAM9K0EbzCdjBh7f/AKq6YlSRVnmVcg5VwccjFUppFKHJBH61pmxuplDpCXjT7zKMgD3PSslrnT5ZWgXULWe4HBhsg17KPYpArsD7ECmoSlsjOVaEN3YFXemchQelUnO9iu3DZ5Iq+I2iB26fdkA9byeKzX8sySj8YhUTs0ZLmewhDf8APtavctn08yVlX/yCaHRf2mkYutGXwpshjVmzDGjuzdABkk/hVe4tzYOw1Sa000yYKLe3CQuc9MKxDH6AGrE1wHQiV9QukJwUuL1o0/GK3EUZ47FSKjguTZoy6TBb6dk/N9hgS3LZ9SgBP4mo5aS3bZDlUeiSX4kU1iszLLtv5Yj91orMwxn3ElyYUI91LfjVEpp0LnKWKtk/664lu2/GOJY0/ATH8Kj1CaSd1eZizk8knJNZMwXa/YL1pqcfsx+/UXJOXxS+7Q0H1y2tHzb/AGovn/lhFFZr+aq83/kam6LqKaprqyPYWTsnWW4ja7lz/wBdJy7g/QiuWmk2y53llJDEelbfw/V3v2dxnzDuJrpoVJSkkcuJhGMXbc9sguJpoEEsruAAAGYkD6VPiqdnxGv0q4eBXqnlDCcdqXsKCfSjPFAwpG9qXNNxmpaENAqTtQoFPC8UuUCu55xTadIMNSA0rAAqoB/xW/gk/wDUTm/9ILurlUx/yO3gn/sJzf8ApBd02tCo7nrtFFFQamXc+HtFudSk1C50jTpr+SI273MlsjStERgoWIyVIJGM4qingbwkltNbp4X0JbeZVWSIafCFcKcqGG3BAPIz0NdFRQBiDwl4cGjHSB4f0gaSX802X2KPyC/97y9u3PvipdN8NaFpcltJpmi6ZZyWyNHA1vaxxmJWOWVSANoJ5IHU1rUUAYh8JeGzc3lyfD+kfaL1WS6l+xR751b7wc7csD3znNJZ+EPDVlbC2s/D2j29uJluRFFZRIolX7smAuNw7N1FblFAHK+I/Aeg63oet6YtnFpo1oKL650+GKKebDbssxU7j1GSCfmOMHmuj0+0g0+wtrKzjWK2t4lhijXoqKAFA+gAqeigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4z4vf8iWP+wppn/pfb1l5wK1Pi7/yJY/7Cmmf+l9vWS5yKuBnMTfk0/dUUYwcmp8irJEzS89s0daeBQAKvGT1p1AooEOo6UlLQMMZprCn0EZ60ARYoY9qeSAKhzk0gCmyHCmnVHIc8U7Es87+MNwx0K1tUHEs+WOfQE4ryO4RCcAcjk16v8ZTt0yxCjJ805/KvLXAWHKk5bGM9a8vGO1Q9fBK9KxJaMqqwJ+fHSrlm5xtLdSSR/Ks2HKSliFAzge5q5DjuAR3rmmrpHVT0bRqQtggds11WkSeUmSBluhxXH20o6jBB4ro9DuclFcDjPPeubZnUtjsrRBIABnd7HFbVsgCMVWQYHJBGBWLYyrvGCNvrW4tyojIaTGeytt49+K6IO5M22Y+o6bp85Nxc6dDezA7t9+7Xm0/7KzF1QegUADtiq1xfXcg8lpXW3XhYlbCAeyjgVeuZbrn97pRj/uyW84bHu4kIz9E/Ks8MzMcJo7d/+Pi5j/Tyn/mK0kpy+0vvOeEox2g/uKFxkNjsecVHKvGB3G4VpyQyMmXs9LI/2NZmBP0DWOPwLfiaaU3JhrOI9spqiH/0KJP0zUqlLuvvKliItbP7jOkUBFUH5iD36cVAZ1Ccp06HNaElqMf8ed0PTZeWTflunTP47fwqGWyV+ltqi/jYOP8Axy8bH44pSoTe35oz9vD+kznrlBLPwQGI78Z9qyLm4JGxdyqy8+h/Guom0PzOQupgdP8AjzDH/wAcds/hmqUnhe5f5YW1EDOf+QLfv/6BA2PxFNYefYHXp9zjLllxtwfu/mK7X4bWT7TKR8hPGazL3wpdE5+0GMqPn8zTb6M/Uh4AR+OK7fwpNpOkWSR3uq2Ub9zIzRj8CwANdmHpOLVzgxVXm0idbCCoFWkbjrWK3iXw2pIPibw+hHVZNTgjb8mcGrtvqmlStti1nSJH67Uv4WP5Bq77o4bMvlfejFEckUq7oZ4JV6bo5VYfmDU5sbzGfslxj18s0BYrmkqZra4U4aCUfVDUfluAdysMeooEIDT0bimYpy4pgNlTPNQVak+4aphsk1PUBC+01WjcN428Ej/qJzf+kF3VhxkmqVuMeO/BQ/6iU3/pBdU3sUtz2WiiisjUKKKqXWpWNpeWlpdXttBdXZZbaGWVVecqMsEUnLYHJx0oAt0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcX8X+PBQ/7Cmmf+l9vWNnPQVtfF4Z8FAf9RTTP/S+3rNRfpVwImRIhqVUqQADsKdVkEWCDTlp5FLigBMUopRQSB1oEIKWmFwKYZfegZMSAOtNZxg1XaTPemF/rQBKz0zcB35qJmyKjJNBDZYL1GzDmoGcj1qJ3bBPNVYXMcT8XQkuhxHBzHKGz9RivK7ZCEMrKH2kBV6bj/gK9Z+IEE11oMqwo0j71G1evXmuAt/DmuS2okg0jUPKBwXa2faPqcYFeXjYPnuj1sBJcjTMAlvOO7kNztx05rQgKNHKTgHAIOfQ9Kg1a0lsZo0naASvztjnSRgBjOQpJHUdcVJbISoVeSx4965GmlZnbG17oIpNsmcgY6V0OiybpQwPLdq5vhGJdSccYx0rU0uQiRNrHA5xXPJ6nTA9IsXwg7MccZraRWlQbNy445lHP5VzGlyq0ahic47ium0tjtG0tt9BxWtNobslqRXMOFwQvud1Y8o2Myqfm7ECt7UnAzyTnnpiudmlzKxCnHrUS3FF3QNIT8pY5HbNVpCS4XPRs/SpcBvmUjPeoJ5Aki4UdDnPc0kTKwySUjiReB7dKq3jKq7lOcjgCrczohAbOWXk47elZNzN8208DO1eegprclK5Q1AAlY+hcYz/AA/WsqYfZp8xHcrfKN386t3gKzlAc8fX8aoXMzGBhwCDkEVomZS6lrw1JcT6usKzzKN2RtcgcHNe5abcXUNuo+1T5x18w/414b4JYHxRZRkj5yw6+xr3GFdsSL6CvUwnwnkYr4y+NSvAMC7uMenmHFV2kjlXZPBbypnO2SFWH5EUwACl25rr0Ocil0vSLht0uj6TI5/iewhY/mVqp/wjPhxGBXwv4eQj+KPTIEP5qoNa0UftU2zilZBdmL/YGiKT5ekWcQP8MIaMfkrAfjUqaLpq42x6hHjp5OrXkZH0KzAj8KvsuKaDiiyHdlc6XbL92715B6f27ev/AOhysfyo/svGPL1jXU9D9sD4/wC+1bP45q1kk8mnr1osg5mUpdNnSMsPEWu49Nli/wD6HbN+mKq/Zrz+DXb8+nm2dkfz2wrn8MfhW1LzGaojAalyi5mVlttSB+XWYD6iXS1b8tsi/wBagEeop4k8PIuoaO+oSXki2Uj6NMAkv2ackuRegYMYkX7h5YcdxqBuKprz448E/wDYTm/9ILuhrQpPU7Ty/HCHP2rw1MPT7NPFj8fMbNbWhnVzbyf26tgJw/yGzZypXA6hhkHOfX+laNFZmh474x8DadqHxy8LXj+F7S602W0vH1CdtPV4nlwNhmbbgt6bufSuI1Kx19PGlhqFzpWsWNrZ+KdadbrStDzIkDwxrFNsSFhIWOQJHVt2OSccfTNFAHz9pOp+PVk0vV9f0LUJdUHhe5aeWz0yAXXn/aP3SCRoyFcx4YxcjOfkJ4rrfgrrfjHVNU8SQeL4dQFlCLWTT5r21MTEOjGRN32eDeVIGf3YwT3GCfVKKACiiigAooooAKKKKACiiigAorAbxp4WXUpNPbxLogv43aN7Y38Xmqy53KU3ZBGDkY4wadp/i7QdS12PSNO1OC7vpLEalGsGXR7cvs8xZANhG7jAOfagDdoorL0LXtN17+0P7JuftH9n3klhc/u2Ty548b0+YDOMjkZHoaANSiiigAoqrZ6lY3091DZXttcTWj+VcRxSq7QvjO1wD8px2NVPDfiHS/EtjLeaLdfabeKeS2d/LZMSIcMuGAPB79KANWiiigDjPi7/AMiWv/YU0v8A9L7es8VqfFaGW48ILHBG8sn9p6a21FLHAvoCTgegBP4Vk3bx2K7r+WG0XGd1xIsQx/wIj0NXEiZKKUcVi/8ACU+HtzLHrmm3DrwUtJxcsD6FYtxz7f4ipf7ct3H+i2OuXXoY9JuI1P0aVEU/XOKq6IszW4pQOTWR/aeoP/qPDeor6Nd3VpCD+CyyMPxUUefr8h+Wx0O2HYvqE07fiogQf+PH+lFx2NjtVadsNjNZrW+tytmTWNNh9rbSnz/31JcMD/3yP60xtOvWP7/X9Yk9o/s0C/nHAG/Nj/Si4W8y+Fkc4RS3+6M06aKSCPzLkeRH/fmIRfzOKyX0O2k/4+TqN17XWrXcq/8AfBl2dv7tMg8OaPbyebBoWipL/wA9RYRGT/vsqW/WjUWgs3iLQopvKbXtIMv/ADzjvY5H/wC+EJb9KkTWLSQA20Wq3QP8VvpN0yH/AIG0YT/x736c1pRNdRxCOKZ4oh/BGdq/kOKQxSOcuxY+pOaLMXMuxnfbrp/9ToOrt/tTyWluv5NOX/8AHP14pDNqzNhNM0mEes+qyO3/AHxHb4/8f/xrQMTDtSeWw7U+XzFfyKDJq78NqGkW4PaHTJZmH/AnuAP/ABymyWt1jM2van/u20FpAv5+Sz/+PVfKP6VBPE5Uk0WFdnL+K2Nho888U2p3UiDO241a72++UjkRT+I9K8yXVjczBzp2jeYoyXfToZn59GkVmH516J4zV10a8wefLbr9K8i0t12Nxzwc49q8/Gtxtys9PApSvzK5b1XVLq+Ea3UpeOInYiqFVSeuAAAKSEERfOSrAcYxWe4YMA2MMx/SrUTM67WABPYdK4m21dnopJaInxknJz6VcsBtmXbxkYqiciQEYDetXLdjvUjGeM1zs6Iqx3eisyhckEemK6uzlKISVXNcXpNx5cS5GTgV2GmM8xjKK3PHXj9aqBM9irezBzJ8wLelZSBnhGOWNb11HGhI2rkcsRz+tZU2FYhflzyMUS3HF3KqALvzke1VZxHOzKWYEZ6dqtXBJQYPOetUlX5i+SS3NSRLVkfzumzaxA7+tZmqMFVNvXdkf4VcWU+UzMzIuSMngVmzSIqMrDzFKcN3BprcSuUryPzJVLlkZVPH+NZMjbm2c8jn0q/eSHCAj74yD9PWqkgDEDOCelWZvcn8POLfxJpTADInQZ+vH9a96QdPpXzyGNtPDJn5kkV1xxyCDX0FbSebBG4OQyhsj3r1MFK8WjzMakpJkjHFPjcetRyU1PvV2nEXlkpweq6jb3pc80APkbFRA96YWy5zTs8UASCpBgVCpFSA5oEPY5Ug1ngkOc1akbANUuppMCbcO1V4/wDkePBP/YTm/wDSC7qTIxUEBz448Ff9hOb/ANILuh7FR3PY6KKKyNQooooAKKKKACiiigAooooAKKKKACiiuG+IGt6lb+JvB3h7Rrr7FPrN5K09yI1crbwR+ZIqhgRub5VBIOMmgDm/A3gvxJpUvj26mvtQsDf61f3llYwvbGK5SRAI5C2wyISe29MbRkDnPCXXgj4h/aLO/ksNZn1k+E10z7db6xHFLDffaGcNK/nKzoFwTjeDkDB7er33xX0DTvGkXhrUEngu5ZXiSbz7aVMqM5ZY5WkjBHTei1g+Mvi7d2/wu1Dxb4Y8O37Wsaxta3uorCLeVTMsZYoswlxycZUdj0oA5/xF4f8AiotxrlvazapdtdvpUlvd2uppFFF5UYW6UK0ism9sthVw2OeeKLrwn45sbTXrbS9JuANT8UahffaLbU2hkit5FTypQkdzCHyQ3yu+VwDtNdvrfxd0jQodaOr6VrFvcaPZ295dwbIXYLNII1VSspUsCwJ5xjuelT3nxX0Oy8Y6f4cu7e6jvL6dbeCRZraRSzD5dyJMZUBzjLIOaAOK8J+D/iFqGreEj4s1fxBp9pZ6Sft7WmqJ+9u0umZEkAZt+Y9uWA5HBbqK3fjFpPjHUNbsJ/CQ1a4hhg2taR3f2W0kdn5aSWO6hmDKozwrr04zmo/DPjDXb34A694kub7frVrb6k8Vz5MY2mJpRGdoXacbV6jnHOaTQvjNptl4Zsx4og1OPWY9Isr6QeTETfecFUNCEfHzOejbMZ6ADgAzNX0D4jSX+qOrarJpcmv285tbTVgk0tgI8OkEhkUoN/Uboya5mx8B/EjTfD2n2enjULGx+36hNdWtreKbnEhHkyFluYt+PQy8HkhulenzfF7RoHFvNpesJqg1aHRZNOKQmaOeVS0ZJEvl7GCnkOarx/GzwyLe1nvLbVLGGdryNnuIowIpbVd0kTEOfnIxtxkHOM54oA6/wvZasngewstTv7xdXW1EUl3PFEJw4GN7KrSIW6fxMDVT/hELmb/kIeLfEl16hZobYfh5MaH9c+9bvh/U11rQ7DU47a5tY7yFJ0huVVZEVhkBgCQDgjjNX6APL/H/AIU0nRvDQvUjvb64+22NuTqOo3N2pWW6hif5ZJCPuu3bAz0qGz0LRbFt1joej2z9d8NhEjE+pIXJPua6P4u/8iYv/YU0v/0vt6zOpq4kTZOtzcbAnmvsAwF3HAHsKbknkmmgGn1RAmKNopCcUhamIUp6UhWjdRuoATFGKUn6U00AFOBxTaAKBkgINLxTQtOxQIMD0qK4QeWxPYVNTJRuiYe1AHnPjSUf2XegkD9038q8f0gHJdMHaM8n2r1f4gKY7S4BGRsbj8K8fsQVRQCeeo9K8/HbI9HAdS5cuFVcj58kfTPenRRFZhCQ2WyOKrBS+CzEHPSrtvITcq2edx7+3auFO6PR6l18i3yBkHge9MUtHGp5CniraqpwQONuQfeoXACrCDls5Nc8tzRM6XTMHbycYxXb6TKGjEbKwJHDBsCuC0nBI5I5znNdpoFy6y7NpOPujPWrgVM1r/aEIU5AUckY5rAu3Az/ABY4Fa2sTZ42CNQvK4xzXPTOM5U8k5x6UT3CGxHPKHZeDwOnrVWZWWVHPEYIKjPf3qw377a4wDkg1Hdo8R2tggng0WtqKSXQo32WJBwEZgAoHQ1l3UUce4rnlcH1OD0rXuweVXlj0rDklxMy4LBT83qBU9Sb6FEx5kA6hs556UOi5G4cj5cmpYZUkT92EIJJDD60l0+AiNyRycjsa0ItdlKYL5iqy5DHCnNezeD7w3nhrT5SQT5So2PUDB/lXjdwBFIHIyNv3fT6V6N8K7vdok1o2CYJTtI7qf8A64NduCnaTi+px4+F4qS6HblqkjXnNQLy1WlHFeoeUBb5sChjgc1C7lXzTGlz2oAeCM08GoQaeHx2oES9KepqMnPPWnIaAFlGYziqK5OavsflP0qgrDkd6TAU1Ba/8j14K/7CU3/pBdVOTUNsc+OfBX/YTm/9ILuiWxUdz2WiiisjUKKKKACiiigAooooAKKKKACiiigArmfGPhZtevdC1CzvvsGp6PefaYJzF5oZGUrJEy7l+V1OOCCODXTUUAcdF8M/CcWsjVI9LdboXraiALufyhcMMNIIt/lgkcH5eePShPhp4VTRr3Rxp9wdHu0Mclg1/cNbqN4f5IjJtjO4AgoAR2rxL4aw+PfEmg2Op6Vea60YtNWhu7q71cul3Kd6WyxRtKSjo+PnKpjHU9+otvBnjjTdC8LNc6l4p1gOjy65YrrSx3KzGALGsU29B5auCSN/JOTuoA7/AFb4WeEdXEg1LTrq4MtslpMz6jc7p4kbciyHzMyYYAgtkjA54qDUPAXgTR75dc1CCKwZdQS/Es+oyxQfa+iybDII95zjpznvXnVx4R+KVzptrHqGo6nLeReGJ4jJZasbcHUfOZoQ22RdzhNoLkbTg5Jqa/8ADXxOS01SKxuNXJubPSpFJ1YFluldDdBCZPkBG7IGFPQZ4oA9esvB+hWXhW68N21js0W5SZJbfzpDuWUsZBuLbhnc3Q8Z4xWRbfCzwbBYXll/Y/nQXUEdtIbm6mncRRkGNEd3LIqkAgKRjA9BXCSeGPiEviU6jDdauAPGHmqjarug/shh82YTJtKggYXG4dgKytI8L/FWKDVzqOpa1JqUmnX0KmG4T7NPMyv5Do7XeYmB2bSkEYHQ/wB6gD1iH4c+Folt/wDiWvJJBqKass0t1NJK10gISR5Gcs+ATgMSPasTxd8ItC13RbLSLVUsdNTWBrF1GUadrhzneoZn+TdnkjI9BXES+Ffihb2V3Fpl9qi+folh5v2jVvNc3isv2lInd2MbFd3zDC56HoRf8Y+HvGt7Boy+FofE2maUjXAvbS41X7RemRkURyiT7au5Ac4XzgAQSUYHBAPcAAoAUAAcADtS1ieCYNRtfCelW+tz3NxqMUCpPLdIiyuw4y4R3XdjGcM31rboA4z4u/8AIlj/ALCml/8Apfb1mitv4naffal4Qkg0qzkvbtL2yuRbxuiM6xXcMjgF2Vc7UbqRXJiXxF/0JGu/+BNh/wDJNXFkSVzVXpS1lifxEP8AmSNd/wDAmw/+SaGn8RHp4I13/wACbD/5JqrojlZoN1ptZ/m+I/8AoSdd/wDAmw/+SaXzvEX/AEJGu/8AgTYf/JNHMh2ZoAUYrP8AN8Rf9CRrv/gTYf8AyTR53iP/AKEjXf8AwJsP/kmldBZmhikOKoed4i/6EnXf/Amw/wDkmjzfEP8A0JGu/wDgRYf/ACTTug5WX+M9aKz/ADfEX/Qka7/4E2H/AMk0eb4i/wChI13/AMCbD/5Jo5kHKzTB96fWWJvEX/Qka7/4E2H/AMk077R4h/6EjXv/AAJsP/kmi6CzNLNLjIIrM+0eIf8AoSNe/wDAmw/+SaPtHiH/AKEjXv8AwJsP/kmi6CzOV+JFsPsTN6q38q8Btpf3rNgj2HOK+iPGGm+K9ZsxFaeC9YRgD/rLqxA/S4NeTw/Cf4hJIWbwrc7SckC9s+f/ACNXFi4OaXLqdmDlGDfMco7lZAUJ3M2MkVcspgJBkYxnp2NdO/ws8fNgf8IreYByP9Ns+v8A3+oj+F3xBR2P/CJ3OD/0+2ec/wDf6uH2NToj0FXp9ynp7CQsp2r6YpL1Srq8R+bcF+tbsPw88fRxOn/CJXnzLjP22z65HP8Arqm/4QDx35QUeEr7rn/j8sv/AI/USw9R7RKWIpdWU9JkKhsjLZIwD0NdTpsp8+BkbuEx9e9ZMXgXxwspZvCOoY9BeWX/AMfrZ0vw14ztBiTwfqZHP3buxP8AOehUKq+yP29Jr4jYuhHGZTMXlVh164rEvlCtG652gjPvXSS2nimaFEk8EasGVcZFzY8/+TFY974e8WzHMfg7VhjoDdWP/wAkVpUo1HshxxNJK1zFuJRFH8rYGccHrUd3ISyknIIzWpL4X8YOhX/hDdTwf+nuy/8AkioZfCPjGWFEfwfqmVwc/a7LqP8At4rP2NXsCrUusjIdoy6ybj5mMD0rBm+WWeSQ7MnJ28jFddL4N8aN93whqIxnH+l2X/x+qd54D8azKAng+/BKkNm8suT/AN/6X1er2I9vT7nFoyhY5I2xhjjsPyq47tJCXcAknt2FbcPw38cLGqSeEb7juLyz/wDj9SH4e+OgTjwjfY7ZvLP/AOP1XsKiWw/b0+5yt2527iC3GMZroPh3qK23iE2wkOy5TbtPI3Dn/GrQ+HnjkMf+KRvipGMG8sv/AI/SWXw98eWt3DcL4SvQ8UgdSLyzz/6PrWjTqRkm0Y16lOpBpM9QibmrW7ArNW28UBVz4K1kEel1Yf8AyTU4j8S7cHwTrf8A4E2H/wAk16/Mjx+VkzkHuKhbrxTTB4kP/Mk63/4E2H/yTTDb+Jf+hJ1r/wACbD/5JobDlZYQjbTlwaqfZvE//Qla1/4E2H/yTThB4nH/ADJWtf8AgTYf/JNO6DlZeBGABTlJFURF4m/6ErW//Amw/wDkmnhPEw/5krW//Amw/wDkmi6Fysu9Qc1QHEj/AFp+3xL/ANCTrf8A4E2H/wAk1Wa28TlmI8Fa1g/9PVh/8k1LY7MnLAVBZtnx34K/7CU3/pBdU02nij/oS9a/8CrD/wCSan0HR/Edx408M3N34Z1DT7Oxu5Z557i4tWVVNrPGBiOZmJLSL2ob0BRdz2OiiioNQooooAKKKKACiiigAooooAKKKKACiiigDgvGnxP0vwnrV7pl1pmrXk9npg1edrRIiqW/meWT88ikkHqADwe9VLr4xeHILiUrb6lNptvJbQ3WpRxJ9nt3nAMYbc4c8EZ2o2M810ut+CfD2uaje3+qaf591e6edKnfzpF32xfeY8KwA+bncMN71Rf4Z+EXvo7ptJ+dPIJjFzMIpDCNsTSRb9khUcAuCaAM/wCEPjbVPGdvrz6tpJsvsGqT2cUibAhVCAEYCRz5g/iIAQ5G0nmqS/GDRrzz7SxtNTi1WP7eksEtvG7WbWqbnaZRKPlJKgAN8xOMjqOz0DwtpHh+91K60e3ktn1GZrm5QXEjRNKxyziMsUVj3KgZwPSqkfgTw1HretavHpca6jrMBtr6YSODNGQAVxuwuQBkqATjJ5oA5PTPjFpEs2gafNDdT6lqljb3gbFvZRkS4ChVmuBls/wI0hHTJNc7P8UtXl8ceG4LE3F7p73us2l7ZW1lFDJcfZY1KBfMlb7pJO4Om7+6OleiSfDfwvLBp9tNZ3ctlYCIW1nJqNy1unlABP3Jk2EjHUqSe+ahuvhZ4QuZI5H02eOWOe5uUkgv7mFxJcY847kkBw4ABHTGQAATQBxSfGKzPiwau99PH4LPhX+1vIa3XzBP9s8n03bv4MbtuefetKX4lR+NfBXiq48DXk+na1ocC3JEwt51f5DIq5RpEZWCspw2VPoRXVj4ceEQmz+w7fyv7N/sjy9z7Psu/wAzZtzjO/5t2N2ec1X1nwDHN4Q1TQdC1TUNPTUYlt5prq6uL8pDyGWMSykISpIyPxBwMAHReFdXXX/DGkaxHGY11C0iugh/h3oGx+Ga1KraZY2+mabaWFlGI7W1hSCJB/CigKo/ICrNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Charlie Goldberg, MD. Image available at meded.ucsd.edu/clinicalmed/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5395=[""].join("\n");
var outline_f5_17_5395=null;
var title_f5_17_5396="Betamethasone and clotrimazole: Patient drug information";
var content_f5_17_5396=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Betamethasone and clotrimazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/47/12022?source=see_link\">",
"     see \"Betamethasone and clotrimazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotrisone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lotriderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700959",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 17 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to betamethasone, clotrimazole, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using under a dressing or diaper.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using on the groin, use a little bit. Do not wear tight clothing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use diapers or plastic pants.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11274 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5396=[""].join("\n");
var outline_f5_17_5396=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140773\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140774\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014744\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014743\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014748\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014749\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014751\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014746\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014747\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014752\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014753\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/47/12022?source=related_link\">",
"      Betamethasone and clotrimazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5397="Disulfiram: Drug information";
var content_f5_17_5397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Disulfiram: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/30/25060?source=see_link\">",
"    see \"Disulfiram: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antabuse&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Aldehyde Dehydrogenase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Alcoholism:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer until the patient has abstained from ethanol for at least 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     500 mg once daily for 1-2 weeks (maximum daily dose: 500 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Average maintenance dose:",
"     </i>",
"     250 mg once daily (range: 125-500 mg; maximum daily dose: 500 mg); duration of therapy is to continue until the patient is fully recovered socially and a basis for permanent self-control has been established; maintenance therapy may be required for months or even years.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with extreme caution in chronic and acute nephritis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with extreme caution in hepatic cirrhosis or insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antabuse&reg;: 250 mg, 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of any medications containing alcohol, including topicals, is contraindicated. Do not administer disulfiram if ethanol has been consumed within the prior 12 hours. Morning administration is preferred, but may be given at bedtime if sedation is experienced.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of chronic alcoholism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Disulfiram may be confused with Diflucan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, headache, fatigue, polyneuritis, psychosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, acneiform eruptions, allergic dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Metallic or garlic-like aftertaste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuritis, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to disulfiram and related compounds or any component of the formulation or to other thiuram derivatives used in pesticides and rubber vulcanization; patients receiving or using ethanol, metronidazole, paraldehyde, or ethanol-containing preparations like cough syrup or tonics; psychosis; severe myocardial disease and coronary occlusion",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Severe (sometimes fatal) hepatitis and/or hepatic failure have been associated with use; may occur in patients with or without prior history of abnormal hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic cirrhosis or impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Use with caution in patients with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephritis: Use with caution in patients with acute or chronic nephritis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol intoxication:",
"     <b>",
"      [U.S. Boxed Warning]: Should never be administered to a patient when he/she is in a state of ethanol intoxication, or without his/her knowledge.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must receive appropriate counseling, including information on &ldquo;disguised&rdquo; forms of ethanol (tonics, mouthwashes, etc) and the duration of the drug's activity (up to 14 days).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F161792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Disulfiram may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlordiazePOXIDE: Disulfiram may increase the serum concentration of ChlordiazePOXIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorzoxazone: Disulfiram may decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: CYP2E1 Inhibitors (Strong) may decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Disulfiram may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Disulfiram may increase the serum concentration of Fosphenytoin.  Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Disulfiram may enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): Disulfiram may enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Disulfiram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: Disulfiram may increase the serum concentration of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Disulfiram may increase the serum concentration of Phenytoin.  Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Disulfiram may enhance the adverse/toxic effect of Ritonavir. This is specific for the lopinavir/ritonavir (Kaletra) oral solution due to its alcohol content (42%).  Management: Concomitant use of Kaletra (lopinavir/ritonavir) oral solution and disulfiram should be avoided. Kaletra contains 42% alcohol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Disulfiram may enhance the adverse/toxic effect of Sertraline. This is specifically related to sertraline oral concentrate due to its alcohol content (12%).  Management: Sertraline Oral Concentrate contains 12% alcohol, and its use should be avoided with disulfiram.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Disulfiram may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tinidazole: May enhance the adverse/toxic effect of Disulfiram.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Disulfiram may enhance the adverse/toxic effect of Tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Disulfiram may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F161757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Disulfiram inhibits ethanol's usual metabolism. Avoid all ethanol. Patients can have a disulfiram reaction (headache, nausea, vomiting, chest, or abdominal pain) if they drink ethanol concurrently. Avoid cough syrups and elixirs containing ethanol. Avoid vinegars, cider, extracts, and foods containing ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9497261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer disulfiram if ethanol has been consumed within the prior 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Antabuse Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $583.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $934.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Disulfiram Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $403.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $645.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F161740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests at baseline and after 10-14 days of treatment; a complete CBC and serum chemistries should also be monitored",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abstensyl (AR);",
"     </li>",
"     <li>",
"      Alcobuse (TH);",
"     </li>",
"     <li>",
"      Alcohol Stop (KP);",
"     </li>",
"     <li>",
"      Antabus (AT, CH, CN, CZ, DE, DK, EC, ES, FI, HR, NL, NO, SE, TR);",
"     </li>",
"     <li>",
"      Antabuse (AU, BE, GB, IE, IT, LU, MX, NZ, SG, ZA);",
"     </li>",
"     <li>",
"      Antaethyl (HN, HU);",
"     </li>",
"     <li>",
"      Anticol (PL);",
"     </li>",
"     <li>",
"      Antietanol (BR);",
"     </li>",
"     <li>",
"      Busetal (PE);",
"     </li>",
"     <li>",
"      Chronol (TH);",
"     </li>",
"     <li>",
"      Deadict (IN);",
"     </li>",
"     <li>",
"      Difiram (TH);",
"     </li>",
"     <li>",
"      Esperal (BG, FR, IN, RU);",
"     </li>",
"     <li>",
"      Refusal (NL);",
"     </li>",
"     <li>",
"      Tetidis (HR);",
"     </li>",
"     <li>",
"      Tetradin (PT);",
"     </li>",
"     <li>",
"      Zincfrin (GR, PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disulfiram is a thiuram derivative which interferes with aldehyde dehydrogenase. When taken concomitantly with alcohol, there is an increase in serum acetaldehyde levels. High acetaldehyde causes uncomfortable symptoms including flushing, nausea, thirst, palpitations, chest pain, vertigo, and hypotension. This reaction is the basis for disulfiram use in postwithdrawal long-term care of alcoholism.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Full effect: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~1-2 weeks after last dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To diethylthiocarbamate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces and exhaled gases (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Motte S, Vincent JL, and Gillet JB, &ldquo;Refractory Hyperdynamic Shock Associated With Alcohol and Disulfiram,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1986, 4(4):323-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/17/5397/abstract-text/3718622/pubmed\" id=\"3718622\" target=\"_blank\">",
"        3718622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pompidou A, Delsaux MC, Telvi L, et al, &ldquo;Isoprinosine and Imuthiol, Two Potentially Active Compounds in Patients With AIDS-Related Complex Symptoms,&rdquo;",
"      <i>",
"       Cancer Res",
"      </i>",
"      , 1985, 45(9 Suppl):4671-3.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9379 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5397=[""].join("\n");
var outline_f5_17_5397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708705\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161760\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161796\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161762\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161763\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804852\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804853\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161742\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161728\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161745\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161743\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161794\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161748\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161732\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161792\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161737\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161757\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161767\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9497261\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161750\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161740\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161751\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161731\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161747\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/30/25060?source=related_link\">",
"      Disulfiram: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5398="Mansonella infections";
var content_f5_17_5398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mansonella infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5398/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/17/5398/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4462369\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three species of Mansonella cause human infections: M. streptocerca, M. perstans, and M. ozzardi. Each species has a limited geographic distribution and typically causes mild symptoms if any at all.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and treatment of Mansonella infections will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef66052 graphicRef70668 \" href=\"UTD.htm?21/30/21997\">",
"     table 1A-B",
"    </a>",
"    ). Other filarial infections, including loiasis, onchocerciasis, and lymphatic filariasis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462376\">",
"    <span class=\"h1\">",
"     MANSONELLA PERSTANS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462384\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. perstans is endemic in a large portion of sub-Saharan Africa, from Senegal to Uganda and south to Zimbabwe, and in Central and South America from Panama to Argentina (",
"    <a class=\"graphic graphic_figure graphicRef85853 \" href=\"UTD.htm?10/31/10751\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/1\">",
"     1",
"    </a>",
"    ]. Since the majority of infected individuals are asymptomatic, the epidemiology of M. perstans has not been clearly defined. Nevertheless, it has been estimated that 114 million people may be infected and as many as 581 million people in 33 countries at risk for M. perstans infection in Africa alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In endemic regions, the probability of infection increases with age with prevalences reaching 100 percent in highly endemic areas. Infection of travelers is uncommon, but it does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonhuman primates are occasionally infected, but they do not appear to be a major reservoir of infection.",
"   </p>",
"   <p>",
"    M. perstans is transmitted by biting midges (Culicoides). The lifecycle is similar to that of other filariae (",
"    <a class=\"graphic graphic_figure graphicRef82920 \" href=\"UTD.htm?25/50/26407\">",
"     figure 2",
"    </a>",
"    ). Infective larvae introduced during the bite of an infected midge mature over months into adult worms. The adult worms live in the pleural, pericardial, and peritoneal cavities, as well as the mesenteric, perirenal, and retroperitoneal tissues, where they produce unsheathed microfilariae that are found in the bloodstream at all times. Microfilariae are responsible for transmission of infection because they are taken up during the blood meal of the insect vector. The life cycle is completed following maturation of microfilariae into infective third-stage larvae within the midge. The lifespan of the adult worms is unknown, although microfilaria-positive cases have been reported up to 10 years after the infected individual has left the endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462398\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with M. perstans infection are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. When symptoms do occur, they are predominantly related to migration of the adult worms and include transient subcutaneous swellings similar to the Calabar swellings of Loa loa infection, serositis (ie, pericarditis and pleuritis) and ocular symptoms (granulomatous nodules in the conjunctiva, retinal lesions, and periorbital inflammation surrounding dead adult worms). Nonspecific symptoms, including pruritus, urticaria, arthralgias, abdominal pain, and fatigue have also been attributed to M. perstans infection. Neuropsychiatric manifestations, meningoencephalitis, and hepatitis have also been described.",
"   </p>",
"   <p>",
"    Nonspecific but characteristic laboratory abnormalities include eosinophilia and elevated serum IgE levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462405\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. perstans infection should be suspected in an individual with an appropriate epidemiologic exposure, consistent clinical findings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unexplained eosinophilia. The definitive diagnosis is established by identifying the adult worm or microfilariae in the blood. Serology may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462412\">",
"    <span class=\"h3\">",
"     Visualizing organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of M. perstans infection can be definitively established by detecting microfilariae in a blood smear (",
"    <a class=\"graphic graphic_picture graphicRef83928 \" href=\"UTD.htm?12/56/13186\">",
"     picture 1",
"    </a>",
"    ) or, rarely, by the identification of adult worms in tissue specimens. Microscopy sensitivity is increased using concentration techniques, such as Knott&rsquo;s concentration or Nuclepore membrane filtration&trade;. However, due to the small size of M. perstans microfilariae, membranes with a 3 mcm pore size are optimal.",
"   </p>",
"   <p>",
"    Adult worms range in length from 3.5 to 4.5 cm for males and 5 to 8 cm for females. Both are no more than 120 mcm wide. Microfilariae of M. perstans are unsheathed and measure 190 to 200 mcm long in stained blood smears. A round terminal nucleus is found at the tip of the tail, which is blunted (",
"    <a class=\"graphic graphic_picture graphicRef83928 \" href=\"UTD.htm?12/56/13186\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    M. perstans has been shown to have a weak diurnal periodicity with peak counts at 8:00 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/5\">",
"     5",
"    </a>",
"    ]. This coincides with the feeding pattern of the vector, thereby potentiating transmission of infection. Their presence in the bloodstream at all times during the day can cause them to be mistaken for microfilariae of L. loa or Wuchereria bancrofti, filarial parasites that overlap in geographic distribution with M. perstans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462419\">",
"    <span class=\"h3\">",
"     Serology and other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests based on crude filarial antigens are positive in M. perstans infection, but do not distinguish between active or past infection and show crossreactivity between the different filarial species and with other nematode infections. Consequently, their utility is limited, although a negative result can exclude the possibility of infection.",
"   </p>",
"   <p>",
"    A real-time polymerase chain reaction (PCR) assay has been developed at the Laboratory of Parasitic Diseases, National Institutes of Health that can detect and quantitate M. perstans microfilaremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/6\">",
"     6",
"    </a>",
"    ]. Assistance with serologic and other diagnostic tests is available from the Laboratory of Parasitic Diseases, National Institutes of Health (301-496-5398).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462433\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. perstans is relatively resistant to standard antifilarial agents, including diethylcarbamazine (DEC),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Recommended treatments include albendazole (400 mg orally twice daily for 10 days) or mebendazole (100 mg orally twice daily for 30 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/8\">",
"     8",
"    </a>",
"    ], although these regimens do not clear microfilaremia in the majority of patients. The intracellular endosymbiont, Wolbachia, has been demonstrated in M. perstans from Mali and Cameroon, but appears to be absent in parasites from Uganda and Gabon.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (200 mg daily for six weeks), which has activity against Wolbachia, has been shown to be 100 percent effective in clearing M. perstans microfilariae from the blood of infected individuals in Mali for up to 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/9\">",
"     9",
"    </a>",
"    ]. The utility of doxycycline in the treatment of M. perstans form other geographic regions has not been explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462440\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no studies of chemoprophylaxis against M. perstans infection. Personal protection measures to limit contact with biting midges may have some utility in individual travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462447\">",
"    <span class=\"h1\">",
"     MANSONELLA OZZARDI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462455\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. ozzardi is endemic in Central America, South America (Argentina, Bolivia, Brazil, Colombia, Guyana, Suriname, and Venezuela), and the Caribbean islands (Antigua, Dominican Republic, Guadeloupe, Haiti, Martinique, Nevis, Puerto Rico, St. Kitts, St. Lucia, St. Vincent, and Trinidad). The overall prevalence of M. ozzardi infection is unknown; up to 70 percent of the residents in endemic foci may have parasites detectable in the blood. Infection of travelers is uncommon but does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonhuman primates can be infected experimentally, but humans are the only major reservoir of infection.",
"   </p>",
"   <p>",
"    M. ozzardi is transmitted by biting midges (Culicoides) and blackflies (Simulium amazonicum). The life cycle is identical to that of M. perstans (",
"    <a class=\"graphic graphic_figure graphicRef83929 \" href=\"UTD.htm?41/63/42999\">",
"     figure 3",
"    </a>",
"    ), except that adult worms are found in the lymphatics as well as the thoracic and peritoneal cavities, and microfilariae are found both in the blood and the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/10\">",
"     10",
"    </a>",
"    ]. The life span of the adult worms is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462469\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with M. ozzardi infection are asymptomatic, although urticaria, pruritic skin eruptions, edema, lymphadenopathy, arthralgias, fever, headache, vertigo, and pulmonary symptoms have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Eosinophilia is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462476\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. ozzardi infection should be suspected in an individual with an appropriate epidemiologic exposure, consistent clinical findings,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unexplained eosinophilia. The definitive diagnosis is established by identifying the microfilariae in the blood or skin. Serology may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462483\">",
"    <span class=\"h3\">",
"     Visualizing organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of M. ozzardi infection can be definitively established by detecting microfilariae in a blood smear (",
"    <a class=\"graphic graphic_picture graphicRef83930 \" href=\"UTD.htm?21/24/21890\">",
"     picture 2",
"    </a>",
"    ) or skin snips (1 mm skin biopsies obtained using a corneoscleral punch or needle and scalpel that are incubated for 30 minutes to 24 hours in saline and examined under low magnification for the presence of motile microfilariae). Adult worms are rarely identified in tissue specimens. Concentration techniques, such as Knott&rsquo;s concentration or Nuclepore membrane filtration&trade;, can be useful in increasing the sensitivity of detection of blood microfilariae.",
"   </p>",
"   <p>",
"    Adult female worms range in length 6.5 to 8.1 cm and up to 250 mcm wide. No intact male worms have been obtained to date. Microfilariae of M. ozzardi are unsheathed and measure 170 to 240 mcm long in stained blood smears. They have a cephalic space that is 2 to 6 mcm long with 2 to 3 overlapping nuclei and caudal space that is 3 to 8 mcm long with oval terminal nuclei (",
"    <a class=\"graphic graphic_picture graphicRef83930 \" href=\"UTD.htm?21/24/21890\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462490\">",
"    <span class=\"h3\">",
"     Serology and other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests based on crude filarial antigens are positive in M. ozzardi infection, but do not distinguish between active or past infection and show cross-reactivity between the different filarial species and with other nematode infections. Consequently, their utility is limited, although a negative result can exclude the possibility of infection.",
"   </p>",
"   <p>",
"    PCR assays have been developed but are not routinely available outside of research laboratories. Assistance with serologic and other diagnostic tests is available from the Laboratory of Parasitic Diseases, National Institutes of Health (301-496-5398).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462504\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for M. ozzardi infection is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    orally), which is effective in reducing microfilarial counts and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/12\">",
"     12",
"    </a>",
"    ]. Other antifilarial therapies, including diethylcarbamazine (DEC) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/13\">",
"     13",
"    </a>",
"    ], appear to be ineffective. Although M. ozzardi does harbor the intracellular endosymbiont, Wolbachia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/14\">",
"     14",
"    </a>",
"    ], there are no published studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or other antibacterial therapies to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462511\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no studies of chemoprophylaxis against M. ozzardi infection. Personal protection measures to limit contact with biting midges and blackflies may have some utility in individual travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462518\">",
"    <span class=\"h1\">",
"     MANSONELLA STREPTOCERCA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462526\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. streptocerca is endemic in the tropical rain forests of western and central Africa, including northern Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Equatorial Guinea, Nigeria, People&rsquo;s Republic of Congo, and western Uganda. The prevalence of M. streptocerca infection is unknown; up to 90 percent of the residents in endemic foci may be infected. Infection of travelers is uncommon but does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonhuman primates are occasionally infected, but do not appear to be a major reservoir of infection. &nbsp;",
"   </p>",
"   <p>",
"    The lifecycle is identical to that of M. perstans (",
"    <a class=\"graphic graphic_figure graphicRef82920 \" href=\"UTD.htm?25/50/26407\">",
"     figure 2",
"    </a>",
"    ) except that adult worms reside in the dermis of the upper trunk and shoulder girdle and microfilariae are found in the skin. The life span of the adult worms is unknown. M. streptocerca is transmitted by biting midges (Culicoides).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462540\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with M. streptocerca infection are asymptomatic. The most common complaint is pruritus, especially over the shoulder girdle and thorax [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/15\">",
"     15",
"    </a>",
"    ]. Dermal thickening, nonanesthetic hypopigmented macules and bilateral axillary or inguinal lymphadenopathy have been described. Unlike O. volvulus, the adult worms do not form subcutaneous nodules. Eosinophilia is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462547\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. streptocerca infection should be suspected in an individual with an appropriate epidemiologic exposure, pruritus, a macular hypopigmented rash or lymphadenopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unexplained eosinophilia. The definitive diagnosis is established by identifying the microfilariae in the skin. Serology may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462554\">",
"    <span class=\"h3\">",
"     Visualizing organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of M. streptocerca infection can be definitively established by detecting microfilariae in skin snips. Reports of adult worms identified in tissue biopsies are extremely few.",
"   </p>",
"   <p>",
"    Adult worms are approximately 1.7 cm x 50 mcm for males and 2.7 cm x 85 mcm for females. Microfilariae of M. streptocerca are unsheathed, 180 to 240 mcm long and have a characteristic sharp curve in the posterior end that is reminiscent of a shepherd&rsquo;s crook (",
"    <a class=\"graphic graphic_picture graphicRef83931 \" href=\"UTD.htm?16/58/17327\">",
"     picture 3",
"    </a>",
"    ). This unusual feature allows an experienced technician to distinguish M. streptocerca from O. volvulus microfilariae without special staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462561\">",
"    <span class=\"h3\">",
"     Serology and other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests based on crude filarial antigens are positive in M. streptocerca infection, but do not distinguish between active or past infection and show cross-reactivity between the different filarial species and with other nematode infections. Consequently, their utility is limited, although a negative result can exclude the possibility of infection.",
"   </p>",
"   <p>",
"    PCR assays have been developed but are not routinely available outside of research laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/16\">",
"     16",
"    </a>",
"    ]. Assistance with serologic and other diagnostic tests is available from the Laboratory of Parasitic Diseases, National Institutes of Health (301-496-5398).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462575\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diethylcarbamazine (DEC) (6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 12 days) is effective for the treatment of M. streptocerca infection and kills both microfilariae and the adult worms, although treatment can be accompanied by exacerbation of clinical symptoms including pruritus, papular eruptions, arthralgias, fever, myalgias, headache, nausea, and vomiting. Furthermore, DEC should not be administered to patients for whom concomitant onchocerciasis cannot be excluded, due to the provocation of serious side effects including exacerbation of ocular disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    as a single dose) is useful in reducing microfilarial loads [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5398/abstract/17\">",
"     17",
"    </a>",
"    ], although the clinical effects of ivermectin in streptocerciasis are unknown. Neither the presence of Wolbachia nor the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in the treatment of M. streptocerca have been explored to date. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462582\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no studies of chemoprophylaxis against M. streptocerca infection. Personal protection measures to limit contact with biting midges may have some utility in individual travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462589\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three species of Mansonella that cause human infections: M. streptocerca, M. perstans, and M. ozzardi. Mansonella infections are frequently asymptomatic, but may complicate diagnosis and treatment of other human filarial infections that overlap in geographic distribution and clinical manifestations. (See",
"      <a class=\"local\" href=\"#H4462369\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The epidemiology, clinical manifestations, diagnosis, and treatment vary between Mansonella species and are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef66052 graphicRef70668 \" href=\"UTD.htm?21/30/21997\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4462376\">",
"       'Mansonella perstans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4462447\">",
"       'Mansonella ozzardi'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4462518\">",
"       'Mansonella streptocerca'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/1\">",
"      Simonsen PE, Onapa AW, Asio SM. Mansonella perstans filariasis in Africa. Acta Trop 2011; 120 Suppl 1:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/2\">",
"      Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007; 1:e88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/3\">",
"      Kiefer G, Battegay M, Gyr N, Hatz C. [Mansonella perstans filariasis after stay in Cameroon. A 19-year-old patient born in Cameroon, in Switzerland for the last 10 years]. Praxis (Bern 1994) 2002; 91:61.",
"     </a>",
"    </li>",
"    <li>",
"     Klion AD, Nutman TB. Loiasis and Mansonella Infections. In: Tropical Infectious Diseases: Principles, Pathoges, and Practice, Guerrant RL, Walker DH, Weller PF.  (Eds), Elsevier, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/5\">",
"      Asio SM, Simonsen PE, Onapa AW. Analysis of the 24-h microfilarial periodicity of Mansonella perstans. Parasitol Res 2009; 104:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/6\">",
"      Keiser PB, Coulibaly Y, Kubofcik J, et al. Molecular identification of Wolbachia from the filarial nematode Mansonella perstans. Mol Biochem Parasitol 2008; 160:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/7\">",
"      Bregani ER, Rovellini A, Mba&iuml;doum N, Magnini MG. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 2006; 100:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/8\">",
"      Drugs for parasitic infections. Med Lett Drugs Ther 2010; 8:e20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/9\">",
"      Coulibaly YI, Dembele B, Diallo AA, et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 2009; 361:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/10\">",
"      Nathan MB, Bartholomew CF, Tikasingh ES. The detection of Mansonella ozzardi microfilariae in the skin and blood with a note on the absence of periodicity. Trans R Soc Trop Med Hyg 1978; 72:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/11\">",
"      Bartoloni A, Cancrini G, Bartalesi F, et al. Mansonella ozzardi infection in Bolivia: prevalence and clinical associations in the Chaco region. Am J Trop Med Hyg 1999; 61:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/12\">",
"      Nutman TB, Nash TE, Ottesen EA. Ivermectin in the successful treatment of a patient with Mansonella ozzardi infection. J Infect Dis 1987; 156:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/13\">",
"      Bartholomew CF, Nathan MB, Tikasingh ES. The failure of diethylcarbamazine in the treatment of Mansonella ozzardi infections. Trans R Soc Trop Med Hyg 1978; 72:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/14\">",
"      Casiraghi M, Favia G, Cancrini G, et al. Molecular identification of Wolbachia from the filarial nematode Mansonella ozzardi. Parasitol Res 2001; 87:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/15\">",
"      Fischer P, Bamuhiiga J, B&uuml;ttner DW. Occurrence and diagnosis of Mansonella streptocerca in Uganda. Acta Trop 1997; 63:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/16\">",
"      Fischer P, B&uuml;ttner DW, Bamuhiiga J, Williams SA. Detection of the filarial parasite Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based assay. Am J Trop Med Hyg 1998; 58:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5398/abstract/17\">",
"      Fischer P, Tukesiga E, B&uuml;ttner DW. Long-term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin. J Infect Dis 1999; 180:1403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83819 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5398=[""].join("\n");
var outline_f5_17_5398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4462589\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462369\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462376\">",
"      MANSONELLA PERSTANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462384\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462398\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462405\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462412\">",
"      - Visualizing organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462419\">",
"      - Serology and other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462433\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462440\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462447\">",
"      MANSONELLA OZZARDI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462455\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462469\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462476\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462483\">",
"      - Visualizing organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462490\">",
"      - Serology and other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462504\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462511\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462518\">",
"      MANSONELLA STREPTOCERCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462526\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462540\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462547\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462554\">",
"      - Visualizing organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4462561\">",
"      - Serology and other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462575\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4462582\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462589\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/83819\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/83819|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/31/10751\" title=\"figure 1\">",
"      Map - Mansonella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/50/26407\" title=\"figure 2\">",
"      M perstans life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/42999\" title=\"figure 3\">",
"      M ozzardi life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/83819|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/56/13186\" title=\"picture 1\">",
"      M perstans microfilariae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/24/21890\" title=\"picture 2\">",
"      M ozzardi microfilariae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/58/17327\" title=\"picture 3\">",
"      M streptocerca microfilariae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/83819|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/12/8396\" title=\"table 1A\">",
"      Features of Mansonella spp I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/35/20028\" title=\"table 1B\">",
"      Features of Mansonella spp II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5399="Related disorders of the hexose monophosphate shunt and glutathione metabolism";
var content_f5_17_5399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Bertil Glader, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5399/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/17/5399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red blood cell is protected from oxidant injury via enzymes of the hexose monophosphate (HMP) shunt pathway and those of the glutathione synthetic and metabolic pathways. The most common abnormality in this system is glucose-6-phosphate dehydrogenase deficiency, which can lead to varying degrees of hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities have been reported in several of the other enzymes in these pathways, some of which are associated with increased red cell destruction (hemolysis). These disorders will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     6-PHOSPHOGLUCONATE DEHYDROGENASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enzyme 6-phosphogluconate dehydrogenase (6PGD) catalyzes the conversion of 6-phosphogluconate to ribulose-5-phosphate and carbon dioxide; in the process NADPH is generated from NADP. Initial observations suggested that 6PGD deficiency does not alter red cell survival, presumably because NADPH is also generated by the proximal enzyme, glucose-6-phosphate dehydrogenase (G6PD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a mutant \"Whitechapel\" 6PGD has been described, transmitted as an autosomal recessive trait. Heterozygotes and homozygotes had 50 and 2 to 5 percent of normal enzyme activity, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/1\">",
"     1",
"    </a>",
"    ]. Neither heterozygotes nor homozygotes demonstrated clinical or hematologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, compensated hemolysis with episodic jaundice and possible oxidant sensitivity has been described in combination with partial 6PGD deficiency in two families [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUTATHIONE REDUCTASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidized glutathione (GSSG) is reduced to glutathione (GSH) in the presence of NADPH by the enzyme glutathione reductase (GSSG-R) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/5\">",
"     5",
"    </a>",
"    ]. This enzyme contains flavin adenine dinucleotide (FAD) as a prosthetic component, and as a result, normal enzyme activity is dependent upon the dietary availability of the water soluble vitamin riboflavin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired partial deficiency of GSSG-R is a relatively common feature of disorders that are compounded by suboptimal nutrition and riboflavin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/6\">",
"     6",
"    </a>",
"    ]. GSSG-R levels are restored within days by the administration of physiologic quantities of riboflavin. However, riboflavin-induced GSSG-R deficiency is not associated with any clinical hematologic abnormalities.",
"   </p>",
"   <p>",
"    Genetically determined GSSG-R deficiency has been documented in three siblings, offspring of a consanguineous marriage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Enzyme activity was not enhanced by incubation of red cell hemolysates with FAD. Despite near absence of erythrocyte GSSG-R activity, the siblings were hematologically normal, except for episodes of hemolysis after the ingestion of fava beans. Very low activity of GSSG-R was found also in leukocytes, but no increased susceptibility to infection was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other than the above family, there have been no other reports of hereditary GSSG-R deficiency associated with hemolysis, although one patient with severe neonatal jaundice has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, mice homozygous for glutathione reductase deficiency, with only 2 percent of residual enzyme activity, do not have hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting observation was made in a Czech proband and her sister with hemoglobin Han&aacute;, an unstable hemoglobin variant with Heinz body hemolytic anemia and reduced GSSG-R activity. Their mother had the same hemoglobin mutation but with normal GSSG-R activity and was asymptomatic. This study provides evidence that partial GSSG-R deficiency may alter the clinical manifestation of an unstable hemoglobinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GLUTATHIONE PEROXIDASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutathione peroxidase (GSH-Px), a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    -containing enzyme, catalyzes the oxidation of reduced glutathione (GSH) by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , resulting in the production of oxidized glutathione and water. Rare cases of hemolysis in association with moderate deficiency of erythrocyte GSH-Px activity have been described in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The most persuasive case linking deficiency of GSH-PX to hemolysis was that of a Japanese child with chronic non-spherocytic hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/14\">",
"     14",
"    </a>",
"    ]. Her erythrocyte GSH-Px activity was 17 percent of control activity, contrasting with levels of 51 to 66 percent in her hematologically normal parents.",
"   </p>",
"   <p>",
"    Levels of RBC GSH-Px in healthy newborn infants are approximately one-half those seen in older children and adults, with adult levels achieved by 6 to 10 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Although GSH-Px deficiency has been incriminated as a cause of neonatal jaundice, no relationship between GSH-Px levels and magnitude of hyperbilirubinemia has been identified in prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/16\">",
"     16",
"    </a>",
"    ]. When cord blood RBCs are stressed with peroxide under conditions preventing regeneration of GSH, the amount of GSH oxidized is similar for cord and adult erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/17\">",
"     17",
"    </a>",
"    ]. Low GSH-Px activity in cord RBC thus appears to be without functional significance.",
"   </p>",
"   <p>",
"    Two additional observations cast doubt on a causative relation between GSH-PX deficiency and hemolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many healthy normal individuals, particularly those of Jewish or Mediterranean ancestry, have reduced GSH-Px activity without evidence of hemolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low GSH-Px activity, in the absence of hemolysis, has been observed in normal people from New Zealand with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, any patient with hemolytic anemia and reduced GSH-Px activity should be extensively evaluated for another enzymopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFECTS IN GLUTATHIONE SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutathione (GSH) is actively synthesized in red cells, with an intracellular half-life of four days due, in part, to cellular efflux of oxidized glutathione (GSSG). RBCs are capable of de novo GSH synthesis, accomplished by two critical enzymes (",
"    <a class=\"graphic graphic_figure graphicRef75361 \" href=\"UTD.htm?4/5/4190\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gamma-glutamyl-cysteine synthetase (gamma GCSynth), which catalyzes formation of gamma-glutamyl-cysteine from glutamic acid and cysteine.",
"     </li>",
"     <li>",
"      Glutathione synthetase (GSHSynth), which catalyzes the formation of GSH from gamma-glutamyl-cysteine and glycine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many tissues, but not RBC, these two enzymes are part of the gamma glutamyl cycle involved in the synthesis and degradation of GSH and perhaps also in amino acid transport across cell membranes. Hereditary hemolytic anemia, characterized by reduced GSH content, has been reported in patients with deficiencies of both gamma GCSynth and GSHSynth activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/21\">",
"     21",
"    </a>",
"    ]. The clinical effects of these disorders depend upon the severity of enzyme deficiency and whether this metabolic cycle is affected in non-erythroid tissues, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gamma-glutamyl-cysteine synthetase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-glutamyl-cysteine synthetase (gammaGCSynth) deficiency is a rare autosomal recessive hemolytic anemia, initially described in two siblings with a life-long history of mild hemolytic anemia, jaundice, gallstones, and splenomegaly. In addition, they manifested severe neurologic dysfunction in the form of spinocerebellar degeneration, along with generalized aminoaciduria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Homozygotes had erythrocyte GSH levels approximately 5 percent of normal, markedly reduced gamma GCSynth activity, and hemolytic anemia. Heterozygotes had 50 percent of normal gammaGCSynth activity, normal erythrocyte GSH levels, and no hematologic disease.",
"   </p>",
"   <p>",
"    In contrast to the above-noted sibling pair, one patient with gammaGCSynth deficiency, a daughter of fifth cousins, had hemolytic anemia, although neurologic symptoms were absent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/24\">",
"     24",
"    </a>",
"    ]. Mutations in the catalytic subunit of this enzyme have been detected in a number of affected subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific therapy for GCSynth deficiency, although it would seem prudent to obtain periodic gallbladder ultrasound examinations, since some affected patients have required cholecystectomy for gallstones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glutathione synthetase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutathione synthetase (GSHSynth) deficiency has been incriminated as the cause of chronic hemolytic anemia and jaundice when the deficiency is isolated to RBC. When the deficiency is found in many tissues, it is responsible for a more generalized syndrome characterized by hemolysis, metabolic acidosis, and mental deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first syndrome has been described in several families [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/21,28\">",
"     21,28",
"    </a>",
"    ]. Splenomegaly has been noted in approximately one half of the reported cases. Exposure to oxidant drugs and to fava beans has occasioned temporary acceleration of hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    .) A concurrent deficiency of glutathione-S-transferase in these patients is thought to be caused by the instability of this enzyme in the absence of adequate intracellular concentrations of GSH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more generalized syndrome is characterized by mild hemolytic anemia, metabolic acidosis presenting in the newborn period, and progressive cerebral and cerebellar degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/27,30-32\">",
"     27,30-32",
"    </a>",
"    ]. Acidosis is caused by the accumulation of 5-oxyproline (5-oxoproline, pyroglutamic acid), a metabolic product of gamma-glutamyl-cysteine. The latter dipeptide is produced in large quantities because of the loss of feedback inhibition of gamma-glutamyl-cysteine synthetase by GSH (",
"    <a class=\"graphic graphic_figure graphicRef75361 \" href=\"UTD.htm?4/5/4190\">",
"     figure 1",
"    </a>",
"    ). The disorder may first be detected in newborn metabolic screening programs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder is suspected in patients with hemolytic anemia and markedly reduced red blood cell GSH content. Virtually no GSHSynth activity is detected in homozygous-deficient individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/28\">",
"     28",
"    </a>",
"    ]. Rarely, therapy with vitamin E is effective for the hematologic consequences of GSH deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/34\">",
"     34",
"    </a>",
"    ], although its efficacy has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/32\">",
"     32",
"    </a>",
"    ]. As in patients with glucose-6-phosphate dehydrogenase deficiency, exposure to drugs and chemicals with oxidant potential should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one patient, splenectomy was efficacious in modifying the anemia, although there was a persistent reticulocytosis post-splenectomy. In individuals with increased production of 5'-oxyproline, administration of oral sodium citrate is necessary for control of the resulting acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GLUTATHIONE S-TRANSFERASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutathione S-transferase (GSH-ST) functions to detoxify various xenobiotics by conjugating them with glutathione, and may play a role in detoxifying carcinogens. It may also play a role in the active transport of such conjugates from the red cell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H32#H32\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Detoxification of carcinogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deficiency of GSH-ST has been detected in an adult male with mild hemolytic anemia, splenomegaly, indirect hyperbilirubinemia, and cholelithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5399/abstract/35\">",
"     35",
"    </a>",
"    ]. Absence of other affected family members has prevented further investigation of the relationship between this enzyme deficiency and hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11580465\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red blood cell is protected from oxidant injury via enzymes of the hexose monophosphate (HMP) shunt pathway and those of the glutathione pathways. The most common abnormality in this system is glucose-6-phosphate dehydrogenase deficiency, which can lead to varying degrees of hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the other enzymes in this pathway very rarely are associated with increased red cell destruction (hemolysis). As follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       6-phosphogluconate dehydrogenase (6PGD) deficiency",
"      </strong>",
"      &mdash; Compensated hemolysis with episodic jaundice and possible oxidant sensitivity has been described in combination with partial 6PGD deficiency in two families. (See",
"      <a class=\"local\" href=\"#H2\">",
"       '6-phosphogluconate dehydrogenase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Glutathione",
"      </strong>",
"      <strong>",
"       reductase (GSSG-R) deficiency",
"      </strong>",
"      &mdash; In one family, three hematologically normal siblings with severe GSSG-R deficiency had episodes of hemolysis after the ingestion of fava beans. In an additional family, partial GSSG-R deficiency appeared to alter the clinical manifestation of an unstable hemoglobinopathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glutathione reductase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Glutathione",
"      </strong>",
"      <strong>",
"       peroxidase (GSH-Px) deficiency",
"      </strong>",
"      &mdash; Very rare cases of hemolysis in association with moderate deficiency of erythrocyte GSH-Px activity have been described in adults and children. However, other observations cast serious doubt on a causative relation between GSH-Px deficiency and hemolysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glutathione peroxidase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Defects in",
"      </strong>",
"      <strong>",
"       glutathione",
"      </strong>",
"      <strong>",
"       synthesis",
"      </strong>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Defects in glutathione synthesis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Gamma-glutamyl-cysteine synthetase deficiency",
"      </strong>",
"      &mdash; This is a rare autosomal recessive hemolytic anemia in association with severe neurologic dysfunction (spinocerebellar degeneration) and generalized aminoaciduria.",
"     </li>",
"     <li>",
"      <strong>",
"       Glutathione",
"      </strong>",
"      <strong>",
"       synthetase deficiency",
"      </strong>",
"      &mdash; This deficiency has been associated with chronic hemolytic anemia when isolated to RBC. When the deficiency is found in many tissues, it is associated with hemolysis, metabolic acidosis, and mental deterioration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Glutathione",
"      </strong>",
"      <strong>",
"       S-transferase (GSH-ST) deficiency",
"      </strong>",
"      : GSH-ST deficiency has been detected in an adult male with mild hemolytic anemia, splenomegaly, indirect hyperbilirubinemia, and cholelithiasis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glutathione S-transferase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/1\">",
"      Parr CW, Fitch LI. Inherited quantitative variations of human phosphogluconate dehydrogenase. Ann Hum Genet 1967; 30:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/2\">",
"      Dern RJ, Brewer GJ, Tashian RE, Shows TB. Hereditary variation of erythrocytic 6-phosphogluconate dehydrogenase. J Lab Clin Med 1966; 67:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/3\">",
"      Caprari P, Caforio MP, Cianciulli P, et al. 6-Phosphogluconate dehydrogenase deficiency in an Italian family. Ann Hematol 2001; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/4\">",
"      Vives Corrons JL, Colomer D, Pujades A, et al. Congenital 6-phosphogluconate dehydrogenase (6PGD) deficiency associated with chronic hemolytic anemia in a Spanish family. Am J Hematol 1996; 53:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/5\">",
"      Krauth-Siegel RL, Blatterspiel R, Saleh M, et al. Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain. Eur J Biochem 1982; 121:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/6\">",
"      Cole HS, Lopez R, Epel R, et al. Nutritional deficiencies in institutionalized mentally retarded and physically disabled individuals. Am J Ment Defic 1985; 89:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/7\">",
"      Loos H, Roos D, Weening R, Houwerzijl J. Familial deficiency of glutathione reductase in human blood cells. Blood 1976; 48:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/8\">",
"      Kamerbeek NM, van Zwieten R, de Boer M, et al. Molecular basis of glutathione reductase deficiency in human blood cells. Blood 2007; 109:3560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/9\">",
"      Roos D, Weening RS, Voetman AA, et al. Protection of phagocytic leukocytes by endogenous glutathione: studies in a family with glutathione reductase deficiency. Blood 1979; 53:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/10\">",
"      Pretsch W. Glutathione reductase activity deficiency in homozygous Gr1a1Neu mice does not cause haemolytic anaemia. Genet Res 1999; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/11\">",
"      Mojzikova R, Dolezel P, Pavlicek J, et al. Partial glutathione reductase deficiency as a cause of diverse clinical manifestations in a family with unstable hemoglobin (Hemoglobin Han&aacute;, &beta;63(E7) His-Asn). Blood Cells Mol Dis 2010; 45:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/12\">",
"      Steinberg M, Brauer MJ, Necheles TF. Acute hemolytic anemia associated with erythrocyte glutathione-peroxidase deficiency. Arch Intern Med 1970; 125:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/13\">",
"      Boivin P, et al. Anemie hemolytique avec deficit en glutathion-peroxidase chez un adulte. Enzyme 1969; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/14\">",
"      Nishimura Y, Chida N, Hayashi T, Arakawa T. Homozygous glutathione-peroxidase deficiency of erythrocytes and leukocytes. Tohoku J Exp Med 1972; 108:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/15\">",
"      Glader BE, Conrad ME. Decreased glutathione peroxidase in neonatal erythrocytes: lack of relation to hydrogen peroxide metabolism. Pediatr Res 1972; 6:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/16\">",
"      Whaun JM, Oski FA. Relation of red blood cell glutathione peroxidase to neonatal jaundice. J Pediatr 1970; 76:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/17\">",
"      Gross RT, Bracci R, Rudolph N, et al. Hydrogen peroxide toxicity and detoxification in the erythrocytes of newborn infants. Blood 1967; 29:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/18\">",
"      Beutler E, Matsumoto F. Ethnic variation in red cell glutathione peroxidase activity. Blood 1975; 46:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/19\">",
"      Thomson CD, Robinson MF, Campbell DR, Rea HM. Effect of prolonged supplementation with daily supplements of selenomethionine and sodium selenite on glutathione peroxidase activity in blood of New Zealand residents. Am J Clin Nutr 1982; 36:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/20\">",
"      Thomson CD, Rea HM, Doesburg VM, Robinson MF. Selenium concentrations and glutathione peroxidase activities in whole blood of New Zealand residents. Br J Nutr 1977; 37:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/21\">",
"      Hirono A, Iyori H, Sekine I, et al. Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Blood 1996; 87:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/22\">",
"      Richards F 2nd, Cooper MR, Pearce LA, et al. Familial spinocerebellar degeneration, hemolytic anemia, and glutathione deficiency. Arch Intern Med 1974; 134:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/23\">",
"      Konrad PN, Richards F 2nd, Valentine WN, Paglia DE. -Glutamyl-cysteine synthetase deficiency. A cause of hereditary hemolytic anemia. N Engl J Med 1972; 286:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/24\">",
"      Beutler E, Moroose R, Kramer L, et al. Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia. Blood 1990; 75:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/25\">",
"      Hamilton D, Wu JH, Alaoui-Jamali M, Batist G. A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. Blood 2003; 102:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/26\">",
"      Nj&aring;lsson R. Glutathione synthetase deficiency. Cell Mol Life Sci 2005; 62:1938.",
"     </a>",
"    </li>",
"    <li>",
"     Larsson A, Anderson ME. Glutathione synthetase deficiency and other disorders of the gamma-glutamyl cycle. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw-Hill, New York 2001. p.2205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/28\">",
"      Mohler DN, Majerus PW, Minnich V, et al. Glutathione synthetase deficiency as a cause of hereditary hemolytic disease. N Engl J Med 1970; 283:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/29\">",
"      Beutler E, Gelbart T, Pegelow C. Erythrocyte glutathione synthetase deficiency leads not only to glutathione but also to glutathione-S-transferase deficiency. J Clin Invest 1986; 77:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/30\">",
"      Spielberg SP, Kramer LI, Goodman SI, et al. 5-oxoprolinuria: biochemical observations and case report. J Pediatr 1977; 91:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/31\">",
"      Skullerud K, Marstein S, Schrader H, et al. The cerebral lesions in a patient with generalized glutathione deficiency and pyroglutamic aciduria (5-oxoprolinuria). Acta Neuropathol 1980; 52:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/32\">",
"      Prchal JT, Crist WM, Roper M, Wellner VP. Hemolytic anemia, recurrent metabolic acidosis, and incomplete albinism associated with glutathione synthetase deficiency. Blood 1983; 62:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/33\">",
"      Simon E, Vogel M, Fingerhut R, et al. Diagnosis of glutathione synthetase deficiency in newborn screening. J Inherit Metab Dis 2009; 32 Suppl 1:S269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/34\">",
"      Boxer LA, Oliver JM, Spielberg SP, et al. Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med 1979; 301:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5399/abstract/35\">",
"      Beutler E, Dunning D, Dabe IB, Forman L. Erythrocyte glutathione S-transferase deficiency and hemolytic anemia. Blood 1988; 72:73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7128 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5399=[""].join("\n");
var outline_f5_17_5399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11580465\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      6-PHOSPHOGLUCONATE DEHYDROGENASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUTATHIONE REDUCTASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GLUTATHIONE PEROXIDASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFECTS IN GLUTATHIONE SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gamma-glutamyl-cysteine synthetase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glutathione synthetase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GLUTATHIONE S-TRANSFERASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11580465\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7128|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/5/4190\" title=\"figure 1\">",
"      Glutathione synthesis pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5400="Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics";
var content_f5_17_5400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cephalosporin-allergic patients: Subsequent use of cephalosporins and related antibiotics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5400/contributors\">",
"     Antonino Romano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5400/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5400/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/17/5400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14737087\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporins are commonly-used antibiotics that can cause a variety of hypersensitivity reactions. The reactions can be broadly classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions are reactions that develop within one hour of administration. These are usually type I, IgE-mediated reactions and are characterized by urticaria, angioedema, bronchospasm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Non-immediate reactions are reactions that develop &gt;1 hour of administration, often after several hours or days. Common delayed reactions include maculopapular rashes and urticarial eruptions. Rare types of delayed reactions include serum sickness-like reactions, drug fever, and drug-induced hypersensitivity syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with past reactions to a specific cephalosporin may require subsequent treatment with a different cephalosporin or a related antibiotic, such as a penicillin, carbapenem, or monobactam. Approaches to these different clinical scenarios will be presented here. The clinical manifestations, pathogenesis, and diagnosis of different types of cephalosporin hypersensitivity reactions are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H999258\">",
"    <span class=\"h1\">",
"     PAST IMMEDIATE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with past immediate reactions to cephalosporins who require subsequent use of other cephalosporins or penicillins should be evaluated by an allergy specialist. The purpose of this evaluation, which usually involves skin testing, is to determine what other drugs may be safely administered to that patient. Most patients will be able to tolerate other cephalosporins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    penicillins.",
"   </p>",
"   <p>",
"    Cross-reactivity among cephalosporins and between cephalosporins and penicillins may arise from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitization to structurally similar R1 side chain groups (most common) or R2 side chain groups (",
"      <a class=\"graphic graphic_figure graphicRef69298 \" href=\"UTD.htm?6/26/6573\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/1-11\">",
"       1-11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sensitization to the core beta-lactam ring, contained in both penicillins and cephalosporins, or metabolites of this ring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sensitization to the R1 side chain group of cephalosporins is believed to be important in determining cross-reactivity among cephalosporins, as well as among cephalosporins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (which share side chains with certain cephalosporins) (",
"    <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because of the different possible sensitization patterns, we suggest evaluating patients with immediate cephalosporin reactions with",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    and intradermal skin testing to all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic penicillin reagents:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"       penicilloyl-polylysine",
"      </a>",
"      (PPL), the minor determinant mixture (MDM), and benzylpenicillin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H27040356#H27040356\">",
"       \"Penicillin skin testing\", section on 'Skin testing reagents and concentrations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (to detect patients who are sensitized to side chain groups that are shared by these aminopenicillins and some cephalosporins).",
"     </li>",
"     <li>",
"      The cephalosporin that caused the past reaction.",
"     </li>",
"     <li>",
"      One or more alternative cephalosporins with different R groups from the culprit drug, which the patient could potentially receive instead.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing to cephalosporins and to penicillins is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H206010#H206010\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Skin testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1968768#H1968768\">",
"     \"Allergy to penicillins\", section on 'Penicillin skin testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209406\">",
"    <span class=\"h2\">",
"     Use of other cephalosporins",
"    </span>",
"    &nbsp;&mdash;&nbsp;When approaching a patient with a history of an immediate cephalosporin reaction, the clinician should be mindful of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similarities among side chain groups alone cannot be relied upon to predict cross sensitivity accurately [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/1-4,7,9\">",
"       1-4,7,9",
"      </a>",
"      ]. Rather, these similarities are best used to select structurally different cephalosporins from the one that caused the initial reaction, to which the patient is less likely to react. The evaluation must still include skin testing and, in case of negative results, graded challenge to determine if the selected cephalosporin can be safely administered. Graded challenges typically involve two or three steps. The starting dose is usually",
"      <span class=\"nowrap\">",
"       1/100",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      of the full dose. Tenfold increasing doses are administered every 30 to 60 minutes until the full therapeutic dose is reached. Graded challenges are discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1968789#H1968789\">",
"       \"Allergy to penicillins\", section on 'Graded challenge (test dosing)'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Specifically, we suggest selecting for evaluation a cephalosporin with a different side chain, especially in the R1 position, from the cephalosporin that caused the past reaction. However, a similar side chain should not absolutely exclude a drug from consideration if it is the most appropriate drug for the clinical situation.",
"     </li>",
"     <li>",
"      The results of skin tests (or in vitro tests, where available) for cephalosporin allergy may not translate into clinical cross-reactivity. For ethical reasons, very few studies have confirmed the accuracy of positive testing results by challenging patients with a drug to which they tested positive. Therefore, skin tests need to be followed by graded challenge to determine if the selected cephalosporin is tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the above caveats in mind, there are studies demonstrating the utility of considering side chain groups when selecting an alternative cephalosporin. As examples,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    have similar or identical R1 side chains (containing a methoxyimino group) and cross-reactivity among these drugs is regularly reported (",
"    <a class=\"graphic graphic_figure graphicRef53755 \" href=\"UTD.htm?39/12/40132\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    has a R1 side chain that is slightly different from ceftriaxone, cefotaxime, cefepime, and cefuroxime. The ceftazidime R1 side chain has an alkoxyimino group that has greater steric hindrance than the methoxyimino moiety, and so would not be expected to be recognized by the same IgE molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/5\">",
"     5",
"    </a>",
"    ]. Consistent with this, one study found a significant degree of cross-reactivity between cefotaxime and ceftriaxone (odds ratio=7.0, 95% CI 2 to 24), but not between these two cephalosporins and ceftazidime [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in some studies by the author&rsquo;s group, there were subjects who had experienced immediate hypersensitivity reactions to ceftazidime, as well as to cefotaxime",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ceftriaxone in separate episodes and displayed positive results in allergy tests with the responsible compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Therefore, cross-reactivity among these cephalosporins seems to be possible as well.",
"   </p>",
"   <p>",
"    The following algorithm depicts an approach to identifying a safe alternative cephalosporin in a patient with a past immediate cephalosporin reaction (",
"    <a class=\"graphic graphic_algorithm graphicRef53392 \" href=\"UTD.htm?5/54/5998\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should choose one or more alternative cephalosporins that have different side chains, especially in the R1 position, from the responsible compounds (",
"      <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53755 \" href=\"UTD.htm?39/12/40132\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Skin testing should be performed to the desired cephalosporin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H206010#H206010\">",
"       \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Skin testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the results are positive, then the patient should be assumed to be allergic to the desired cephalosporin and it should only be administered using a desensitization protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the results are negative, then the desired cephalosporin can be administered by graded challenge to confirm that the drug is tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H999698\">",
"    <span class=\"h2\">",
"     Use of the same cephalosporin that caused a previous reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, a patient requires the same cephalosporin to which there is evidence of IgE-mediated allergy. A formal desensitization protocol should be performed in this situation. The procedure described for penicillin desensitization would be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209413\">",
"    <span class=\"h2\">",
"     Use of penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with immediate reactions to cephalosporins, and",
"    <strong>",
"     no",
"    </strong>",
"    history of reacting to penicillins, will tolerate penicillins. However, there are patients who react to both groups of drugs, and there are at least three allergenic determinants that are shared by penicillins and cephalosporins that may be responsible for this cross-reactivity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Side chain groups",
"      </strong>",
"      &mdash; Side chain groups may be the most common source of cross-reactivity between cephalosporins and penicillins. In one study, patients with past reactions to cephalosporins with similar or identical side chains with penicillins demonstrated a threefold increased incidence of positive results in allergy tests with that penicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      has the same side chain as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"       cefadroxil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/22/14693?source=see_link\">",
"       cefprozil",
"      </a>",
"      , and cefatrizine;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      has the same side chain as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"       cefaclor",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      , cephradine, cephaloglycin, and loracarbef (",
"      <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Small moieties",
"      </strong>",
"      &mdash; Small moieties shared by cephalosporins and penicillins can also be allergenically important. In one study, a population of IgE antibodies recognizing a methylene group present in both cephalothin and benzylpenicillin was identified in patient sera [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/10\">",
"       10",
"      </a>",
"      ]. Positive skin tests to both benzylpenicillin and cephalothin have been observed in such patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Beta-lactam ring",
"      </strong>",
"      &mdash; A small percentage of patients with primary cephalosporin reactions may be sensitized to the beta-lactam core that is common to both cephalosporins and penicillins (",
"      <a class=\"graphic graphic_figure graphicRef69298 \" href=\"UTD.htm?6/26/6573\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/3\">",
"       3",
"      </a>",
"      ]. The pathophysiology of penicillin allergy and the role of the beta-lactam ring are reviewed in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1965552#H1965552\">",
"       \"Allergy to penicillins\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, if a patient reacted to a cephalosporin in the past and now requires a penicillin, then penicillin skin testing is indicated to guide management as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef72898 \" href=\"UTD.htm?21/7/21629\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative results on penicillin skin testing indicate that the patient's reaction to the cephalosporin was probably due to a unique cephalosporin determinant. Therefore, the patient is not at increased risk for reacting to a penicillin, provided that penicillin does not share a side chain with the cephalosporin that caused the initial reaction (",
"      <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Positive results on penicillin skin testing indicate that the patient may be reactive to the beta-lactam core, provided that the penicillin and cephalosporin in question do not share similar side chains. The patient may be treated with a non-beta-lactam antibiotic or desensitized to the desired penicillin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"       \"Allergy to penicillins\", section on 'Desensitization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If penicillin skin testing is not available, we would suggest selecting a penicillin that does NOT have a side chain similar to that on the culprit cephalosporin, and skin testing with that penicillin (in its native form) (",
"    <a class=\"graphic graphic_figure graphicRef65497 \" href=\"UTD.htm?12/55/13171\">",
"     figure 2",
"    </a>",
"    ). If negative, we suggest performing a graded challenge to the penicillin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209441\">",
"    <span class=\"h2\">",
"     Use of carbapenems and monobactams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with immediate cephalosporin allergy usually tolerate carbapenems (eg,",
"    <span class=\"nowrap\">",
"     imipenem/cilastin,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    ) and monobactams (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    ). In the largest study available, 98 patients with convincing histories of immediate cephalosporin reactions and positive skin tests to the culprit cephalosporin underwent allergy evaluation and graded challenge with several related medications. Overall, fewer than 5 percent had positive skin tests to carbapenems or monobactams [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"     11",
"    </a>",
"    ]. For ethical reasons, patients with positive skin tests were not challenged to determine if the positive results were true:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carbapenems share a common 4 membered beta-lactam ring with cephalosporins (and penicillins) and hence the potential for allergic cross-reactivity (",
"      <a class=\"graphic graphic_figure graphicRef79230 \" href=\"UTD.htm?22/52/23373\">",
"       figure 4",
"      </a>",
"      ). However, clinical cross-reactivity with cephalosporins appears to be rare. In the study mentioned above, only",
"      <span class=\"nowrap\">",
"       1/98",
"      </span>",
"      subjects was skin-test positive to both cephalosporins and carbapenems (both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      and",
"      <span class=\"nowrap\">",
"       imipenem/cilastatin),",
"      </span>",
"      and this patient also tested positive to penicillin reagents [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"       11",
"      </a>",
"      ]. In the 97 subjects with negative skin tests to carbapenems, graded challenges were performed with meropenem and",
"      <span class=\"nowrap\">",
"       imipenem/cilastin",
"      </span>",
"      and were well tolerated by 96 patients. The one remaining subject developed a mild urticarial eruption 30 minutes after the full dose of",
"      <span class=\"nowrap\">",
"       imipenem/cilastatin.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      author&rsquo;s recommended approach to patients with a history of an immediate reaction to a cephalosporin, who now require a carbapenem, is to obtain an allergy consultation and perform skin testing with the carbapenem in question. The concentrations used in the study above were meropenem at 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       imipenem/cilastin",
"      </span>",
"      at 0.5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      for each component [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If skin tests are negative, the carbapenem can be given by graded challenge (eg,",
"      <span class=\"nowrap\">",
"       1/100,",
"      </span>",
"      then",
"      <span class=\"nowrap\">",
"       1/10,",
"      </span>",
"      then full dose, each separated by 30 to 60 minutes of observation)",
"     </li>",
"     <li>",
"      If skin tests are positive, the carbapenem should be given",
"      <strong>",
"       only",
"      </strong>",
"      if there is no alternative drug and then, using a desensitization protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       Aztreonam",
"      </a>",
"      is the only monobactam clinically available. Although it contains a monocyclic beta-lactam core, it does not pose a risk to patients allergic to penicillin. However, aztreonam shares a side chain structure with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , and clinical cross-reactivity has been reported between aztreonam and ceftazidime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Despite the similarity in side chain groups, not all ceftazidime-allergic patients react to aztreonam [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11,14\">",
"       11,14",
"      </a>",
"      ], and not all aztreonam-allergic patients react to ceftazidime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/15\">",
"       15",
"      </a>",
"      ]. Therefore, we suggest that patients who experienced immediate reactions to ceftazidime in the past and now require aztreonam be skin tested to aztreonam (2",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      skin test results are negative, the patient can receive the drug using a graded challenge.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      skin tests to aztreonam are positive and the patient has a particular need for this drug, then it should be administered using a rapid desensitization protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If an allergy evaluation is not possible, then we suggest informing the patient that the risk of reacting to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      is estimated at less than 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"       11",
"      </a>",
"      ] and then performing a graded challenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998970\">",
"    <span class=\"h1\">",
"     PAST NON-IMMEDIATE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management options for patients with past non-immediate reactions to cephalosporins depend upon the specific type of reaction that occurred. Structural similarities among drugs might predict the recurrence of some non-immediate reactions. Cross-reactivity between aminopenicillins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and bacampicillin) and aminocephalosporins, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998977\">",
"    <span class=\"h2\">",
"     Past maculopapular rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of this common type of non-immediate reaction does not necessitate future avoidance of the culprit suspected medication in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/17\">",
"     17",
"    </a>",
"    ]. These reactions are not accompanied by fever, blistering of the skin or mucous membranes, or systemic symptoms. The presence of fever, mucosal involvement, or systemic symptoms should be interpreted as a more severe type of drug reaction and the culprit cephalosporin should not be given again.",
"   </p>",
"   <p>",
"    It is the author&rsquo;s approach to perform patch testing, delayed-reading intradermal tests, and in patients with negative results, challenges with the suspected drugs. This evaluation is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H208530#H208530\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Evaluation of non-immediate reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the author&rsquo;s center of 105 children with delayed reactions to cephalosporins, all had negative reactions to patch testing and delayed readings of intradermal testing, and just one had positive skin test results for IgE-mediated penicillin allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/18\">",
"       18",
"      </a>",
"      ]. The 104 children with negative tests were offered challenge with the cephalosporin to which they initially reacted. Of the 95 patients who accepted challenge, all tolerated the drug. One patient developed hives to a suspension of the drug, but tolerated it in capsules, indicating that the reaction was due to an excipient [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/18\">",
"       18",
"      </a>",
"      ]. In another study of 105 adults with non-immediate reactions, only five patients demonstrated positive responses to delayed-reading intradermal tests with the responsible cephalosporins, of whom three were also patch-test positive [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study by a different group, 12 (4.1 percent) of 290 patients with cutaneous adverse reactions to cephalosporins displayed positive responses to patch tests with the responsible cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/19\">",
"       19",
"      </a>",
"      ]. Only one of the 75 patients with cutaneous eruptions associated with cephalosporins and negative results in patch tests reacted to the provocation tests with the suspected cephalosporins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"       cefadroxil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the most common approach is simply to use a different cephalosporin in the future. If the culprit cephalosporin is specifically required, it can be administered using a graded challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1471624\">",
"    <span class=\"h2\">",
"     Delayed onset urticaria/angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of non-immediate reaction to cephalosporins is managed similarly to maculopapular rash, although immediate-type skin testing should be performed to exclude IgE sensitization. The evaluation of delayed onset",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H208530#H208530\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Evaluation of non-immediate reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H998984\">",
"    <span class=\"h2\">",
"     Past serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/11/27829?source=see_link\">",
"     Cefaclor",
"    </a>",
"    is the cephalosporin most commonly implicated in serum sickness-like reactions, particularly in children. These patients can receive other cephalosporins normally in the future, including the structurally similar agent loracarbef [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5400/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231606\">",
"    <span class=\"h1\">",
"     USE OF CEPHALOSPORINS IN PATIENTS ALLERGIC TO PENICILLINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients reporting a penicillin allergy, 1 to 11 percent can be expected to react to a cephalosporin if no objective diagnostic testing is performed. Aspects of the history, including the clinical features and severity of the penicillin reaction and the time elapsed since the reaction, are important in estimating an individual's risk. An approach to treating penicillin-allergic patients with cephalosporins, with and without additional testing, is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link&amp;anchor=H4#H4\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\", section on 'Cephalosporins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14737187\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1471568\">",
"    <span class=\"h2\">",
"     Immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate reactions are reactions that develop within one hour of administration. These are usually type I, IgE-mediated reactions and are characterized by urticaria, angioedema, bronchospasm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H202204#H202204\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Immediate reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with past immediate reactions to a cephalosporin can often be safely treated with other beta-lactam drugs, including structurally dissimilar cephalosporins, penicillins, carbapenems, and monobactams. However, this requires an understanding of what is known about cross-reactivity patterns among cephalosporins and related drugs. (See",
"      <a class=\"local\" href=\"#H14737087\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cross-reactivity among cephalosporins, and between cephalosporins and penicillins, most commonly arises from structural similarities in side chain groups or rarely from sensitization to the core beta-lactam ring (present both penicillins and cephalosporins) or metabolites of this ring (",
"      <a class=\"graphic graphic_figure graphicRef69298 \" href=\"UTD.htm?6/26/6573\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H999258\">",
"       'Past immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with past immediate reactions to cephalosporins who require subsequent use of related antibiotics should be evaluated by an allergy specialist when possible. The purpose of this evaluation is to determine what other drugs may be safely administered to that patient. An algorithm depicts the approach to identifying a safe alternative cephalosporin in a patient with a past immediate cephalosporin reaction (",
"      <a class=\"graphic graphic_algorithm graphicRef53392 \" href=\"UTD.htm?5/54/5998\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H209406\">",
"       'Use of other cephalosporins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with immediate reactions to cephalosporins, and",
"      <strong>",
"       no",
"      </strong>",
"      history of reacting to penicillins, will tolerate penicillins. If a patient reacted to a cephalosporin in the past and now requires a penicillin, then penicillin skin testing is indicated to guide management as shown (",
"      <a class=\"graphic graphic_algorithm graphicRef72898 \" href=\"UTD.htm?21/7/21629\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H209413\">",
"       'Use of penicillins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with immediate cephalosporin allergy usually tolerate carbapenems (eg,",
"      <span class=\"nowrap\">",
"       imipenem/cilastin,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"       doripenem",
"      </a>",
"      ). An approach to evaluating such patients, which involves carbapenem skin testing, is described. (See",
"      <a class=\"local\" href=\"#H209441\">",
"       'Use of carbapenems and monobactams'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       Aztreonam",
"      </a>",
"      is the only monobactam currently available for clinical use. There is no evidence of immunologic cross-reactivity between the core cephalosporin structure and monobactams, so most cephalosporin-allergic patients may receive aztreonam normally. An exception is the patient with a past immediate reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , because aztreonam and ceftazidime share an identical side chain, and cross-reactivity between the two drugs is reported. An approach to evaluating such patients, which involves aztreonam skin testing, is described. (See",
"      <a class=\"local\" href=\"#H209441\">",
"       'Use of carbapenems and monobactams'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1471577\">",
"    <span class=\"h2\">",
"     Non-immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-immediate reactions are reactions that develop &gt;1 hour after administration, and include uncomplicated maculopapular rashes, delayed-onset",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    and serum sickness. These reactions are",
"    <strong>",
"     not",
"    </strong>",
"    accompanied by fever, blistering of the skin or mucous membranes, or systemic symptoms. The presence of fever, mucosal involvement, or systemic symptoms should be interpreted as a more severe type of drug reaction and the culprit cephalosporin should not be given again. (See",
"    <a class=\"local\" href=\"#H998970\">",
"     'Past non-immediate reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structural similarities among drugs might predict the recurrence of non-immediate reactions. Cross-reactivity between aminopenicillins and aminocephalosporins has been described. Management options depend upon the type of reaction that occurred. Patients can safely receive other cephalosporins, and in many cases, the same cephalosporin again in the future. (See",
"      <a class=\"local\" href=\"#H998970\">",
"       'Past non-immediate reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/1\">",
"      Romano A, Quaratino D, Aimone-Gastin I, et al. Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens. Int J Immunopathol Pharmacol 1997; 10:Suppl 2:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/2\">",
"      Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000; 106:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/3\">",
"      Romano A, Gu&eacute;ant-Rodriguez RM, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005; 35:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/4\">",
"      Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/5\">",
"      Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships. Ann Pharmacother 2007; 41:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/6\">",
"      Varela Losada S, Gonz&aacute;lez de la Cuesta C, Alvarez-Eire MG, Gonz&aacute;lez Gonz&aacute;lez C. Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime. J Investig Allergol Clin Immunol 2009; 19:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/7\">",
"      Nagakura N, Shimizu T, Masuzawa T, Yanagihara Y. Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams. Int Arch Allergy Appl Immunol 1990; 93:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/8\">",
"      Perez-Inestrosa E, Suau R, Monta&ntilde;ez MI, et al. Cephalosporin chemical reactivity and its immunological implications. Curr Opin Allergy Clin Immunol 2005; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/9\">",
"      Gu&eacute;ant JL, Gu&eacute;ant-Rodriguez RM, Viola M, et al. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12:3335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/10\">",
"      Zhao Z, Baldo BA, Rimmer J. beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. Clin Exp Allergy 2002; 32:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/11\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/12\">",
"      P&eacute;rez Pimiento A, G&oacute;mez Mart&iacute;nez M, M&iacute;nguez Mena A, et al. Aztreonam and ceftazidime: evidence of in vivo cross allergenicity. Allergy 1998; 53:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/13\">",
"      Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am J Med 1990; 88:12S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/14\">",
"      Moss RB. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. J Allergy Clin Immunol 1991; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/15\">",
"      Iglesias Cadarso A, S&aacute;ez Jim&eacute;nez SA, Vidal Pan C, Rodriguez Mosquera M. Aztreonam-induced anaphylaxis. Lancet 1990; 336:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/16\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 2012; 129:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/17\">",
"      Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/18\">",
"      Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/19\">",
"      Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5400/abstract/20\">",
"      Kearns GL, Wheeler JG, Rieder MJ, Reid J. Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clin Pharmacol Ther 1998; 63:686.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13536 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5400=[""].join("\n");
var outline_f5_17_5400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14737187\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14737087\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H999258\">",
"      PAST IMMEDIATE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209406\">",
"      Use of other cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H999698\">",
"      Use of the same cephalosporin that caused a previous reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209413\">",
"      Use of penicillins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209441\">",
"      Use of carbapenems and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H998970\">",
"      PAST NON-IMMEDIATE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H998977\">",
"      Past maculopapular rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1471624\">",
"      Delayed onset urticaria/angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H998984\">",
"      Past serum sickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231606\">",
"      USE OF CEPHALOSPORINS IN PATIENTS ALLERGIC TO PENICILLINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14737187\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1471568\">",
"      Immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1471577\">",
"      Non-immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13536|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/54/5998\" title=\"algorithm 1\">",
"      Administering cephalosporins to a historically allergic patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/7/21629\" title=\"algorithm 2\">",
"      Admin PCN to patient with immediate rxn ceph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13536|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/26/6573\" title=\"figure 1\">",
"      Comparison of cephalosporin and penicillin structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/55/13171\" title=\"figure 2\">",
"      Penicillins and cephalosporins - common side chains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/12/40132\" title=\"figure 3\">",
"      Cephalosporin side chains - common moeities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23373\" title=\"figure 4\">",
"      Beta-lactam drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=related_link\">",
"      Cephalosporin allergy: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5401="Transplant glomerulopathy Light";
var content_f5_17_5401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transplant glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of transplant glomerulopathy shows a membranoproliferative pattern with capillary wall thickening and a double-contour appearance due to mesangial interposition (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1C+8maG3hV8yzNhyOB+NLDYGK4hS0AVm+8c9ua6DU7Ow1LSWu4mWMKCwcetYmnC9uEVoI2YgbRIRjOfSqjO8dD0ozb20OTkvLiLWrm1mJxuIAzU0zxWYaScgAjDZq7q2lPHqCtcoElxuLbuSK4nxsl6+qp5UhW1jT7o/iz61304xqNJM6MRVjGClE6J5rbU4GuLOXdd22CoHcDt71p6dcxwweYwzDcElWPRWxyK53wLZPPfLtzFCeWJ6E46fpW74g019KDNbyCW3lJJi7fh6VM1Hm9ncuhU9vBQn8iadDdho5jiNlzjPWsS+0do3WSEDJJwPQVr6e0MTxLeFmjdf3TE4yP7prnfFOtyQXslrAQhAGST7/AMqdJS5uVBKtLCleYvDJ5U+RjpzVjTojez/u8lf7xPSqOmvLrenzs+GaGXy1b1GBXU+H7EwWkhXkjBPHb0rWcuReZ3fXIzoqa3NKLMUeFO1uAMnmuV1xS/iCzhZgVL54rqpR5ZwzdBkg9RXNaJbnV/FpkiXdFE3J6+3WsaWl5eRlhXZub6I9i8M2i2unpgZ8z5qo/EvQW8ReEbyxTG/AlQHuVOcV0drCIoI0H8KhRzVbXLlLPSLy5kOFjiJ/SvHjUarKcd7nhS/eSfmfNvgfRnsI72Rk2mUiMn2Bz+HP8q760tVkjBn5K9CRWTb+a7NE21Uxkknpntn1qO91grEIY2Kx9B7gV70+apK59Dh8M401Th0Na6uLW3gkkUebMowinoD0ya5uTWpQqI4AZVxlRjJ9T61Rvr7ZDGzKczE7VB+Zqg+yCC2e51aOdZG/494V5L+pNXGmludUnRwseaqJrN/MmnTSpvZQdvHTJ6Cs/QNKvNa1AW9plyhxMx6IT2zXTR2baloCafc25xLKskSoNpLA+tdx4anh8KWgt30prbJDO453kdyfxpVK3JBqKuzzKuLxFaanQ0j08zJg+FBiRZZ5jx2Fb1v8KdLe0Ilkk88jG8Hoa7PTtf0/UFVIrhVc/wAJ61orJGzhEcEeleRUxmI6uxyVcdinpJtHzR4l+FPijT7uQaUourfqGVsHGe+aseHfh/41lUyybbWPHyhm5PPfmvpUAEkg5Pr6UbQV2nqPSr/tSo42aVzGnjK9N3U389T5w1fQ/F+hWjzzQmdFbHyDccDvXMweMNRhk33FjONvRmiI5H4V9aPGrqoYAgeo61Tm0ixlzvtYSPdBzVwzKO043OiWaVn0X3HzXofi681a+FvDCWuGOQMYNWdb8I6jqkzz3WnT5chmw5+YivdrrStF06+guRaW0Uu7aGwBj6CtopE67lCEEDBxVyzBRacI2uEsa5wSqU0z5w0fSYdBlXbp8sPmDBfburTn8RWi7khuZWQjDBjkE969o8R6DFq2kXNomIpZEIV1HKnHX9a8Om+Ht3bXZghgkkC8E45IzW9DEU66bm7MFj4Q+Gn9wlrrWlT7Ujk+dDncBVHxRof9vvHPZ3wMW0R+UBg8d67zwB8MorH7ZcalH/rkCLE3OBUniH4b/ZLSS70W4MUsYLeWTwe9V9apRqcsZG0cRRxUVGto/wADi9A02LRbPynfLjBY+vbFdfp9wsqmIM4Y89f8+v61xpv5UVoNShdJM/ex3Fa2n3a5RkbJ/vg1dSLlqzuqYa0LRWx0wnuPMYI4RRxhTwKsWchkiG7crSjuO1cze37BHOAshbnB+U1oaQ0/2UzzccfL6dun8655U7RueZJOMuVo6q2VIlYgZYcAg+nNc94w1e5so5PsEixytydw681V8YeMH8O2lvDYReZdTL5hdhkYrnbbW77VHtm1yCOWK4k2MqrtK5HB/WlSoS+OS0OKpVTfKty54C1nUh4ktk1GZJbS6PlkE9Seh5ruPGmmLbOk1uSM/Mw7daztO8O6Zp9y0/mkzRMJIhnOCBwKL3xEtzeQ2c0RkRzvZj2A6VM5c9VSprQKfNB+8U7q5by1nOQUGAMc1jxx6jdyM3mlcjjd0Wuh1mCEIHDBiMnH+faqtru+zb0/ixtGOQK0g1bQ9Wjy8nNYW20S18kvezPcP2DHgfhVHW5ILaJAoCpjjHp3qS+u0tI0SWYo+eQvPFc5dLdatOqLG0dsTgFvvNVwi27t6HRRhrzyegyBbjVrgiJmSBeDg9a17LSLRlkadXZl4VvepLO2ESRW8ZCryOnJIqa+uFsrK5k2cKN4XtnFVKTbtEivinq46IqSae0eNruuPX/PrUtrqsmmT/Zr0iSNuME5OK4y317UZb21kDq6u2XHUcdhXS6xp73kqSA4z+anFVKFrKZy08b7XRq6L88SWd6r2xzZTkEHspNbrS6HaHy76eUzdTg1zmiESxz6dcnJB+QmsjUY7gXTrMu9hxuJ6gVk6fO7NmuJozn8Gr/Ndz0y+vx/ZsFjZKWtlG6ZiMZwfuiuptdWsFt4VjYRhhhQRjpWPpC20pX7YM7Y/MUL0Ap+nWtlqFyzIhECOVQH9a82fK1Z9Dz6kY7M5/xP59zdFmk3DG0EDPGeBWZLcwXwEVxGpMaY5HUiu71XR1W3m2sqRbc/N656V5lqltOt1JJEm2IHAK9xXZh5Kasuh1YZQqx5DSEsdrC77dkajp0qCbxHb6pbR20iuityjHgg8c4qmsq39g1vJIIpOeScbqrWOkJbXC+Y2/BDKmf0rdQild7iqRqU6iUVsdJYyQ3EMelanEFmBIjlXo3cfjXnnjDQ7q01mS7ljknjC+XnPB9Ca72/tWubcYwkw+dCD0Yc1NeX1te+FtS1C4C/6Pbu8in+FkUk0qdX2T5unU1qRjVh7+35eZieCdOhtNFkiuWCTzM0gAOdp7D8q6KydrdWXGd3Bz0xXyrpvi+TXNN07Q9TvjZp5mby9klI8yJeVUHsx6E+wPc17vbatearpqHTZYrmzb5RPG4dWxxjIqf4zbTFhqMKqtTemm/+Rp+IdVCL9ntjuuHOAF/Ku7+Gvhk6XYi4uf8Aj5k+Y57Vyngnw6i6hFdXzb3Vg2evP1r1bUdV0/RbYz6hcxW8K8Zc4rnxdSyVKn1FjaqpR9jT+bL4IXcM8Hoa8++Jms+ZCunwsCm8NMR6D+H86pa78QheOsfh9SYf4p2GN30FcVJcyzXHmXYPl5LEt/E3NLC4SUXzzFgsDJtVJ/Ih1G8aCFVj5yfmya5zUbzMYyxV8EcVPq1ws6Lh8EE7hn34rO0qwuNc1eGxtdpkk42166Sirs+khy04c0tEjW8C2z6p4gg81DMhRggPbtmverbwdpx+ySXKebLGmPm6VS8MeArHRJorxmZ7tV+ig49K7AShY8kHgV4+LxXtJfunofJYvEyxEm29P6sed3dqo8exwRAIilQu0dOM1vasvmTSQXSqyg5xjr71538WPFtv4O1u31WRTNcMQLe0T7879gPbkZP/ANYHmfAXiO/utVvvEHii9ml1fUyE+zo5W2s4RyqIueo7t/8AXLXyTnyuPY0lJc0Irt9x2es6c2nkXNo5C5JBHQH/AArkItd1y1v47y3vJJQ0oWSPPA/DtXq1+LebSJGWVDE0ef8ADFeQ3mtroltfQJbxyTzMDE/cfX8q68PL2kWmrs2qxlXp3vbl/I9Un8aSWcKh4t8rYCrnnJ56UQ+K9XKqxs2GRyNnWvIvAXidZPFsA1VknAySwzhOK+j9IW1e0Royknqw5zXLiacMPo43MnOjGCko81+pyUXxAEUoXULVoge4BH8617/xdaQWccyDMbgFSSOa1tZ0fT7+zljvIIyhBO4jkV4DpMzm7lhld5LSCUqr5yAM8Gs6FGjXTaVrGmHoUcVdpWsdTf6teavK08+4xhjsXpxWl4e1+4srm3gu5Ga3ZwOe1WbDTYbpVZG8yNhxt61j+L1gsDbR2uWn3ghAck4710+5P93Y6/3c/wB0keuLcRCBpjKqp3YnAArz/UviEy3k6abYmS2jcp9ok6MfYVmaPZ3niHS0u7y+kWGQEiJOMYJ4NS63ZwxaSkFtDiMHGc9f8e9c1PDU4y5Zas46WFpRnyzd2bdh4z+2AQrHiVjgN2H1rpLC1LhmuZfMDDOCcjmvH4ruLTo95BMzHCAfqa7bwnrFzcQMTG+yNtpJ+hqq+GUI3hoZ4mnCEnCkbeu+G7G/UExKpPAyOTXD6h8OjJAZ9JnMcw48snj/AD/9en+LfiGIpfItgY3ViAGHXFdX4d1/TbyCDfdwx3BUZhLjrilH6xQgpEUsTVoq0X8jyK7hv9NmMWpQNvX+NOnpVzTdXnjXy0KTW+MkE816z4g06HVFXao2MCGfHbtXhvi61n0/U5XskljcHIRVJzz2xXbQqxxCs1qd8cfSqR/fRsdVdLp+vwRJLIYLiFSqE9vY0aZpkseoW0urTrLHAQUEa4DdgDXH2WrTowh1C0kidxgO0ZA+vtVjXrvUrC0im0uV5YXJLKo3FfTitPZSXupnPXwdGzrReh6dqEtvPdbrcHYoyeO5zWFNoUYvxOk5IU4AHp6VyHw/8Ra9qmuGwlsy6PH80zRldldlcPdxNm4JtzG2Gbbj8q53TlSly3MIUo1tYvQdrEqmVUj/ANa20BV9MVBe3v8AZNiqDDO3RF78/wBKqi+s7V3Z1d3X5vTP41Aqte3Rup9pweEU5Ce1Uo6Wex6UaappKey/ESw06W8la5vsbwCwU9BzU1xdGH5oSFwcrx3FTPIVR1J/dg5UZzism7+afcVwGGBjuapLmeo4N1Z3lsSx3uCpbqCST7+tSLNDeW8ltcDCyDBwcGqUds7TCIjk9D14qS6tzbHOf4tvvmraRpOjTl7rIrHwza2NzHJ9oaUK25I26Z/yK3VU5G1hu6DPesOKZxMjMxO08ZPSta2mLhS5wVJPFTPmerZyPCqivdK+sW5iEc8J2zoeTimySvKEeZPMYqPmwOf1qXXJytkoBdguPlPXJ6n+VCpmKLd12CiPw3Z1Un7iua8msQ6dqaQhz5ZwsjDp/wDqrs4NQ02y0hZoZYZJs9Izkk5rzDUE0uK9e03u1wWwMDIq74buRo2p7Lu3DrKoHzAZXNc1SgpK6/4c5q2GjOKavf8AM7W6vptYMSTRNb20mCrE/eqpfW/kzpFEEl3HKAfwjPJPtWjrLpLbWrooEKEYKjhQOgp2jo0UcsoRWcggD+6v/wCuueMuWN0cMW0ro5PVvC15LepJEYokdsbR0WsTWNGu9LjNwzCSMHaXU8d69C1nVFWJVCBQuMjPOcda5DWNaZrNrRSSpJbkDqa66NSpK1z08LVrTaTWhBo98JEEb8MPWuJ+Kl42j+GNdkgLLFd2hiYDuXYJ/Jj+FdVo28yPK2OwPHT6Vb1iQQ3OnzrkSLMFAI7HrWjWriupU4rnlTXVHiHgH4Tm2SLWfG0RS08sSxWAJDk9vN/ujGDtHPPOMEH1238UWqwfY4rJbaGFQqmMAIFHAAHt7Vva3NA9qLORS7OSXycYGeAPyrBXwylzdwzedmMoUMQHAzRRhTjH3jgVGdC0qa0/Myrrxlq9vP8AZ9OAjRidrFMn6j8aLHS7rxKiXPiJp8l/uMeCB04rpNQGlaXfxWgMKXDp8oxyB61oxzpLbuIxwuD0xzWjmkk4K3mbxptvmm7+Rmiwt7FQIz+7QYCDoMVha/J5kkgRgkYHT0Pc10N7dJBC7uyrJ/CP89q5LTNPv/FOom2sYwecM7dFHenDT3pHq4eKgnUnsjC02wutSuxb2kZclvvdB+Jr2z4b+AX8O/8AEyuJVk1B+Bt+6gNZ1n4TlttmmabNDb26MPtV65+dzjlVH1r0q3u7PS9PSITiQRr1LbmNceLxLkuSHU8jMce8S+Sn8K/EmvdStLC0jl1CZIInlSEMxwDI7BFX6lmArmviL4603wJo32q7DXV7cHyrGxh5lupT0VR1xkjJxxkdSQD4L+1p4+juv7I8OaQ7xGKT7fcsp2kN0jHH1Zv++ah+DPjPT/FHi641nxQ17qHjJx5VqTalrazh6YiC52E85ZgOvXlifPVF7M8hay5Tu/DXw41bW5p/FXjV47jxHcpiG2BzFYREZESDpuwTk+565Jbkb/w1NaXMtuD+4LZAY4KV7zpN0nlNG0hL+nWuF+IenSySvNaQlvM6+v8A9avTwdWUJOHQ9KhQhUfsqnyZnwXSWfhyK3SYySJHh887Rj1rlD4avNbha8bMSsSY3Y4zVqz0bUDKkM7BIXx5iqc4HvXeeMdcs7bw9aW9ohSVVCeWOQpHBrp5nTklDW56UoRhH2NON7nkMfhu80oW0cogjIkEgZeZHyMYJr1rwr4X1b7IsiXEsTMAwIkOBmq/gDw5HrN2b/UsuiqNmTzng8V7FahY4FQAKQMVy43GNe6tzhrzhg06NL5nmmu+HfFS2Y261JLFj505Bx9a5aNBo0DWEsKrHKwDNjJ4/wD117pLJkZI4HevLfiCba5LvAAQxxuXpkcZFZ4Wu5+5JF4Gu6suSS+4zbS+a1iYWpcDAPB7Vq2kll4f8P3Gv6sPNu5N0cKNzn/PNc74LhfULyOGbdt6MO+Aefp0rR+K2nDU9X07RdKYrII8yoRlUXoM/lXRNJ1FTfz9EXjJP+HT3ZU+GWotqJ1AurQaezl40XjBPYfWuh8VCe0s088qp+8q/wAWO2fetPwzYWWk2NlYiNP3AyzqMbm9T+Ncz8QtXtB4hiW4f90qZKqc5YDoKyUvaV7xWhnTm/aXlsl+RzWraJqhnjcRTG3lRWjlQZKHvXoGhwy6T4OvJ7hw02zLfU1f8Ga/bahpDWrRSGa2ABQryQehqr4tQt4cvlZCiyLtVSeh9f50p1ZVGqclazOOHv1HLuzzjW/B+t3tm+riDfbiNmVFPzY7H8K86gZkt7ea3klS7gYBl3fMWya+iJ/iRp1lpsUb27O6RLuA6AdK4DwxpularqM+tyQnyjctIkAHykZ4rtoYiai/axsuhNSjKq5WVnE9t06QHQbVgPmaFGwevIGf51zGu6vZadfyG4tfMdUC7eOPc03xJ4idJEtLABHRAWOPu5xgflWDo+lXmuawz3LkoOWYjP8AnrXmUqKinOeiN6GGSXtKuiLd3rvhvVrdIbyMWzMSuW9fwrldQ0LUdLgur22hmaBeUHqPp+Ncl8RdMudE12+tM5DodrHsCNwI9692+Gmpf2/8PdKluR5k3kiOUOO44/liuqq/q1NVIaxZk8RKjNqlseUaN4xCTm1l3Ws5xkjjg+tdVKF/s7ElwZd+dvfHpV74j+AotQ0yW602PbcINwVeDx71xHgTVWVJ7PUIneS0PCOcbiKtOFWHtKfzR0Yesqzs17y/EZLbPcxSnPzBsZ+napNFjms7lI3jfyyhBzxnjrV7wtH9vhMtxhUaZ3bJHr0rf1AxNF5joPIjGwKeDxzmqnUs+VmuJV6130MC5m5KoucAAk/pToIJTCssowByvHWpPDtpJf3TvEm6IHcR7V0msoi2XkLCd5AK8cAVMpqL5UdPNGk1BHISSHzQyKxx0PpUM0rXBQO2D0yegrdtlRAXeJht4YH6Hp+lYswi+1SJG+5SSQcVcZJs2hPndmi/DpsVxEI1kCyKMlj0Off0qjBMiTrCsis2edrA1la1dSx2kcSyOivKBIRk8Dvn0qj4Ts7sagn2xMsGbcVPAQ4wa0UPdbbOGriXTq+ykro6rVGGyJFYMxOAAtW4Y444wlyh3rx8uOlU4YlvLl3YEQq21RnkmqGqeIbC2vpYJL6MyRna2X5yOKys2uVG8moRUW7CaSy3OqJNIql5JMjPYdK7HVbTdHLLgbl+ZWHr6Cud8QfZba5ECo8dzE2Y3AxwB/jWpY3pn04SS7j8uCep69ambbtNCxV5xVSGi2KWlajdhpUuJneFmDHcTjI6Aelb9xrv2eCJwxVs4Ow8n1+lY+sRKlhD5BGB94AY5rLs4JLqQKSfLB5J6UckZ+8Rh8ND2V5HaSyJf30cT/KXyxLfyzXI66h/ti6VU2YfAXNdFC0kEiTtuMedqt/e9RVS4sUu9a3M5jjc8tjJGBnP9Kim+R67WFhqipyb6EGn3VnpsYtp5M3J7Hp9c1Ut0Gpa3vkm/wBFgYMO+TxWB4iiuodRdTG7xkEIQnbOAc+1V5ri9sNAWaFHk3TsGCKc49K6VS6p6s56WJb9pOXQ7/W44jcecBtwAAwPA+lN0o72dS5CxpuUZ+92xUPgWO4fw7qk2tfNEIysIYfdb09ar6Q8gtpBncBhdoxmsbbx7HThqntqOnQ5uLTtXuviOt+9ttslUhnk6MmMcV2f2mPTYrgzRDeY8IPr0pst/DZWYeViZSmPpXD6trNxql4UhIWMfePbHTmtLOq7taI2wmEet9nqMvJ21PUYLdCSWcbiDwR3rvNOv/7Nga20eJI0UcyH+I9+a5rw94WvrkefDDNsbjzSuCw9s9q6uWx+wQBJQ6kLnDDpmio4t8p0YidOo1BO9uhDZwXepTENOMN8wI4xzSXWnX+mMZpmkSMk4ZwdpxVDRdSksvEVsEXzI/NVe3zZPSvYNe8i50K9Fwu1BEzYIxjANc9Wq6U1G2jOHEVXRmo20Z8tax8MV1XxJNruszvqf26Qu0EeY1hX+AZBy3AAyMfSvoX4eQabp+gx6dp1ha2McYy6Qxqm4+px1PvXA6Qs2q2tnaCSWC12fvJVHOAec1oXNtbWjO+hXd0ZoTjaW3F/WlVoxkuTZ/1uczwMVNq+/wDWp6LDDbQzu0cSgE84/pWL40v4baAlthBBHvk1P4IvP7bsZPMYq0LDIA5/OvJ/ilqd3a+NxpbSk2oQSRl+ARj2rGhRc63I3qjOCjTqtVXaxrah4lsLTToEUh7gj5sKAB7fjXGapfz3dyry48oKMBe3P869G8N6LoOv6RBcxxATL8rcg5P0rI8d+GZLV7RI4wkcpKqxGMHriu6lUgp8nU9bDV6F+WO77nffDy7iutL/AHQjV0IVhnnoOa0fFmsx6baqonAlJ6K3Irw63tfEGlypHatKPPPybCQTk9K66LwWyWc15rGpbrqONpZI95LA4+7/AErnnhoKpzyloznr4SlGrzyno+hYv/H8l5/osLeUnCknq341TRptUmS0s4hJJIcgdce9cJZR/aGRovmwWbaT2FejeEdP1lbea9stsSopHK5Le2fyronThRj7uh11KVPDQvCy9S/aRjwjaSkRiXVCBGnOQSx7/jXVeHvDcK6eby8mNzqN4BLNcE85I4A9APSuKtorq+1R1uizTbxgMMc9a6S3vrq2t2gSVkAHIBGVNcdeMmvdevU82vSk17stWJfXdpp09xbSTF5YsFccDn1rxbWJrm71qea62sAzKjNwoJ/+sa9STw/earNLLbqzIcYkb/PNIngiQ3MRk8sRBiW3jOG244/IVvRqU6N7vUyxNo0vZwd27XJvhfYT29zKZCJYgn3hwOcfnVz4g65b6fZS2w8tvM4IJ+6TXSXElr4c0ldvB2hF/wBtsV83+Lb/AFLXtd1FnyHhm+4CB9MDv0rPD0/rVV1HojlpNUl7Sa0WxDq4FyzQTStEApxh8YGc8+1dJ8O9Xt9MuEgdxLb+YGUZ4rznxBBJc3MN2inyjGFbHO1sYwa6PwNB5OtWfmKWDspMYPTC8V6lWC9m0z1KFVYipK0LJrVnrnil0tr+e8tSHWUK7AYwhxTfBXj2wRHgvswuT8rlePxxXKeOXbw9Mwa9/d3KEbRyVB5x/OuF0i7S+b93FLEu/Ypk78Z6dq44YaNWlaQqbo1Kap1XZvbueweP7Kw1ryrosksrL1HO0ds1l/CbXJdI1e80q8UraykPH/s9q6D4e6FDcaZ9ovCZVY7V6gemK5T4m3SS6nJ4Z8BRmXXoVM2oXq8xadDjnce8h7L+Nc8qsFF4eWpz1XSg/ZPU9vt7q2u2lFtcQzGF/LlWNw2xsA7Wx0OCDg+teZfE3w/Bp0kGsWcCp++AnKjqp/ya2/hXpWl+GPAMH2JSqNuuby7mb5ppD96V2P069ABWib/SvHXg2a50S6F3Yz71jlCMAzISpwCAeoP1rhozdGp5bM5KE3QrJvoeO/2wuhW9zEArt9pCwq/A+YZz9KX+3724ma31OGNBK5gWSJsgP6Gsl7NtTaOEgG6Rti7hwWTsfqKt6boGoswlvBGkEMxmEa5JJ+vTivdcKe73O3GKrDErl2dj1LwKILfwvdsdv2hW57nGOBU1yS1izIA8uMY64NUPBU8C+cNzMxAyuB7V0ZaziV/tDbd5BAxyR6ivJqXjUbJr3jVl5nFjbBLKoZWZhlVPb2rm5wqTHy2y2eR15rrNWtbeRZmto3CAHGew7ZNcr9knQ7greo9a7aLurnoUNuZsgKeYcsFZQc4PNbEDwxRyMqKuU+YoOtRWdshyRuLgE5NQatLM/kWFmubq6baoxzz3q5PmdhVUqs0gi1C2tNGluJHXdHnYmep968jlk1GKeUW0SzIzlt525yea+m9H8A6ZBpYj1GJZ5mj2sSOBnuK8o1jw1Y6Vq97ZH5hFKQp9sDFVhcTTlKSiefiIrGz5afQt6uZLllk53rx83Gfet7QowLABlDMBnr0rltTM92AkG523YZF64rQ8AWV1dzSNdI8EfKADgk9uDSqJKne+x2YysouNGxtyRyXk80MOAu0kA+1WbG3WIRgjchUBh+gP4VftraKCeRMqX2kFlOaIoma0ZQyou7bnrt9DXM5dDnc2o8qOck8Taepe3jaSWCN2jZwOA4OOO/FbsMoIR1l5C8Nt6/jXmE9v9gS5sVtZ/tjnAZl+V/8AaHFekabFLBpFvE2CEUDdzwe4+tb1qcYW5TjoVZTbUgv1/ds7goxGFbHFc/4RuxDDM0i+YkFwWBHO/Jpdf1IqTawFjJIPug5xWjpNkmn6SkUqASNmRm7ihRtDXqezSp8tJ83Usaje3V6ZTuKQKcqmcY/xqrpb+QjHO04zkjtSzSo4VA2Yiu5j1rn/ABPr2WawskLTBedvr6VUI391G0YLl5UtCp4gkm1KeR0ci2jbYAo5c+wqPTLOC3vtLkvEcW0siMRu4YZ5Bqloeg6lq+r21taPJFPJHuDPkLGa7+f4S6zcC1jmvoAIGLiRBznjt+Fa1J06S5JSseTUzSc5qMVaB7UkcTQR+SqiPA2hQABXn3xSxZxRPGw+dSpHHH+eabNo3ie0VfJuZ2IAGVlzmuO8UNfibyNVMzkAAbh615mFw6jU5lJM0wmGUanMppnLWet+Rq9vIqM3lPuxjJJr0XxB4/t9T8PyWlrmK4lGxz6V51BoEPnfaILhwUY444Un0ov9OezjiZmcrJnJI4J9jXp1KVOck+qPQjCNaS9uveT0sem+AkgkspbaS5iVJU2IcYPHPBrfh0C106cXdvMjxjq5ORmvGdMh1DULlrO1lbEY5Cn+WK2tPurnTbb7NqVw6QAkhd3H4+9c1WhJybUvkZ18LJyclK1+h23hKT+zPGF3bw/Pb3BBBX061R+MvhqHW2ttTWOeNrTKSTIBkr3H/wBetD4bWdtNJLqUlwGk+7Gu4HA9au+LtfXyr3T4SjloTtJGQzHNc/M44i8N1ucFZKddJK+1yl8HrDT4NKc21x50wcj58EqM8f8A660/iwsTeH1LMBPGd6D6V5Z4Au5NG3XjSsqDDPk4GQ1WvFHjBtVlfcRNEmFG0/pWrw03iPabo6FgXTxKUHojT1DUPLk0xEgbdCu4nPX0wfzq94jltrnTL640+d1vWhCqmeP9r8TzV290v+3/AA5ZaxpKLGFi2+Wf4iOPwrkLXVzb3CM6ApuYPH02kHkVpBKesd0bQ5ai93eJz+jQ2lxcWSKHADATb+MHPP4V9JaV9hgsIYrRo/KAHC968EnsFuNeu5LSR7bSpyGkfbuCZH3c/wCeldppGma/4dvI7qNBf2wQ87iQwPORUYyCqpa28iMxj7bl1t5F/wAWs2l6hHqJTZG7YPHf/wDVVu5e3uo0v1b9zKqkqnG49/pWF458Uw67pcdkttNaBJN1xLMhCxgdvcmsODxTZ2kIikSQWpCqJUyfmBOcj8qiFGcoJtar8jl5lGMVUdn+h6ZH4gt7e1jVLfYqgAoCOPpSWviiykmaFuJnb5FPfgd64WxvRe2zXL4KLng9/en6DDHqmvwCHYqICxJ7Y6VEsLBJtmksHTSbl0O18YaW2paPwWMsZDjB4FcDpfgrSvFVq7sjjVbdwDMr7fLI6H36V6lEVZ9rElh1wcKBXKaPex+HfHF9ZXS+VbartkhkYYHmDIK+2R+tZUas4wahutTjjJypOna/VGM3wvubbR5rS1uIDGW80hwSxfuS1ecahp954f1RfPjMN1Ed49x2I9q9o8dePrDw7Z3QgP2m5ReRGeEz6/4V5LrnixvF2nw6jc2iQF/ki2nkgdc/ma7cJOvNc1RaM6ssxE+f2PRm54k8NSeNvDsGqWjIb2NNrRtwGGOo965q28Kr4X1PSYPE94kFxq1ylpawqejFSQxPpkKv1cVo6F4iudKjW36xKu5QeMHvxXh3xs8X3fiXxtGsUz7NMUQQCNvuyZyxGO+cD/gIoq1KtGPKnp0IxtJ4eXtV30PebrxFq1nqt18P/CEsB1R2PnX7ENHp0R5Le746L61r6zBp/wAMfh3f2elbmlmRvOuZ8GW5lb70rk9Sf0rwn4deI77Q9Rs9H1LTk066uke4+1zuySSE5O+QNk87TycdvxveI9fvfiHqMNtPPLF4dgJBmQEG6YdQv+zn/PphCkpyU932MZOHL7eTvLt5/wBbs9F8ItrHxe0bTtHXzdN8Dacix380ZKyanKvPlJ3EY7n198Y+gNOsbXTbCCy06CO2s4EEcUUahVRR0AFea/AFZ7Tw1cWH2do7SKYm3BwMIR1x9a9RA3kHcRjPHauHFQcaskziae8t2fO+pFdP8UazDHz5N15iFvQn/wCvXYPL59rhJPkdBuUY/IVgfFGGLT/HBkiH7m4iAfHc1h+INX3Q2luJHWEIAyRHG445yfyr2Ix9rGLR7mLqqNCFY7bw6htr6RWdYleM7c9c/wCRW9qBSaPdGemOSeQMeteV+Dbx21Au0kktqu0necgHk4B+n8q37/U3S0mvLiYwW+/b8oJLE9h71NSg+cmMlWgq8nZFy8vXjcQxneOh5p9na3d47bAAg5z35rI8Oz21+8joxdoz86t1X0/GtnxHrlxoNoi2oWGXJ3Puyx7fjRJNPkitQrYqMY3p6osC2S0jkaRPmjGG5IxVP4fsl/42+2zj5VBWDJ7+tcvJ4pmvzeWtwJDI0Sur4Azz/wDX/Sq1zrFzpt9ZWOnJ/pSwm5aQdExk5J/A1XsZcri92RCtB4eVST30PovUb6HTrZ7m5lWOFB1NfPviPVpLrWbq43BfOcvtx0BPH6YpsPiu91m4mi1SZrt4NqxGGTdGxPoOma6Ww8NzNbLI6h5JPmfK5wfT+VY0aKwus92GEdPDU/bPW5hadMIdXZ0YFS+dyn1zXWzbt+9HPHzHB7fhXB6ajraWkzN95QenXmu+gQS2p2k/OB8/4c1rW3udGKXNGE+6EsmWSVniUjK7Qzdc1Q8TXlzpemo8QQTO2Fdug6nPv0/WtWzjjWN4mU5IOGOcKfUVzmra3p2u29zoUdvc3EloGaSWLChB7Z6kYqKavO7Wh5+JnyppMo+H/Elzca2tpeSRzEgMsuwLg9unauj8Q3ZtbAuhAkJxnPU1y/hrw2YZLW9N35toiAxkIQT9a2PFlwjokK8tkHGK1mououXYvL4ym0pj/DeivNqUN3co22Q5XI6j1/StmaKSWG/kY7Ao2de3IrR8E2dxqFtal5NoRSq/7I/x/wAa4Xxh4te38U3OlaUEFtA/lzM4J8wjggY6H3rOLlUqOK6HVXxcY1OWfp+JBq1ybHQ5DGuHZditnHeu7+EHgW3t9MTWNWiE13c/NGr87F9fqa891pG1HV9L0qMcBgWUe9fRukxRQ6fBFCCqIgG3HIrHHVZQgoxerLzKq6VGNOP2t/Q5PxsBpMmnHSBFBfyzfKQoweMcj06VBc+L9b0KLzfEWiBrZCN1zaNlRn1B5FHiB01Dx5Z25wVt2QHPr1NdR4okthot1HcDKzRlAMZzkcVzXSUIzV7/AHnmcqjGEXG7ZXPjDQhaRXEmowpHIgYFm5waxdY17w7qts8Utys28YBUEla5f4a+GLLWZry51ONblbKbyI4m+6cAHJH49K7e58K6LcxvHBb/AGc9MxcDPsKbhRoztd3Ro4UKFTlbd12ODTTtCs1kNs2o3MrtlIYkyGOOuB+FVNQuG1bw++lG2Mc8IJRXX5hzkivVPDeh2mkLI0Y3TOeXJ5I9K4r4k+XpOuW16koid/mboMgcY/KuilXVSpyrXsdNHEKrW5Y3fZs8p068l027E9vMLadcjLHr7VY1KW88T30cl1CZkACho2xtOTk7R1zXJeKbmddYuLmzeN4VlCmFgPmVu4+ler/CLwxNq2hie/nlis2k3bY/lMhH+16V6VaUaMfaMnFV44hzpSVuXr+h2PgCxOhWTLcQstxIABEPT1PYVN4titzFJcLB5bhPvHrkjFN1nwWltY3F3pF7d290q7l3Skocc4Oa8ybxdqk22K7uVaPG0R7MnNebTh7abqQfqLCYVVfepPbuZoykEtvMdqnOcnt+H1qnpXhyOCO5u5dSj+xhCyouT847fyq/qOmXt4iTSxsnQbMdRVG3WaCymtJeEM3mYxjjFeom+XRndWh7XERSW3VHceCvFM2iRWOneVJNasoeVGH3SxHI/CtPxboqyiXWNIjF1ZXLb3WMfMjY9BXEyaZaawsItpsSqBgeYQT6f/qrf03VNW8B3sZvZDc2hGHt0bdgccn3rknT5Zc1P4u3c5JqpRrylpr+J1fw71HT7rRJrGYRpNkhopF6gisvxC+paLeJp/hzV91tjK2svzeXnsD6exrpINN8K+NLcajbgQ3LD5nhkMbqfcD/ADxWJq/w28oQ3Wm6ldy3O4BvNkHIzxz+lcsJ0/aPmdvJrqTCrSdVuel+jWlzL1B/E+seGprC+0V51J8wTxYwfqK8l1C6lhUac6tHOHw4cYC5OOn1PSvpCCx12y01beNpPlwowwOBXAa1oE9tftdXEK/aS+4eYoOT1yDXVhq8U2tLeRnLD08S3ytJ+RPpPhG4t0trG0u2uoHUNKF42nA4598/lXVRJpui3Bju/wB3KB8yr1xVjTdVX+z4IXPkXRcZkGMZPFcf408NXc99BcPdvPtYlWjlABznkj1Ga51J1ZctR2RlVrVUuToek6dd2s8IeyY4DYIP9f8APas3x5pEfiDTY7aGJTdId4cEZRf/ANeK85a9vtK0i5iiZHnRcrnOQf61zOleMtT0zUJpVv3uZxGPMkkJ2H2A9qcMFPm54PYx51TkpbMpah4Q1q2vJZG89WQtuk64z3HPpVixs109rddji3iO35jyeMk17r4V1ay13TleRc/ulZ9wGCx61meKfCWn61o9y9qzW84LNGwHGcHjFaLHNy5Kisd9CvCjN3haT6nz9rWobWYlt8jqDvU/dJJNT6DFomiIFt7GGK6DEyXsgMkhJ65duh61CmkLFpw/tIJAsVyQ8jScyEdFC/Xk5qh5I1KWGFZRO0kxSWHBw6E46fjXoypxkvQwoVqlN3qq7vpf8TznUodb+InjG9uNHsLq+kmkxGsaEhEHC7j0XgDrjmvoL4QaXq+lWt7aeLYtNmFrEkNvDHCC8TdvmGFxjPQHJ716H4UttH8J+GolKxJebSWjiAVV4OAAOMVj+H7yKa4vrq4Kw/apAI2YZBUf/Xrx4RfvPUcKHK5zk3r8r6npXha3gTSkaFQGb75HHP8Ak1rtGvIIb8zWL4S05rC0meSfzHnbfx0A7f59q2vMjLFd4LjtmvNqv33ZnBUfNJs83+K3hNLvQ5r60B863w49cDr+Fea6NZWGs28K3wO8A4ZTg47rX0jcQxzQSRyrujdSpGM5Br5qj09rHxTq2mElTazMYiOMc5H6V6eArSnFwb1R62CaxNGVCp01R09xpUNvZRw6bsjSNclB3J96j1Pw5d6t4cjto3WKaJ/OiZ2wNxBGD+tXNMmNygDcOuBlR345qhqnjq206f7LFbi4jtiVmmDY59Pw55rde0btHVoyxM+Sn7GeiMHwvpOpaRq5/tNFRdhSTYBtY9ePxrsdbjs9RiCzLI0XGN2OPXFO+1Q6lZQXlvKH8xdw3A5xnvWRrl4IbYRQKDcSnaq55GablKpNPZiw+GjNKCON8UahpeihTal5HHCo2Msc5wOOma7Q+AGv7SDU7yd1sms1mmKjDOcfcB9KxPiz4GbTvAGn6rGDJcqV84Y5G48f0FXrbUb690qC1juZWt0gAEbNtU4Xv61o5upBSpS62ZdOCxE5UIWUI/1cq+DLCH+0yLeNY4YlzGo4wScD8a9Os9MvRDgTrHz9wg8d64b4fKv9ozhhhkCtyOce1eufvJQr2jxSREdXO05+lceNqNSsh5g+Spyx0SPHdUsBp8VraggmGNQfQHFbOi3Qa0ZSCzJleSao+IpUe9dkOVP3Peq+mXbwurHLFuCBXQ480D0Z03OgkdRNEFgZS21imBg565rzubTtQsZJgtrNJLKDEpSMlHXHBLg/jzXaXt9Ha6dPeM2FUbj3/SsDRvEU17dr5pzG5wvTv3HOadHmjFtao8HERjKSjJ6m74ftU0/RbeCabDRLyoHBPU4rMijfVdTAdcljjjsKdq98EBQyBIyw4J7+lXfCVhNfX6iBXJIOSvRRxyfSl8MXNnrYeKo03O/Q7vwvKumQmMLhduB9e1fPGjWEl14wvCxZl+0v0HH3iSTX0/Y6XCIxCz/vABzivPdX8NWnh06hcw7jMzFizHjB54rHC14pzS3djzFCNevF/ec/oEfl/EKB5VVzENxwc4GK9Y1nxAljZjyConIwmfXHcV494Iu0t9Su727DMV4UZrX8S6hPqf2Sa3MoRJcKmACPxH4Vdaj7Sor7I9PE041MRGEuiOu8DRvfavPqN6v3TkSdAWPWrvjuTyriHe58kDH0rj/+EumsoUtRHGu4DkcdO9cd4k17Vb27853YxcKFJJ4FTHDzlV53oh08HUnW53ouh0tp4iXwtqc08Ez/AGW6IdkXkPgenr7+9OuPjH8zR2+l7Yw33nk+Ygf/AKq86uPtl8ymZCwAyqjjH5d6teG9Dvbi6Mz2TS2R+WRm4BPXAxXTLD03701qdlbDYeKU6yuzqb34p6pdEtasIOcCNEycepPrVfRtO1rxZqH2m+MkozuZ3XICg9Bmr9hbaHY332meyXAO0RglgfwHeui1vxqxsVXw/GLKGOMm4lmj6dcBf8ah+5pSjv1OaVRUlalBLzPPNb03S21pba5liijLYw4GQfQV6F4N8Rf2DZjTW2tbRsSgJ2ECvNfDNidY8bWavOJZrqXzGmVslI8enbjOa7Dx5G2q+P5bPRpkggFuZJpNwAbYADgnjPP6VdaMZtUpdrnn1MbCpzc0Pd/E2vF3j9JLeS0tkKeZgbickj2xxV34beFLC4MmpXluskg/1YbkA+uPWvIJ70yg2+nxG5+zSsiTH+IHoTx2NepfBzX7ua5+w3o3TMCG+XGMDqe3asq9F0qL9np3HVxNONL2dDRtXPSNa0O01G1ZGiXzVU7CB0rxi0tLaXSNRtdhfVrq9+yxEj5VAYZPp616J4z8b/2Jcz2kEG+aNcksxHUduOteZ6JrSi2ivipDpf8Amujf7R5/z7VhhKdVQbe3QMvnOSlFPazIPE3gjWPDaJexy+fEhBLx8FfqPSqCQ6nrunI2n3Ekl6hPmQ45VeTvz+le0eJ9Y0+TwzdySTRM8sOUiVgSSRwBivDLC+utDv0ltGKTBSDtwcg9RXVh6s6kbyWqOzklmFBxqq0lszpvD9pNomiQX67RcqzLPbg8uuTz7HFbNnqt/ryPbafcTxuWV4kz90jB5/KuKu9UmutTZluNsbxdHBwzE5xj1Hr7123wf1O1e8jjZ0Eu0rtb/GivHlg6jV2Zq0KbTV5R7lrxR8Qta8IG1g1W0tJfNBAkJIHH9ea568+JP9uiIXix26SDaoByuT/WvYPEvhuw8S2nk3io6kYyQG47V5NrPwPSGeM6TcnySdxR+qkelc2GqYWSvNcsjylWtPmSWvysa3gfTYwt9d6hcqtpGuWJfIHuc9K7TTrrw1fosVpd2dzOcYBkBP5V4/dw3pgudKjlEcVtLlozkGQ4+6W7464NczNp2rajqKKRaWTRklLgSkun0IH6e9bTwvtW5OdjWvGpGfLBNo+iLzwjYT3PmsnLjL4GPy9K5vWvhPojlrm0R1kbHyO5K5riH8TatBJNCdRa4+zoAsuTkeuPWn6F8UNXttUitr5ftVmxyzAZdOBWSw+JgrwkaVMHOKi5O/kes6FoMWhWaohUPjnJ46Ve+z3K534ZC2RgY/IU/Q7y21S1+127iUnnGegq/fTRwW7O3QdhXmznLn13OWc589pbnzX8T7cWXjRLq1s2MMZ3mH+8SOo/GqfwotvJ8QC91GN5LdicMQOw4/Hk16Pb25t7nVLvVtE1GW9nZzCwiLxqpOQMjgDmqFrbPp0P2mSNY1uJiRDn7h6cj8K9yNa9P2fyPShRpSqe062tv5WPNtV8U3F340u2uA6af5xSGI9AoPHSunM8z/ZmtZMusTOFYfKDn+Y44rY1XwXo2sWtzeorLdEGQbX2pvH3ciuc8J69p6eIhp2p2/kxyyeTDcj5yJT13egJPUVfNGUfcWxy1faKi4VXs9D2zwLrP9raYY/vGLALqeD6478c10K20aTeaRl8Y5NZfhbQ00WOZQhDE4B68cmtzdvGQQR6g189WlHnbhscOq0EcAA/xegr5/8AHEgt/ijJNtKeevzL0zgY/pXvV5bG4a3ZLiaERSCRljIxIAD8rZB45zx6V4L8U7iNviIjFtqwr8zZxiurL1+8a8j0sp/jP0ZNBOLS5V1yUJJ2jtXASQXltPNDDBJmViGIHyuM5z0r2jw34c0XWtOJivZ3vGTcWB2gZ7gHqK5/VtCfTdUmspZQzKocE9HXBOR+R/KvTpYiKk49TarChjZWTs1+Jl2VybPTo7ZAAqRhS/v3rT8CaG2r62Z7okpEd/P1rj9V1FG8QWNtZh5IkYCQqerZ547iu10bV5tMuW2FldgAcU6sZKLcd2bUpKVOUMP00ueo+LLi2s/Dt213EssQjICsuQWxwPzr5/ldbSUQSK3zEhgO5xkiu78U69NcQRpPOjRKQwzwCR0z681xdz5sjWt2kIkMMxkZwwxKp4IyO9YYOk6UXzdSKEJ4WjOUbcxo6Fcx3WvrHY7gRHuaMjDD0H867yNrsou3c4A7jOPavOvCUyHxWlxGTKrJjamTsU9BuPOa7bxDeaxZ34htLKR4QgwURcd/UZzTxEffSX4nJVxHtYxqSRwutXYto1lCbnJKj2FLpWpifMkcRV0bGCcg0/XrVrmERKFLBuvpVTRLQ2cTxMys27J56CunTlPZvPnt0OiN7HcwzxTRLll2spyM5rmrHSJYNWWQTN5cBzH7Z7e9dKqp9n3sqk4yzZzj8vxqCSSO4RXh+dW/n61MZWTS6nPOhSqS95alW9smvvlLg7DuwT19q9t8F6Mmi6JEpj/0iVRJN7n0x6AV5tpqwR/2eHA2ySKXPTvnH6V7LGc4IxtxxjFebj6rsodDgzCVrRW3+Q7apGSuePTqa8w+LN95McsKOBkDK989q77UdQFpu2gs+CSB1FeQTwTeLvHNvZuR5fmebKV/hUcms8FT5ZOpLZE5fC0/ay2WpZ0zwsIfDiX5lKSeWRJnOMH29feoob/SPsH2CVSt0HBE2eM/T6V3PxB0GQ+ELoaV5zXUQBWNMncB1GPpk15x4F8OJ4l8z7TdssUSDeiR5bPSuylVVSDqTeiZ0UfZ1efETetylrk+jW+fMufOK87txwo9M9/wrL0bWNKbUdsloWBbKtId2Rjriun8SfC29kuFfQbmK4fYVMVxGR34IYd6p+GfhTqv2tm1uRIDGCysEzvbsMg9P/r11e2o8msifr03Plj8K+9lC5uUhbLpk9F2/wCf1o0rUyVSOCRocnkKxA/LvXd+FvBdnqdpKuowNHdRkqGPAb3xTNG8KWMXjj7G4EkduDJtJ9+nX3rN4in7y7Hf9eoyi7p3RJp2gyz2ySrbTMNoweayfEWhTT2slsQcP13dB+Fe0WzIqsq7QqnAA6VnatYxXiBo4wX65JxuFcEMa+bVHlrG8zcZrRnkXgPQH0+7uDEY/tTL5fmlQNo9B9a1tW8Bwm2ea91B7OcBwrQgcKe3P0z+Fafi4P4Ys2ubMiWb7wz3xXm138Sb/Ube4jvLd3TlbgAcxrnnH4d67Ye1rP2lN6GNWpRcuVaRO8+EmiaVdaTeQyW/nr5md0mCTjv9a9A0DwxpWhPM+nWwSWbl5GJLH8a4D4QXNu8cht5U2SklB688fpXpwnHJLH5PQYFcGLlP2kld2FiqfLU93ayPPvivpmmyKJhdiDVZNqgZGSo5yfwBrxG6vpLcLBbxLEg/icklsdyfXNa3j3xVBJrt3FLM7bHb93GmTvHQsewrCs7aS4u3u2UyIyL5W7k+5wPr1r2cNSdOmlN3KwftHUUKW/VnSaIl9qVxFZxMWLHO4j7g7n6126/DCe6gE/2qQOvKiQ9T0rL+HMZSZ22EtJjkjgAV7dDMPJQZGcDv1/zmuDF4mdKVoHp47GVKMkqeh8w+JvDeo6dcfZ7mKRSW+STacN+fWqlvaXkCm4BO5xlPJGAMcV9WTxRzxkXMKPHwdrqDz+NeXnTbO0+IN3YSAJazqJwoOACRyB7Z/nWlHHOpFprYihjIVZupKHvJfeW/hr4rJtorC/Lm6bj5zjHYY/Ouw8Q6ibXSrqfO10XCkHofWvG/il53hnxNHPYDZbuAy8YG4YNMuviHda5aQWNyFjMf+sJBXJ9+azlhPaNVYLR7mEqVOvWUodd0bWo6dHJ4NutRAPmtMCfUjof8+1dH4b8K2VxosMq5DyLnPT2/GuY8Q6ys+gabpcMkUsZk+Z1fqe+a9Y8OWqw6RaxA5VIxUYipOnC/n+BWJqVKUObZt/gea+NvApS3W6sZsTYIbHG7vXJeCNDD6zJDIoW4/wBXgrkHPvXvmvmOPSbqVwvyRNjPr2/WvGdX1UaDdRalEhO6UDA74GcVeFrzqwcepphsVOpSfPuupvTnUfA1u08cbvEMkqhDbh6fWovDnxYt9b1yGz1WwOnQE4Essgxu7Aiun0rxXpPiqAW06eTLIPlDkYYY7H19q8x8ZaDZWOvwRfuVMk4DAkABffHSlTjCq3GtG0zlhF4uST0Z65J4x0dG8mOfeWOF2DiuA+JF9bTySLaMPPZFPyn8z+VOWys9c1Fxp9ukNjZJhjH8okYDt6jOK3dAstLjtryO7hhD7BsdwBuP19aiEKdB86vfsbRp06DU1e66Hl9ld308CWjzCCFgB5sgwPzrP8F+H7iTxrpcdwgaEXYuCQwIk54Ofaum0/xVa2WqXELaXG3lT8MxypAOPp0rQ1vUtGnnt73S/Ls7iJwyvG2CDnocV3ucleKjuaYpLEySaske2sQSeM4PrVcxYcyRHBI+72NQW0sktlDMkxJZQxBHFWY3Z1yQu31BzXznK4niNNGZquuQaVZS3V/+6hjBJIGfwxXzL4+vpde1qefSI5boXcyrGEQscY9BzXp/7SN/cW2gabBCQFlmbcxzzxjH615foou9K0aGexMiyB9wkVSdvft+Ve3l9FRgqq3Z24OPPGolppuexfCrwxqempDe6vHJHII8IkhG5QeNuAf/AK9UviBdHVfE89tZcG3gMO+PqWIyRn2ziuPt/FvjTVL1LOza4niOA5NuYwVxyQ3bHPNdjDa2ukxfvpPNvohkBG4U5ycnuTnrSlTnCp7Spa72SHg4xV5Xu9jyddFv7XVY12Th0YFHCEEH6jt2refXrJLiKNvNDo+xpgP3ZcdV3exr0qHV5LpWnaONHEe1w7YQj1Hoa8gOk6xbteWFuEa0lnZ1mRhnY4wQc966qdX2r99Wt5gnXwv8NXTfqdNrFtLexx5kHkbcrz1HXggda1NGSBdHeyvmS5mkVppJB8gjx0xnr/OodK8q2srW2mXBhVYhKf4yB3HvV6WwiaIyT7VRgduBwT6VjKWnKeg6cZSU5KzK11evHJaz2v2dljIEjKBuPbp+Fd3pniG2ubOOSSZEfoVwTivO20udbZjaozpnDEYOORWQkl984DhAGI2knioqUI1Y2T2KqYWFVWT2PRNW8LMFLH9z6kjg/jXEWelm7vH8uVSoO1WUY6GvRvH3iKGLS3gL5LggRjqx+lcBpl3cRQKqqkY6kjrSw8qjheQ8I6sqfNI1oEt4dscrluASqj9KsxRaYXVIoJFj6joM+prGdZVzkqW65FEl2+7YigHqPb6Vpy36mrgm99TRu49t7AIgCEbIGRzivS/DTxPpsfnNiUj5wW6V5VpZZrz94FZlXoa6K0uJZJltzjYxypYYrDEUueNrnLi6LnFK+xr+PNatLJY4bF0N25IO09qyfgvbefc6rqcjEuWES8dq4y/mebXZYwEYo5Un0HSvQvgtGDoFyckFbhlIHalXpqjh3FdbE1qSoYRpdbHoJLJ8o5z0Feba1c2fhvxrdGz2RfabMSTRoOPM3nBOPUZr0PULY3VrPDGxiaRCgcHlcivnPxbpWreHdaktbmaOR5GDfaOpZSTjJNc+ApRqNpv5Hn4R04tuo9O3c978IXMd5pK3MTbmkclx/dPpW2yqylSMrjvXz/8ADXxjqGk3M6y2U9xFIP3kC9iOjL7EV3Z1fxX4qZoNLsBo9i3BubgHzMe3/wBalXwk4VHd2XcVSjzS54v3X1NPxHrFppt3tW7ijjVPmIblT+Arlfhot7qvii41VUlNs24PNICA2egXPX1rrtK8B6ZbKjagX1CdSGLzH5c+uBXVqohiVIlVI1OAAMAD6UOvCEHCGrfUuWIhCDp09b9SpqME7IVtzt3dSPSmzXdvEUt2BM7ZRV2nng/lxWgc7SDg1BcQ+YC6MAQpGRXInfRnIpdGYHiPw8Nc0wRyTFWA+XB7Y6fnXmY+Et3dXM88UsUMgciQSnKzDHHAr168uIrPTjczSKAgBOa5x/iBpVoERo72eVgC3lQE7fWu2hWrxjanqaqjKom1G5yfh7RLvwDfKLtEeFlLK0fI/lXa23i20mkAkidY/wA/8iug0m9tdZ06K+t1EkMy4G9cHGehrNvPD1jczqViWLBOdhxSlWjVf71am6qwn7taOq0PHvGfwti1bV7nW/CmohZ3y0lrI2wdOxrjtJtp7GxtIJ1JcymNW3BiTnoD6CvddW8IXT3HlWN8I4ZEb5iOc9AK8x8TaBeaBqNtaXqpt3F4nDZU/j27V6eGxCnHkcr/AJm+ChCFW9GWr/I9U8F6Nb22mWxDBwF2vuHU11EWzYYzzIoxkdPauC8La/DDYRJNJ0+9kZ5+lbkniKGG2kdRliN2wEA4+teZWpTlNkYihVlUdzo5LxYrN5pZVAjQu4PoBXzpqPji71Px699BGn7pf3GzPzKh5UnpnmvXrnxpoM9pJbXMpKzq0TIgyeRg14e+mQWWoyC0vJbq3tSxt1aPaRnOQeffrXZgaKjzc61FhcPXjWjaOnX0PU/iSdP8Q+CLe6mKpPKBMhJxt9RXh7aYXK/a/tc9jGu0mBgGJySOT0H+FekahpU954AsJbhlaO2d/kcYAHbPr1q94O0fUrHSbgapoV1dWtyqsjx4DAeuCc9DXRRmqFNpO+oVKSbdJrRPe/4eZ5r4YgncFrouEjfcmeu0YzX1hYLGLK2eBiIjGu05zkY45r5+1rT47G6a/wBKmZrFzteORcMh7qQe9d94F8X2MOhQ6dqF4IZbdsI75+aPqPxHSufHwlWipROvGYeUqEPZttR+86f4gXosvC95JI2fu/L6ncOK5KfwzDrPg+zjuSoVQZdxOCNwOTn2qf4ia7pt14bltLW5SeW5I2Kp5BBGMmpfiBrUGl+CEt1haJ5YAu1ekYx/X2rnoxnCMVFatnLThOMIwtuzyjT9Jms9aNnYTfaYg+4NCx+UA8D86NaTUJdcjhmKy3LLwS3p6+9YC6nqmn6pZMkb2zzRrLHEerRnPzHHY89a7HT9Mvr27/tW9UrGPlBQDIz14PpmvWneLuz0cFOkoynS229Wel+BvDkuk6BPFcbZbqdC3HQA9v1qPRkie5ks9ShVo3Plsrjv2Oa0PDN9e3NokbEttXarc5YdM1keL7HUYJ5LyxDqmA0gPr/eFeQnKU5Rk9WcMajnVlGb1fU831vSDZazcpZRmSLzHARsHCk8VxPiMy2F7bx3FtJAhYIItjAy5PXJ6V6RY6xHbask2oIQm/BfHA+prv8A4j2dnq1z4UhMcUwmvkZHwCNgGSPpXofWHSlGMle/U0x6k+SD+86DwXplxp/h2yS8kkkuPLBcMSdvHT8K2QJkIC/MpPPHNWXGVAAye1MYnI/p1r56U3NuT6njyk5O7PLPj3psWoeHbd5fkngmQxjrnOQRWXpdq9to8NqqjbOo2k4G31J/WtH4uX4u9Y0zSg2BEfPl46emfwrnYZrnWp13yMmnRDYNvBkAJ6+3869igmqEU9tz28LRUKCk9L6v9DRklLs1tpEjTBPle55VAehx61LHaTLC0a33ynKuI8DJ+vekhdLaARJ8sQbCqMDFVJ75nuPLtB5jHIUYOfXir1eiGpSm+WA+LSbS2uEjdXnCkZDyEhv1pz6RYM8XlRiIyFsbCQVGe+OtB0LxBcKJxaz/AN4DOMfhVN5b6xuIl1CGSHbkgOpB96NXtILTesZ3fqXJtBuDF5mm3TzZyNsy/Kw9z2/HNaXhTV3mlh0a8jiZmcxPFIuSjYOP8iq8N4fKVIZSMbmCcdx6elYHiIyW00OpW0p+0wMpYY5xkYJ+lRyua5JfIUXKqvZ1N+nqewQeG9PjiEbRNKgycMxxnvxVW58FaLcSeYYHQ46K3H61qaJqI1bSLW9TC+egbb/dPcfzrhNS8Sa1p2o3NsZPMCSEKREOB6VwU41pycVKzR5DqVIN66nA6jvtohf6mzvuOEAxnPsKt6Fd2N9c+TIgEmFwhbJ57H0rR8U6dJqejSrZx7548Oq+oHH9axfDeksdQjmeFYHCjeSOCR6Huc166lGVO/U7MRi6zq2WxN4svhHqFxDZsyJEpMUanmQjsa27DSYdV0a3u4J1R3j8xlkYDA6kfzqhq2hNJdPMk0SiVi+4g5GRyeP8aS4iFqFtIGTyYovkLfT1PHWh2cYqDMYYitSbk3oN069TTtTVbkkpna4BzxXRefFcDzI2+VjhcenfFcJFBdy2X265tRbYO0fMX3D1zWx4dvd6zW0jcqxKjHb0pzgt0e3TaxFJV1ox5tgdemaMZbGck8Guj+DOoLbavrGkzsUZnE0YLYHcH9MVyuq6jFo93JcX4ZTlUUDqSR/gKdYalDpXjbS9SQ5tbsAMV96itB1Kbj5fkTWUasJUlvY+hTkHO3J9q5/xJ4ctPEM8JuVKPCDhwOea3EfzUBUgqVz1pwwAAvA/pXhwm4O8XqfNmLZ6Xp/h3THe3iWOOJS8j4+dvUk96yF8f6HCi/aHuYY85DPA2MdsYzW/4nTd4d1IMeBAxx9BXl1r4gXTdOCCFLhTEAVxlgcV10aSrpylds7cLh1Wi21sejx+MPD7wpIurWzK3+1yfwrC8b+ObbT9NC6ZL5s8yHDqpwvH5Z5rx83CDVZ5ZohCCMqm3g//AF6jvb5bxlTeEjI2kSsdoyRkcf1rup5fTjJN6nRXyxwhzU7tnSR/Fa80+OSIQPPdAqnmSnCqD1Le+fQV03h34n745Y9Ts3FwDuQp0cZ9/qK4Oz0HSdQ0+8LanClwE2rGVLM+OS2eM9h+FT6Fo9jZKJWmupdgAZ2Iyo9vbNa1MPh5J2WpyUsNWm/ejodDrfi2W7dvtLpFZqxKhjyT6f0rS+HlzZXgv7xpo1bBiILAYz/jXnHxA0e4t7VLiFZJLF+UdBkEE+v5dKxNL1VfDIgkt/Ma4flkYDBHQZzV/V4zpWp9Tvc04umtFbc+gPhdqMcmlXdqZB5ltMy+WOwrp7sSzZVMqH9xx65rx34Z6ms/ihri3maOC4XDxY43dP6V7DLAY0kMEhWVwdufmANeViafs6rfc5cTT9nU5u+p4l40+IOr6dq066XdeR9lnMKwSxhi4A6+pGeOKg8ReKrjxNYWF7qWmSWlzCCjrn5Xz3A6iu3+Guk6Zeazq02pRRz6raznYsgyEX+8B/vZ59qo/Hi6t0Gn28aqblss+P7vbNd0J01VVOMdV1NsDFLFKL1/Q86stRnBeK1jZ3mYCNBz/kV1w8NXqRwtqdxJJNccGKMngds4q/8ABbwxHK0ur36bhgRQqy9fevZREgC7EUYPpWeJxns58kEdWOzD2dT2dNbbnzdruhXthN5bRP5HJWVoyM/iasaboN7PbtcafLHNJEhYoOpA6j/PrXvXiC2jutLnikAO5SOa+edLg1Hwz4rNwglWBMnJPysrdQ3sa1w+IdeDa0a/EVHH1asLRWp2WuapY6r4LtooYvJvLRwZoG+UqR29wa9E8J+KLDXbKDy3EVwUGYXODkdceuK+fbq8udV1i5/s9LZN+5tqybWCA5xg1HpWq3ENnINLKxOsgczMNuxuc8n6duKdTBKpC19f8zjxHsppxjKzTe56F8XEtYPFmnquEMyg3CKPvYPBPvU48KWl/t3sUEgXbtGc56VxmqarLrN+s95L5tyFVXfHXbzjp9a9vs5Le4h065tQvksgZWQdRj2rKq5UIRj1OmpUlQo01BnmVr4T/szXo9P1FAmTmK66qw+nrVH4h+bcXEmnzMJpI5Nh2/d29uPxr0fx+0EttAkoPnB87kOGUV4prmoAauqxuwkVv3gPIbnH51ph5Sq2nI6cHKeIaqS7Gz4Q+GepXey9mnRdqiNTJliFHavQD4IlgtnFpqTC4UfKCvyk+hA7VoeAvEdlq+nxWcJdbiCPDKVwOO/8q0bnxDpNteiyl1C3S7LABWYcZ6Z/+vXLWxFdzce3keZUrVaMnTXupdDI8BaxE8Lw3RSG9V/KkhzyCOMg+ldSVXUpJFI/cnh/XA7V4P8AFKG40zxkXsp8rLIpyjbQGdQc/pXWfB/x9JqjXGlahHm5jOfMzndj3706+Fbh7eBhWcHJuO7scT8U9Kn0LW7i2gWUxy/vUdVz8nf649K1Pg2+o6prWnQaldhrfT0a8t1C53BsqRntjjivbtZ0TT9csnttSt0nibn3H0PrWT4U8GaV4Tmu5dLEmbrG5pPmIA/hB7D2pPHwnQcGveMvb1dr6HTg7uccdPeq2oTpZ2k9zcPiKJC7E8cAU9QQME8da86+MusvFp0GjwSFWuuZSOojHUfjivPo0nVqKKHh6LrVFTXU86tZZ/FniSeeZ9jXknzOTgJED0yegxjk12mmR2skZh0vULK8EYKvDBICyj6dx9K4bU9PubLwXdPbLIJ52RmwCf3API459M1yen4kvLaLS5ljvmYNEYcjaAQOfTPU+1fQey9qvddkjtx2M5aipQ2R6XrjkfuVOxi2Cqjt/wDrr0bwX4Yg0uyhurmFX1Bhvy3OzPYfhXK6ZaLqPi+ySeMMMb5MDIOOc8e4FeqEAd+vbrivLxdVqKguu4sXWcacacdL6sazbSWJ4965DxQYL6K1aa3LZLKCxAOPUV0l5Z+dlxIQ+RjuB+FU9Z0NdQtYYmuXgaNidyKOSa5KUowknc4qclBqR5tr+lxWcn2izldQUz19fX+tNW3i1DT3SRciWMjryCRjOPrXYa1oFrBo4jjVpLjhWfOSeRya4KO+MUz2mSjK5TkY56969OlU9pH3XserCftoJrdHX/B2/abRbnTJ2xcWch4J5we/0zXS6ro1nd3XmzgByMd+fevKLHUP+Ec8T2uqx/8AHpcERXSgdBng9Oor3NG3IGVuGAII7iuPFxdOpzx2Zw42nyz5+kjyU2oh35lVDjIjXLEf5/rVQT+VJH9rhfy5CMSDsD/+qul0uS3jYgZkc/IcrncD71LfmymtpTNFtdSIwhH3R611KetmjoVTW0lcz44YVcMskM8DALktlsUrWUaZVFEkXIQuBz7VgXelTM4awmjBHzFH6Y9MioPt2r2KbZ4JFROBIPnVQfUiteRv4WavDxmvckT+LLiOG3FqgHzYJGMYHcVk6ACmpxyxZDZz689quWunvqqvJuSQnoc5GTW1YaJHZSRNGWZ84KngZ9jWt4wjynfCUKFPke5yfxQ0SXW9PcxuWvGIdFXjp2/Kud0a3vm8FpHdRSrcWMvyB1OcV6zcRRHzRcLlHUqoZMDkj/CsO7WFIFVAS68MVPBHbI/KqhUvFR7HLRglVVVb7eR3nw08VQa9o0ELELeQrtdSfmOO9dlu3N1AI74r5z05v+Eb8W2d9bSN9kMyiUDgc9ePSvoWFoJlSePY3y4Vx6Hrz/npXk4yiqU7x2Zw5hh40anNDZk7RxsrCfawPBU8j8q818V+EjYTT6noqia1JzNa4LMvqU/wr0lW+YbiPxGakGGwARj6daxo1pUndHJRrSoy5onz94kFtc2UJiQGYnChRgj2rX8DeCZtRuo7rUogLSEgxpjh27k+o4qf4si40fUY00y0SYXH74MDt8s55+vOK6/4Wa9a6xoIijYpdW5ZJIj94HNerWrTVBThsz06mP5qVqe/U1tV8IaNqUareWqKF4DR/KR+IrnJfhxaB3Q6hc/Zm5VTgnr0Jr0TaOM849RWH4q12y0Kwa4vZYw5PyR78M30FedSrVr8sWcFGtWvywb1PM5xd6PKNMupUutAMyo0bD54lY8FT6Vh/GPwxplnO1zZyC1TygMMc7j16n8Kz9e8QXGsXl15UbJC7AiNTyFHI/WsnVku/EUckd880rqFG6TOYxXt0qcoyUm7dz2amFnyc++mq7s1/hNpsGst5Vtez2uoIpeKTKshwM8jqa9t8HzzajZzw6m4N/ZzNBMEJGSOjD2IryP4WiLRfEd/eXLSaldJCsdslrHhQuOSx456DpXoNtfz2N7eeIruy+y2d5GsewSDIZc4LDjOScVyYxOc2vu9ex5jjXnDlqKz6HJ/EtP+Ed8V21xosz20skRZmQ88nBHvXJ2tpca1q0pubhnYcyNIdzH8fwp/xEv77U9dE12jRKy7o1xkso6f/XrJ8J6jPbTyajIrNC7lDt547967KdOUaSfU9XC1VFKivjS3PoXRIjpXh6NIYi5RQQo/iPc+tYEnxGf7Y0EGnzzsg+dVAypzXReGZPO0KCZZmYhSRnqB2H6CuE8Q2mpWOprqPlxxTTKTGw6E+jflmvMowhOclNXZ59GEKk5RqK7NU+N/7VlAihlt3iO1kl9cdT7VozzaHa2UN9qTwtHIdzr97gjpXDNYfZ9Stp3vWkuzGJZh/eJB2rgdhk5/CtW38OLrai2mO2OM7y2RlevQVu6VOO2iN50YRjeOiOMtdE8OeLPFl3Ho1+LFgzOgdyGYf7OP5Zqtq/gO50S8MLXLyRR/MGjIZB/vDHB+temw/DnSrORJGmkfYdwXGCPYEdPwrvdJgtYrciCJY1b7ykdfrnrRUx3s9YO6/rqcDrJvnqQT/rufJupB9NnKJGSGCqpGOM9W966LwZ4r1fTJAlqWGdyhSDtcevpXqfxH8B2d1bNf6UohnXlo0Hyn3Hp9K8+0aS20reLu12XTYRGI4z/nBFdcK8K9O9rno4enGrerT2e8T0fRtBnedrvxBMzs6/dVjtQ89f8APavIPFGmGw8WXNvaTLJHNJ+6LjkAnivb/D+raTqenJ/pQlnXCSxM33T0rN1r4baXrmpR3ivNG6nnbIdvA4Pr6Vx0q/s5v2uhnTxk8PNtry8jz1bQ6XobNZ3M1vqgVo3I4WQHrgjr14rio7G8vNLmjC24meRWZ5pm80bR0UdDn3r2zxhpNqmmC3EqqLG32ow+87e5rx57t0LyMSGIwPX0rtoVeaLkjeODp5hFTqN3R0fgrSbrUtP1Kw/sr7eLhNrichVh9wex+ldVoHwn1DQj/aWlawp1NRkQyRZjOP4cg/rWX4H8YvoDO80Kz25T94I+CgGOcmtu5+L9nNvGk27SMeAcGueu8Q5NU1ozixFPkmlC2nW6/U7HwT4kl1Jb2y1W3FpqVi+yWIHIwehFdRLgrhTkE5yO9cf4C0y6ihvtT1BFa41KQSuc5wAMKK2fEutQ6HpM15Ou7yl4TpuP1ryatNOramjirKKm+U098NpASxVI4wWOT265rwPWb9vE/i15hgW/mbVYDjYMCq3ijVtdn1eG6vb5Ua6X93BGxKCNvpWl4as22zSQRM0kfyJt7EivSoYb6vFzbu2ell8FCnKs99kdHZDMgMWGUD7p4xx2HeqFyLO1uHkjtoYbqUlCUiUZPvgZxVm3mVD5LyK02MMm7kfhUWmwoPE1pNexF4pGDYcZHtQtLsUIxk25a2Op8BaC9rNJf3LHew2IpHQHBJrtHZEUs7KB6sQAK53UdQv7WMy2sCSdiB1AHfipdVs11bTIVu5Fzw+3HfFebV5qkuafU4KrdSfNI17d1lt0k3Ek9DiklmEYCk5JFULAm0sEhLqDGcDHIIzxj8O1RXAlF9NI8mIVGAOuPf8AWslG7M1C7KV1ewyPNbSlWUMFIXr681xnjfT/AC5baeOJgfuEH25HT/PFdZaWklxK1xaRJIGOSznAJGRn+dYPiu5uLfzFukRyP4AThR64ruoaTSid+GfLVSRyV6j6tplymxU2r26A9eK7z4d+K7ZvC9tHqUkn2mAmE8dQOn6Vx+mRgQNJIQEc7sA8muevHl066mihU+WzFx36111KMaycGdsqEa96fZnUPq72l6wCAYUBlcdSK04b77WrNw285Zt2ce1bD6VYaxcXkjN/q13cg/Njvnr3rE0XRZTCbyMlbB5RHIGUqQCcZH4/zrPng1fZo5vaUZx10ZYW7trKAmTKjJYIw+83+AqxpB+1wEySEQuwaQg4yM+9Tav4BnuJke1vuMDiRRn6HFYWlibS7+5065UNIDnB/TFKPJON4PUUVTnC8HqifUtEsorxn0yV7SQYJkjbG4ntt70kEHiS2gN1LHHfWajLeWwVwPXFbNhbv9ohUIvmu2AW5P69OlR+KvE+k+Gri1gcyXF/yskMTA7Aeue1PnnJqCV2ZyxTh7stfUz7a7s9SimnZGkdU27JThkPuKrX0Nu8kNvb2yiaVVVXjQ5bHUVJqMllq9t/bOgMYplCiSA5DOp6oc9x1H86NH1hrdhNZgAlSpVl6jvVpO119x0wftI89M5/WLB5LCePDiUdPQgV3Pw18Ti/023s5BiaPEeRyTx161ztxP595LFIAxY7izDGN3aub8A3w034hQwSEpFJKyYzwCRjNVWpqrSae61OitR+sUJX3Wp9AmNy6MrFcHJxUjBUXcSWI7ZxU6hTzgc9cVGIuOrflzXiLQ+cuc9rWm2upQyXFxHuMSkgA5J7457V5BeavHBOb3SWFrPFJtLwnJP+8D1r1L4ha3J4e0GS7ttjzlhGkXHzZyB+HrXiWgRzXWp3FxfEtcyPk4UAZP04BzXtYKLdNylsb0+b2keXqehaVqnjHxKqxR6ilrATgukYDkdz7Vu23hLR9LD3+rmbU51OPNunL5PYAGqGianNpqGWJCHC7QNuRirV9e3uuYWGymkjXJ/doQCfr+FZzUua0fdj5HpTg1K0bRj9xUudOh1rVIZlsxFbRnDvEmDgc4AHU1F4budN0vxLeNqLCOJ22o0y4xzxnPTiu+8J262+mICgE3O8dx9feuX+J1np66ZePEkQvHhJPqeRzUQrKcnS6bGca6nN0emxe8Q2FvZkazpLW9u4TLFFG1vf0Neda94pfVGtZ5l3WsMqy3CKQFXnHSn6ZqUy+G/9LJ8uBflLZO72rgdbb+0niV7VrWHdkiPjepPqa7MPQSdp626nbDDypQbtzOOx9BTz+EvEWlw+dNZlAAY9zBWRh3B6g/jg1zdv4f0xoZNN0nyXeV2IIw3ynq34814beQCyNuIN724LB4mYgKD0OR3zW14T1W80nWUubRz5EO3ZzwTk5H5VX1OUIvkmebhoP2rSTUvM9Vso9b8G+STi+0tQd+1cMh/p/wDrpmu/ETSdXXTYzaTuyTb3gC5yQCAAR2556dK2tW1OTX/DzNDMmZ/vRp945Hf8v5V4vNp81rqMqJ5jMrgoI+GIz2/HOayo0o1XzVFaSNpxlODm4++u3+R0z6q17rckdxZJYPHIHKZDHGfUfrXqfg8qYZ5sHeRg4xj8q8nvtITw9p8d5rl60l9cEtBDHgkL1w3vXffD/wAQRalFJHGjj5QSMYxjIOf50sVFOneGxKqSq4fll8SO4CJcEclWPAz3NWdkdshHO4DOPXNZ/mMrqYA8iqfvDkD6VBJPNJKPMVic98dP8/55ry+Vs43BvroaKyF4FYDO49DjFeJ/FeS00W+SOeEzecMRBf4cE5z+de02suYwZOIwOoHNeafG7R2vrWC/s0bzrZxhgBkjPI/WurAyUaqT2ZpRqTpt+z36HnkNs8EKahpVxNFKDghgeR6e9eieE/HEt1pQtZZI4buPILM2N3GeOeteK2MGoXdnqEzLeNJauBbhW+RGzkg+p4PNbaPs1CynYiNZ4Vkl3HhSRyf516tahGatLU76eJ/tCnJOPvRPXfGOo6ZpngmczBLrULuL5SWBYZ7j2HNeMXKP9jjdl+crtzn+I11fji8tdXvbaDTWE0UEKp5gTbuPBNc5PCIdNW8uJsmB9uwDkH1x9cVnh6fJHzZ3UIrDYdznfuzpvBfhK812ACT9zZzxkNkY7dOucdK0NE+Hl7BrKfbFSKEvtMoGAoA4Ax16VyXhvxNqyavZ+RFL9mEymQQg859D+tfRqYubPdan5cfxnJzWWLrVaDt0Z80nGfvJGjbxRxWyRoMRooAx3Fc/8RIwfCt9IY1dETeR7A8mtG3M4kQCUMxzyRkE1H4k2poV09zN8kaEtgdfQV49NctRPzFyXlyrqfNvh8PqOrJLcf6uIM6KQBxyV/nXceHGI0a4WMr5xlYqG9fXiufj04XGjXtx5rx3t1L+6AwMLnrW58PGjgnubGQbygyN3PHc17tZ80W+x7jpqnRdKK0VtSqnhzWUvfNf5VLBi2cFOPXrXT2shvL9bDdklQgc8478GrMl7Cd6w3HmyLwWA3cj+nFZZnks9XivGVd5cDag+8AewFczm6i13OTD0lqkdgp+wxrEkxcKMZPU01ryXYEBYgnOP/r1PG1tfxSXELBAiklW4IPeq0Nq967FpjHCpIUL1bHXNcWn2jO6W4pu58AFSxBGMr0p81/PNbMqx7owCGUDrn3pklhdWkDyGJmVeS2/O4etQXV9FYabM06hUZgVK9c/0otF7K4rKXwq51GmXFo9lEtsyoirjy+hXHtXG+ObNNU1O1lsrhSYoysuORjPfH41hXWqTy3UM1uY5IEJwHGByOQTTrUG0hlbdt8xjna33STnjFaQw/s5c99TSFD2L576mNfahFp9zJaovnNEMswOB+OetV757e4aKWORUDRgkZ6nJqTWLK1WZriUyO5bKx46ms2/uoI5wL5XMpUELEDtQdh0rvgk0mjbDOUJOpUdkexyaXeXdg9xbXdvFvjISONeCh52lj+X4UXN7NfaPBaW1m6CUeVI7DhDwCR6mqSazp1zp6Payk3PKbFbaFPuKualc3kGmQvAqJCBjcxO4v7e1eXaV1fe55vJJaSRBqpvo9QgjnuzmNv3TgYDkDOD6E1z3iaOVb2HVI5A7Rbt7d+vp9a17IveSpHIwlbzPMZh1DYxwa6J7DdayoYwLfyyHBXJIxWiqKk0mbRqexkm0cvod0byNdVuSzFW3eWB973H414p4mj1Cz1G8W8tHnupJnkjZ85cZ4APp3r2doRHoV1crMqG0UhIiecYz07niucg1ZtVlha5iYqvygsOh/HpXbhpuDlJK6CeGeIvKHQh8A6bPaeGjJeBI5biXe0Lkkrxjmr1/ZSAyS2MuyVsMUPKOcenb6ijXLpdNiWCCYKGXOevXt9c1X8PvcXrlXkJt9nzN1Ofan72tRl0qvsnyRJLW4gv7GVHhMVyhxIh42t3x+FcT4usbjSruHVrWT5hMCvYqRyD+Nd1rcKabm5toAoRQZQX3b19fTIrL1q2Oq6HNHEASQGU+uOR/hVU5dVsz2MPNXutnue0eGNVi1nQbLUImDJPErEgdG7j86084XqCfWvF/gN4jeOSbQLwjbky2+ex/iX+v5165dQ3UvyrIqIT0749K8etR9lUcDwMVh3QrOm9v0OK+MWnm90BZrcBpY5FJXrkCuf+H+gNeRXUzL+8Cgqr9R9Pxr0OLTsSl7geYhBUK3zFq5+w8Na/okk13otzbujZ/wBEnzyM8fN2NdVOval7NPUuEowjo9TFu2ureRogvlur7TmtvQvED2TKlwNxYc8Y/GsjUNTfWb90ayktdUiwJofQ+o9c1WuBKJNjghs5HHQ84rdxU42kj0OSNWCU0X/if4hu7Ozt5NKZ7SSbI3n/AJaf7I/x4qbRfBceu6Pb32rX11NeToCTnhPYVieJp21exgjugrS2koKqF7Hv+Na8vie6bRWsNHVLaZY/L84j7vXkD1pcs1CKp6PqzmjRqxVqe5y99pyzahPYRu/2WAhZWQYUkd8471ufD/w3YazeX19dr5tvbyiG2Q8dBncRj6VLo9k1toLW0Uke+4DGVpDuYse/P1pfC+qDwuDb3DRMjYZsnn8KupKUoOMHqdVWdSpBxg9To/FdnodlpU8l1ZW4JjZVZYgDnH0rifBfhI3ulW8M8fkrIS4cjBX6fpWle6kfF2uQwgpFYRuAxJwDznFdr4u1htC8NzX0EaNJEFWMAjGSQPyxXOpTpRVNfE/wOZSqUIqmvil+B59r3hd9GsvtWjXEyvE2Jgz5BPpiuV0LVLVfE9nfapEfs3zI6qckEDAJH416D4f8JJrOny6jrrfaLq+JkRN52xg85xnrVDxJ8L5HYPoBjjKrzHI2AT9a6IV4K8Jy17nXSxNKN6dWWvcyvibZW3iHT7S/0u9G+FsrkHPPXnH0qp8OlTTtTKXLhHl6KmdvuDUcMWoaAy22s2zxA4G8glSfY9KopKx1N2gk/iJAJ+8Petox/d+zT0NaeDp2bi91ufQlu0c9vGVxxg4B6Gs/xCyQQLLkBxwBnH1rE8Ma4lzpKyNKsYiHlszcfifer9whv1WdD5qEYBByCPb+VeP7NwnqeJ7L2dS0uha0W3ElorsxwR0/z9f1rmfihK+nafFJBGW3bg24ZDcfd5rpbK4+xx7JCOOg6Y//AFVleKobTXdPeyuhuVzlWU8oR3FXSdqqk9hNT5rxPG9c0bQdRuYtS0/zBFcxb5LWOTYFkHBDDB96r3F5bwHyk05boRvtZumAo+6B/npXWxeGlW61JLRnkkRPkTHLFccD9c1554kt7iO6BtScO24wsCVLZ5+nvXtU5Rl7rex6KpVfZf7OrTe/c6K31TTLq4jsdNs7qyldN8j3CjG3IwR7VveJdA0q88NGGxjebV2585DgOx7Y9v6VmeCPCWs+KdSl1O9f7NanEbOQR8o6IintXuOlaLZabGiQxAuo++wya48TiI0ZJReqMqlZ04pVneXVdPmcd8MfAMHh/S0k1LNxfuxdg4GEOOgH07+9dzJG4GYMAZyVAxkVNIVTdIx2gDB9PrXGeK/H+n6Z/o2msL3UGHCRHIX6mvOcquJndas4KNKdWXLTRs6nq2n6NJHJqNzHCmCQWPP5V514r8SXnjJ/sGhwSJpu7Ely6kBq5ebUPtOqPfasVvLtj8sQ+cJW5Brmqrpr+RpVwI34R/LKge/vXfTwqpNS3f4HrUsJ7FqSV5ee3yLNrYLNPZ2WzfFAvlkbep7k/lVPxZYP4f1a31G0QJAfkkUHoDxVfw54m/s25drpG3vzukGPyrofFWu2OtW8McRZmb5WyhCj861fPGok1odNqlOqote71IreKJYQtvEpWQh9yjBbj+VQavDNLgxq0csfIZfXHbFVrC7bSytpclmtTxHIRjjPAJqfXdYls9Oll3FlRflz3OOmR2qOWSlocc70Jc3QteH7m4UPFdYWA8NvOGcn1Heuk0S/tjJNJA2UBKneT+X6V4fpviXUrq5WRbpnjPzMhHQZxjB/nXYfYb0sPKbEb/NtLYGTVV8N/M7XIpzp4pybdj06XUoJtysyLC/BLNjGO1cp4zaFtMRopGmhHClTkK1YD6dM52vcAKGxnkikm0qdN6wzK3bB4yP/ANdZQoxhJNSN6NGlTkmplHU9W/s/w6jQoPNJ2gnt71gaT4vu3cNqSxiPORtUgt2z9a6i+06GbTFtZ8q/LBgeh7Z9q5a28MvPcRBZ0uFVQv3flXk12U/ZtPmOStTrTqt09jr7BoNRunlL74wPkyMg5qPWPC9tfXYmaSVH2BWEblBx7VauZYPD2lwwooww4bbya58X+q3uZrVJnjzjODxWSUnrF2R6H1f20U38PmXY9+nXrKwAI9ec1v6rrhu9Oto45m89fk2gYAHrUOq263aI6hfMOMgHH5VhOrW82yVcOnahKNSze6HFRxFnLdHeaIJLG3WR9pdMfMByOOuO9bK+Ir8M/m2inKjZhsFm+lcp4fu/ttq8xBLxN9xTjcMcZruNC08KHuJ/mnkGd2fug9cVw11GN3NXPLxEVGT51qVbXQ0ktGa+jje7kbewB6e1Z91bqySTNHG0UbBdoTaRxj866m5mS1DLk7yNwA6/hWDd2V1O4bzisRcOq5wDis6c29WzKFRnG+KdGaWxEseWKoGKD7yj/GsvR9UMMEVsqKIh8oPQj616SzTX93O0kUUUixbQhP3uetcn4j8Mstuby3UieNN8yZ4wa7KVZSShM7cNUpy9yotX1HtbCaAtz5Q/8eH0rzfx6+qeH7W2udNkYmxfeYf4ZoD2PuOn5V6D4cvFmgaCV9sq4CgnlqTXNMa6tSsaruj+dWfkMfQ57HpitqcuSVpbGk4tXpN28/yZ56FmX7F4k0UvCZQtxtGcqcZr2vwX8QLHXdLZrz9xewrmWM9+2RXI6dClxYRPFGihV+5jhMdRj9K5bxFpy6VeC609mjST7y5xg9SPp060p04V/dluup01aUcVD2cvjS0Z7xZ63p9xMFWdUmY8K/ynHtWs0gA5OfpXytrF9NF4f+1+c32jeFVd3T2Fe0/CLxRHrnh2K3mZhqEA+ZH+8Vz19648TgXRj7SLuj5v7Ti90WPFun3Vvrdv4i0+DMsK+VNGw++gzz9ea569ubzV9R8+BPvHoq9BXc+NPEdnoOkSNckPPKu2OEclieOlcXpXjZLq0SPTtMa1Y4V5HwTnjp+tVQ53Dm5fK56OFnO2kbvodZ4e8L28ViX1CLfPMdzBuoqnqngK3lmWWwmeFj94Z4NVdP8AFd0175ZQMAfmxngV3lvMs8CSRnIYZrGpOtSlzN7kVJ16MuZvc8p8ReF9TTcyozxJ12n/AArmdNiAneC7tykijOG6175I8auVLAN3HtXG+O9DtZrRLoR+VOr43p1wc8H15xW9HFuXuSR00Mwb92aOH8J+HbbWdRuVupJEhRQ6KhPXPauwl+H9vc2D26XV1Hn+9KWXHbg9a47R9Zm8N6l58wPlhdr59K6/Tfidpt3dlTDKLbcEMyjIVj61pX9vzc1PYvE1KznzUnoZ+nvqfgvUrWHVszWMo8rzUOU/2T7H+dekWN5BeWyy28gZcc88j61534o8eeHJ/tWj3e67kkXcuxcheODk9KyvA0d9rFoH069RXQFJV34IweOPp/Ksp0XUh7Sa5X+ZzOMcSnKbtJbnp2raZYanpskGoqjQyA8k4K/Q+1eAeIrFvDeqzxK5v0Rl2SBtoGfX3xXp0vgzUruR47y/dk6gq52j2xWT4h8FzWFneTmQNamPcy56N+P0rTCyhSfLzXv0OnBzjSvBVNzz8apLFZmOcn7HJJvdT6dBn6ZzXoXwr1S63XGl3EcSQRxBo2X1yc8fQivPtGeH+1Y7fU4vOsmk2TKe6Hgk49K9M8BaLp+n6zrdpYN9oaCTasrPuYIQML+GRXRi3H2bi0RmOH5aymtrHXxrFMC6uN/3SCe30qstssIzKM4JH0zV2JSz+Sqojudpbv3q4NNj2YeSRmP3iT1ryeaxxOoonJ+IoItH1bTtQgZQ80nlyKD1HriuN16wgF9cw3YAkDb454yF2Nxz+NdB8VJYNLjhkZ2ZnQiIEk7SD1/UVU+HER1PVJ49ZiMuIFkj3jhs5H6DFd1J8tL2rOynXjSjGbd3Yg8O+MdV0u1W3nt7a8QjcHE2w5468Y98VTu/iV4rurp47LRobOFM5lmBYHnHGcVn+JL7SrfxnqOnaaRutcM6dVXI5wfTmqFqLnxBerbROxgRdpznB9hWyo03+8cdzqjQo10q0UkupT1TWfEevTzLqWo3MkanHk2nyJx24q7ovhqTYhmJRX+VkH5ZPrXcaf4fGh20MVxF87/NG55Gccg1evZo9J0ySeMIZmwRG/3WHoKTrpe7SQqmNjCNqK0MG1trHRNLuJhal2j6Ecknpgn0rko/iN4j/ttonazS1RiDbeXuQr2GcZ59a7zwmI/EtldebhCpAZF6E5P6Vf0f4daPp+rG7eEzTFxKoK8KR/8Ar6VHtqVNyVZXZ4+JqSqyUkypruio6rcXEUYWZVwhB43AcfmTXnviT+zdMne3srmRZYuJNrZjJ9PrXs+v2VxqSTorjagHlBTghh3rxAeGPElldX0F5p8slopPk7F3mTJyTn9aeDmpL3n8jb65WpxXIzZ0y6MUSxalG81nONis44RupHv1p97p032J1s2+0Wmc+W33lI7qT/Wrek6Vdp4Qh0+9UqRI0wJHzBumT9BiqM+ozLpBKNIJ7dikwXk4xwQfTvWt7y93ud3tXUo88lfuv1Kuk6fYW1550sjm5yAElTaV78f/AFq6dnR1++q7hj2FZOlTR6to7S3hD7CUzIv3hj+dT6R4In1iRTZSzWtuPvOWPH0FTVa1c3awqVOhyc6fKiaW4VAGMiqccjruqjea3ArAQANKBjANdSnwm09kP2zVdRmYHOVcKM/TFUfFngPT9E0S6v8ATRcySW8Zcq77ifpWMK9CUlG9yY18NF6ts5qwtLjVJi1zJgZyEZsZ74robO0tltyzTi1gQ5JAyQM14TpF5q8+uSSK90BkErvOBn+deqNJLerBAGPm4AbHQnua661Jx6m9GssUm43jFFrVJYtcuxZ2gdrOE5kuH6tj0rYWx8lESAmOMAYBHX3qSztI7O1+VWAIxtH4c59aillTeTJJJuPtmuVyvpHoZVJ865Y7Iwke+0K/Ola6m1s/u5SOG+hq1qdt9qBlg5KgZr13xBoGn6/ZG2v4Q6/wupwyH1B/OvJtT0u/8K3i2moEzWchxBcr39m9DRRrxq6rSXb/ACFQxKqyutJfgzGt7i4sJN8RIl5H1Fej6b47shpKtMrLMihfLA6kcViaZpUOpwnzVRwnOA3b61hXmkNbas8ca4hY5XJqpxp1naW6OifscTpUVmj0DTdQa7uo77UWVY5QfLReqr2BrZTVLKZg8rKqBj1bgAen5Zrl4ovMiKKgZXVUZRj06CrkWl20csu4BiDsIDZIGAeK5J04vU8qcYuVtjX1nyJprKW3C+XuPzI2Cx7D+dVpr2KBXhuwWlkU5Qc8ds1i27xLr0XnXAWCM7whPLHkD+vSt2+kVjJe2oHmquPQ9MYo5eW0WNw5LI85sNKuY7/eQBGrDkg856Vv3VzYWsqxXGoQCYtnY7Yx3PFXLnUAY/Od4pLlU9OA2MfjXhV7b6hNOrLb3Et6JC7BIyxfJwR716FKm6+snaxeKxk202j1iSSGzuRcRyK1lcOA7A5Cs3Qj2Pf8KoeJtJuL2MiIZMZ+XB+8DjH41leEdP1Ka21BdTgkhtplKJFKckMTnI9MYrTsvEVhothazaxHLPvDQmNDg717n0/+vT5ZRl7urR10MVan7Z6NHDSte2gMcsEUjwSBwsiZ59D+FaOm3cmn6lZeINGaG1WAEzxs5+Zu6Fa6bSJbLX7W5uUjKpuwxbllPYH/ADzXL6zCukXF0VhWRSmQG6Z6g/hXQpc94MMXhqeMXt6Okt35/wDBPX/BOh2evmTxDfxee1ySY45PmCg9a7C10bTYDmGziTB4G39a8r+B3ju1uNNXRb6VYpI3byN3HBOdpr2fjHvXiYpVIVHGWn+R5decua6ej29DntZ8Ox3TedYsIJ8Yx0U+9c/Lp/iKw+W0y4xk7W4r0E4xkdaGIzk4Az1qIV5RVnqOGKnFWeq8zybWbTWNLl/tG482aVsSSBWJG3uPwrrxqNr4ghtY9KnjbK733HlRjpj1yaxPiP4wisy+l6bH9qucB5HQ5WMc8H3ry6bVIrHSm1F7qS3Z38tI05Jb2rvhRlWipSVn0PQjT9tSVWp7tj0XxJpltHMIZTFJK43MJMD/ADxXMaVpNqZGtLV0S3mfdIsXr6153ZeKItSv1hmglcSShTI773yfQV6JokS+HPEl22rTfYo44xKu9cbwOcCuh05Uo2b1NKMqLg5Qkm15HBeKdA8t7g3QldiQqSocbsev4VY0Oa+06KGe1lnhuYh+7uA2GI7hvWvQZfFGgeJdMXSnT7KXJKSOBvduwH+e1cpbxCF5Le4kRkiBxJ1/D61tGcpR5Zo3wqpVpuqlZ9ezOm0T4rahZNIur2wumLAHZwRwBkevStTU/iXp2s6XPaS21xbrKuCSAQD1rE8P+CLzxDpK31qsMEbcR7urY6muWs9D1K91p9JtIQ95GzI+5vlXHqa5vY4dybW6L9hg5zbWjj57CmZTe5VgwcMoJBAzjg8/lXdeA76aC0leMsL2AnajMMyw9QCfUdK5TUvCOu6PEJdQtv8AR423GVGyAM459qvi5a01mztdLimlnaMPNOAcDJ6L/wDXrSfLVjaOosbKi0qnNdPTuj2vS9V0y8tIZoZ4wxXdtc4YHHOQe9X5bqCKMyPKgQfxZ4ryi4tY7W8eW4CzoybieMAn9KmuZJbuOEQssducblduMV5rwqbunoeY8Cm7qWgvjK5tdYvbS4ul3WKylCT/AAjjn2p3xN1dfD2nafa6CpgnmYB5oeSkePX1PGKyNdkgjuI7eGRWV+HPvRcNcbnjt1DRbMuGGQAB1yeldcaaXK+i6HTVwinGKTtZM8/0fQHl1OV0EjTXX3SeWbuzMa9g0nTYtCs4ltCN2zdvUclq5jwO0jalLdBUEnMSbhwo4z+Neg6jpl3c2MdtaTxiRQWeTbjP0/Sniqzc1F7GddfV4KhHYxtf1mT7MhnAdlBILcYGK57StXg8Tar/AGRMcTAYG0Hp65/pWnpvhPxFJeQW+s3NtNaO+5sZ3KME8e9dp4e8LadoVxLLEivcP/y0ZRkD0rnlUp0Y2Wr6WPOdRvbYy/DnhyDw4LgtLiMjOT94nOa6KwJuizyeaEXhSRtDZ+n4VanjjkciRQy57irCJ8vJGRwcdK8+pVc9ZbkcysVVCRziPbtXqCe/NS3Dqu0KMuegHc1JLGkqYY9e4rNibY7vI3CH7xPSoWuoLXUzvEWnxxwK5AZpHCMgH381514j05bSRpUHlvHw6ngmrfiH4iyQ+I4re1tBefZmYbAcDp19z147Umu+MdL8T6CFhga21EYZ42HIGccHuK9WhTq0+VtaM7MJXcaqgtTPWNEtI5dp3SEFRjGemSMV0+k6w2mwgiYMjLjY3RT615TfXN7PrSRQu+YSECgkY7M34nP5V1MVnOYgkyncBy7ZOfpXTVopxSk9zvjONfmU9kzv7DxpbfavJvnjVSPlYdM1Y17xLpYsnht7uGaVztKjsMc15lPpUghDFlbtg0y03WNwd8YRvda5/qlPm5osX1KjJ80H8hZ9JtbSSW8tYzG7/KPftkenWr/hm1TzZppcFvupz371V1S4zCPNYs7MM85AHtV3wvrOnRWstncDcWPmeZjIUen/ANat6nM4GtWKo0Hyq12bN1iRCuCGAwBmmJFGwLNAZSf4iKNTmi023a/Yh4AuVzwGB/pXn2o+KfE6XJ+xJb/Z2AZQAvAI6ZPWsaVOU/hPLlWjT3PpG2ljnhEkMgKN6HvTdRsrXUrR7a+hEsLggq3b3rhvCmszxxRKACkgDbSfumu+tmMkKs3UivMqU5UpaHNVpSoyszy7UbO68F3nloxk0u4O2KZuTGf7rH+tRsfOlVgBk9OvevQfEccF7Y3NldQiSKSMjr09xXmGgykxyRc4jbrnk130J+0hzPc7qUnVg5vdHQfa106bznjEqbfkHXnoDUmnz300DliYVmLbg4yQPUVOiJp2hteFFnlzuIk6YA3Ae1ecSePtYl1O5kYxeRK6xmHb/CfeqhSlUvyo5alVRlZndRaAZ9S/tCE+YIjgtjnj0FdDb3Frdwyl4wSQRIFHSq9rqbWWnyeXErHlgSelS+Es3PhrzydsskruzfieP0rnnJyXM/RG1SUnG8umiOb1bw9FqKXU9hIYJo2AjU8h/b+dYOhT3EF1LbXTFGiJ6rjBHvXoD2ws5o5VbcZDgjGAMf8A6q8/mnMviKSQjBZjnnrXXRm5Jp7Hbh5ucXCWqOil8t4nk2Ntx1HeuU1LQIdXvpbJj5bXGJoGbs3Q/wBK6u5uzHarlQ2U5HQcAdq5rxTM0NtBfxfJPbyqybeO/T9Kuk2noRTipXpy66G/4P8ACCeGNKuLK8Zbm8uiJHO3AUgcBTXM+LLJLiOWQjY6Nswxxkd69SlvWuNEt7p1HnSR8t6cV59qUa3cF5vzna3J55wef0qMPUlOTlLcnAydG76I8z0jQ5hdPPp37u5tphIOfvD0x6/4V7JafGDw5Y2KQ6xdNBfxrhoypOT25rjP2f5Te60xuAHCwsMHnoetd58Tvhf4f8UabcXMlutpfRoXFxCuCcDuOAa0xU6c6vs63TqcmMjGnLlprSVpLyuZmmfEK+uonubVI5onOUR26ZNZ/iHWNfvoN97ei2hI+ZIDj5epOay/gh4cjukmtby4aWGCc4G3BYDsTmvU9W8PWUOi3MSJ95GAZuStZzlRo1OVI3lWpRScY2k0eS+GfGOi6U1zbyWE7/aFHlyTAMCe5J+tdn4R8DaL4l8FWkmsQNcRyyNOm1yu3qOorzW8sIrq4hUkqrs2QOmRxxXrXwnv3t/D9xprLvSxlZEfOCwPPT2zWuLXs4c1J2fU5fa1KtOUX5G34c8B+G/Djh9L0yGOQch3+cg+uT0rhfjvYz6le6RaWMYmu5AzLF3bB/8Ar16tLelP4M5964fwhOdZ+ImtXt0oL2kSQwDr5anJOK4KFSam60ne3/DE0qbSlJ7JHN6P8LbnWLi2vPESR2AiwVhtm+YDHTPat7xB8OQ1uYtFYLuU/wCtY9fc16WcbfxpKUsbVcr3Io1pUXeB5foh8ZadpR0aDR0jZiQt00oKRg9SP5/jXU+FPCNpokZmlJuNRl+aadj1J9Paun7UHtWU8Q5p20vvYupiZTv0vvbqcd8VrkWXgi9IJBl2xADvuI/wrgtNttRk0y5nltmtItP2LMpbDtkZyvbHr9a6f4v3Befw1ppB8m6vl3nPYEDp+NZXxMvbpDq9nBN5VvIiK6qOvGOv0FduGuoRiuv/AAEehhZONFRS3u/yRn6Pr+nXN9Lp736lZk2AHBAYjoW6A/4VHc2sy2s7W8qXcCyFVkhYSYCnHzY6V5Fp+n/ar6Sy81kVSTuxnNejfCuE6Pf36LI0irHtVR8o5zyR3ruq0VSTlF/I56GOqqa91WZIJLe1D3l0xYw7jvPC8VN4M1BruzuL+WVZrN2dmQ9Rjt9KreKQLy5ewdUWL5W4X17VDpSLp2kvZ2w2oX6/U4PH4Umk4anquNSpJN/C0dF4CSK+aaRt0O8kxjsfXmvRrJ3jtlVZMsBwD9K8n3PpMsMcDkohLBeg+ldtp+ryXHlyPGAVTAwa48TTcnzLY58bRcnzLY3Jb24g1COWcFYlyAAcjPer9rq9vfny0c7j0x3/ABrhfFmo3DeFL5gwVkw4IHPXpmsfRb64soIJkkLM5875uoz2+lY/VueHM9zyakkmtD18p5MTYAwvPJqxHIjIpB4IqpE5eJC38ShsfUf/AF6nEY37AcAc157S6kNdyRiBuJ6445rB15XWwmMPBbGcfWszx34km8NaS11BCszh8AO2O2a4HRPHGoa1qjQXccexlDYHQceldWHws2udbIuC5ZK5kavpV9pV3enSUE17LN5lvKQSBnr9DS6bYz/a1utTjiS5jjVGjhPGc8knvmup1Rzb6d5kfDyE8+lcP4h1OXT/AC1hH+sbBOea9enKU1Y78Nh40lLEN3tsV7i6uIrqeWxUwsWG0sAep6/nXoulW0xtoJNSh+8gLMDjaSPSuB8HznUr3dcqCHDcehAGD+lemSSSyx7Zn3grtBIxgAcVOKdrRsY0pym3NvcrX1qtsCRICFIIJ9KqzW8coKttUnjcTTbyRpEZTwPlX9P/AK1UbeUzMxbPyEEDPHFYJNK52qDS5rlLU4ZFbyHUZTo4/i+lZ1vDFBfrJIpx/Guetdfd26XMUjOMBRuA9DXOanbfZ7koHLHZu3H+VbQnfQ66VSNaPs5HTaokWsaXDYmU7SpGCoIGPu/04rGbwZrW1FuLa0uCi7VdmAO3txVDTb97e3lcDcY4mkXJ6ECskX+pXIE0mpXKs4DYRsAZHQCphTnF2i18zxMbRVOfIz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5401=[""].join("\n");
var outline_f5_17_5401=null;
var title_f5_17_5402="Causes of hypokalemia";
var content_f5_17_5402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of hypokalemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5402/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5402/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/17/5402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/17/5402/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/17/5402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia is a common clinical problem. Potassium enters the body via oral intake or intravenous infusion, is largely stored in the cells, and then excreted in the urine. Thus, decreased intake, increased translocation into the cells, or, most often, increased losses in the urine, gastrointestinal tract, or sweat can lead to a reduction in the serum potassium concentration (",
"    <a class=\"graphic graphic_table graphicRef62892 \" href=\"UTD.htm?9/59/10172\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the major causes of hypokalemia. The evaluation and treatment of hypokalemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link\">",
"     \"Evaluation of the patient with hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DECREASED POTASSIUM INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium intake is normally 40 to 120 meq per day, most of which is then excreted in the urine. The kidney is able to lower potassium excretion to a minimum of 5 to 25 meq per day in the presence of potassium depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, decreased intake alone rarely causes significant hypokalemia. This was demonstrated in a study of normal individuals in whom lowering potassium intake to 20 meq per day was associated with a reduction in serum potassium from 4.1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at baseline to 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/2\">",
"     2",
"    </a>",
"    ]. Such a decline is required to provide the stimulus to reduce urinary potassium excretion to the level of intake so that a steady state can be maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H838162389#H838162389\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'The steady state'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a low potassium intake can contribute to the severity of potassium depletion when another cause of hypokalemia is superimposed, such as diuretic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCREASED ENTRY INTO CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 98 percent of total body potassium is intracellular, chiefly in muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The normal distribution of potassium between cells and the extracellular fluid is primarily maintained by the Na-K-ATPase pump in the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Increased activity of the Na-K-ATPase pump",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alterations in other potassium transport pathways can result in transient hypokalemia due to increased potassium entry into cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17666515\">",
"    <span class=\"h2\">",
"     Increased availability of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin promotes the entry of potassium into skeletal muscle and hepatic cells, predominantly by increasing the activity of the Na-K-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3\">",
"     3",
"    </a>",
"    ]. This effect is most prominent after the administration of exogenous insulin to patients with diabetic ketoacidosis or severe nonketotic hyperglycemia who are often normokalemic or hyperkalemic at presentation, even though they have lost potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/5\">",
"     5",
"    </a>",
"    ]. Hypokalemia can rarely result from an insulin overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Potassium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endogenous insulin released in response to a carbohydrate load may also contribute to hypokalemia. This has been described in patients with refeeding syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/7\">",
"     7",
"    </a>",
"    ] and after the administration of intravenous potassium in a dextrose in water solution. Thus, initial intravenous potassium therapy for hypokalemia should be given in a saline rather than dextrose solution. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H18820461#H18820461\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Intravenous potassium repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17666854\">",
"    <span class=\"h2\">",
"     Elevated beta-adrenergic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous catecholamines, acting via beta-2 adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/4,8\">",
"     4,8",
"    </a>",
"    ], can promote potassium entry into cells by increasing the activities of the Na-K-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/9\">",
"     9",
"    </a>",
"    ] and the Na-K-2Cl (NKCC1) cotransporter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/10\">",
"     10",
"    </a>",
"    ] and possibly by increasing the release of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/11\">",
"     11",
"    </a>",
"    ]. A proposed physiologic role for this effect of increased beta-2 adrenergic activity is to moderate the acute hyperkalemia of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of potassium flux into cells, transient hypokalemia can develop in any setting in which there is stress-induced release of epinephrine, including alcohol withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,13\">",
"     3,13",
"    </a>",
"    ], acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,14\">",
"     3,14",
"    </a>",
"    ], head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/15\">",
"     15",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar effects, in which the serum potassium concentration can fall acutely by more than 0.5 to 1",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    have been observed in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the administration of exogenous beta-adrenergic agonists (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) to treat asthma or heart failure or to prevent premature labor [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,18-21\">",
"       3,18-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ingestion of over-the-counter sympathomimetics found in decongestants or dieting agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      and ephedrine [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,22\">",
"       3,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exposure to heroin or meats contaminated with the beta-adrenergic agonist clenbuterol [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the cause of increased beta-adrenergic activity, the degree of hypokalemia will be greater in patients with preexisting hypokalemia due, for example, to diuretic therapy (",
"    <a class=\"graphic graphic_figure graphicRef57078 \" href=\"UTD.htm?26/12/26829\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27627359\">",
"     'Diuretics'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    This potassium lowering effect of beta-agonists may be particularly likely to induce arrhythmias in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When administered concurrently with diuretic therapy in patients with hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2021?source=see_link\">",
"       \"Treatment of hypertension in asthma and COPD\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women with preterm labor. One study, for example, found that 3 of 14 patients treated with either ritodrine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      for the prevention of preterm labor developed a symptomatic arrhythmia, such as supraventricular tachycardia or premature atrial and ventricular beats [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, beta agonists can be given acutely to treat severe hyperkalemia. On the other hand, beta blockers raise the serum potassium, particularly if given with a potassium load (",
"    <a class=\"graphic graphic_figure graphicRef62538 \" href=\"UTD.htm?29/51/30525\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prevention of hyperkalemia in adults\", section on 'Beta-2 adrenergic agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Beta blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Elevation in extracellular pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either metabolic or respiratory alkalosis can promote potassium entry into cells. In the presence of alkalemia, hydrogen ions leave the cells to minimize the increase in extracellular pH; the necessity to maintain electroneutrality then requires the entry of some potassium (and sodium) into the cells. The serum potassium concentration falls by less than 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 0.1 unit rise in pH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to alkalemia leading to cellular potassium uptake, metabolic alkalosis is a common finding in hypokalemia, primarily because the major causes of hypokalemia (such as diuretics, vomiting, and hyperaldosteronism, described below) also lead to losses of hydrogen ions. Hypokalemia is an important cofactor in the",
"    <strong>",
"     maintenance",
"    </strong>",
"    of metabolic alkalosis, since it promotes bicarbonate reabsorption, thereby impairing correction of the alkalemia by excretion of the excess bicarbonate (",
"    <a class=\"graphic graphic_figure graphicRef76787 \" href=\"UTD.htm?1/17/1309\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of metabolic alkalosis\", section on 'Hypokalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypokalemic periodic paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemic periodic paralysis is a rare neuromuscular disorder characterized by potentially fatal episodes of muscle weakness or paralysis that can affect the respiratory muscles. It may be hereditary, with an autosomal dominant mode of inheritance, or acquired in patients with hyperthyroidism. Acute attacks, in which the sudden movement of potassium into the cells can reduce the serum potassium to as low as 1.5 to 2.5",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    are often precipitated by rest after exercise, stress, or a carbohydrate meal. The serum potassium is normal during periods between the recurrent attacks of paralysis, a characteristic which can help distinguish periodic paralysis from other forms of hypokalemic paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link\">",
"     \"Hypokalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased blood cell production",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute increase in hematopoietic cell production is associated with potassium uptake by the new cells and this may lead to hypokalemia. Administration of vitamin B12 or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to treat a megaloblastic anemia or use of granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat neutropenia are the most common scenarios in which this occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar mechanism may lead to spurious hypokalemia in blood samples drawn from patients with many metabolically active blood cells, such as patients with acute myeloid leukemia and a high white blood cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/26\">",
"     26",
"    </a>",
"    ]. If the blood is allowed to stand at room temperature prior to measurement of the potassium concentration, the measured value may be below 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    even though the patient is without symptoms, signs, or sequelae of hypokalemia. This spurious hypokalemia can be prevented by either rapid separation of the plasma from the cells following venipuncture, or storage of the blood at 4&deg;C before assay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link&amp;anchor=H896838#H896838\">",
"     \"Overview of the complications of acute myeloid leukemia\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25915856\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental or induced hypothermia can drive potassium into the cells and lower the serum potassium concentration to 3.0 to 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In contrast, hypothermic patients who are essentially dead and thus unresponsive to resuscitation may have marked pre-terminal hyperkalemia, due to irreversible tissue necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25915863\">",
"    <span class=\"h2\">",
"     Barium intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    intoxication, which usually results from the ingestion of contaminated food or from a suicide attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/29\">",
"     29",
"    </a>",
"    ], can cause hypokalemia by blocking the potassium channels in the cell membrane that normally allow cellular potassium to diffuse into the extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment of barium poisoning with potassium replacement serves to both increase the serum potassium concentration and to displace barium from affected potassium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/30\">",
"     30",
"    </a>",
"    ]. Hemodialysis is also an effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients undergoing radiographic procedures are not at risk for this complication since the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    sulfate used in these studies does not enter the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59114396\">",
"    <span class=\"h2\">",
"     Cesium intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesium intoxication, usually due to the use of cesium chloride as an alternative therapy for cancer, can be associated with hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/32\">",
"     32",
"    </a>",
"    ]. How this occurs is unclear, but may result from cesium blockade of membrane potassium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chloroquine intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia, with the serum potassium concentration falling below 2.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in severe cases, is a common finding in acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/6\">",
"     6",
"    </a>",
"    ]. This effect is presumably mediated by potassium movement into the cells and can be exacerbated by the administration of epinephrine to help treat the intoxication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172581345\">",
"    <span class=\"h2\">",
"     Antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia is a rare complication of therapy with selected antipsychotic drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INCREASED GASTROINTESTINAL LOSSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of gastric or intestinal secretions from any cause (vomiting, diarrhea, laxatives, or tube drainage) is associated with potassium losses and possibly hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17667289\">",
"    <span class=\"h2\">",
"     Upper gastrointestinal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of potassium in gastric secretions is only 5 to 10",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    thus, potassium depletion in this setting is primarily due to increased urinary losses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following sequence is responsible for the urinary potassium loss with removal of gastric acid. The associated metabolic alkalosis and rise in plasma bicarbonate concentration increases the filtered bicarbonate load above its reabsorptive threshold. As a result, more",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    and water are delivered to the distal potassium secretory site. In combination with a hypovolemia-induced increase in aldosterone release, the net effect is increased potassium secretion and potentially large urinary potassium losses. Because of inappropriate sodium wasting with bicarbonate, a low urine chloride concentration is used to detect the presence of volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urinary potassium wasting seen with loss of gastric secretions is typically most prominent in the first few days; thereafter, bicarbonate reabsorptive capacity increases, leading to a marked reduction in urinary sodium, bicarbonate, and potassium losses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/25\">",
"     25",
"    </a>",
"    ]. At this time, the urine pH falls from above 7.0 (due to bicarbonate wasting) to below 6.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17667296\">",
"    <span class=\"h2\">",
"     Lower gastrointestinal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to gastric secretions, the potassium concentration in lower intestinal losses is relatively high (20 to 50",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in most cases. In addition, hypokalemia due to lower gastrointestinal tract losses (usually from diarrhea) are typically associated with bicarbonate wasting and hyperchloremic metabolic acidosis rather than the metabolic alkalosis observed with upper gastrointestinal losses. However, some patients with hypokalemia due to factitious diarrhea or surreptitious laxative abuse develop metabolic alkalosis via an uncertain mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=see_link&amp;anchor=H4#H4\">",
"     \"Factitious diarrhea\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia from lower gastrointestinal losses is most common when the losses occur over a prolonged period, as with a villous adenoma, a vasoactive intestinal peptide secreting tumor (VIPoma), or with persistent infectious diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In many cases, increased fecal losses cannot explain the entire potassium deficit. Since most people ingest an average of 80 meq of potassium per day and urinary potassium excretion should fall below 15 to 25",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    in the presence of hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/39\">",
"     39",
"    </a>",
"    ], fecal losses (which are normally about 10",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    must exceed 55 to 65",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    to directly induce hypokalemia. However, many patients with diarrhea who become hypokalemic have fecal potassium excretion below this level, indicating that other factors, such as decreased intake and volume depletion with increased aldosterone activity, must also play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Increased urinary losses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other causes of hypokalemia due to lower gastrointestinal losses have been described. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bowel cleansing for colonoscopy with both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      (which is now infrequently used) and polyethylene-glycol (PEG)-based preparations, particularly among the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"       \"Acute phosphate nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute colonic pseudo-obstruction (Ogilvie&rsquo;s syndrome), which is associated with a secretory diarrhea characterized by an abnormally high potassium content due to activation of colonic potassium secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link&amp;anchor=H4#H4\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ingestion of clay (&ldquo;geophagia&rdquo;), which binds potassium in the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INCREASED URINARY LOSSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary potassium excretion is derived mostly from the secretion of potassium in the distal nephron, particularly by the principal cells in the connecting tubule and cortical collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,45\">",
"     3,45",
"    </a>",
"    ]. Hypokalemia due to increased urinary losses is primarily due to two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/39,46\">",
"     39,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased mineralocorticoid activity &minus; Aldosterone acts mainly by stimulating sodium reabsorption via the epithelial sodium channel (ENaC). Reabsorption of cationic sodium makes the lumen relatively electronegative, thereby promoting passive potassium secretion from the tubular cell into the lumen through potassium channels (eg, ROMK) in the luminal membrane (",
"      <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Increased distal delivery of sodium and water &minus; Enhanced potassium secretion can result from increased delivery of sodium to the collecting tubule, particularly if accompanied by nonreabsorbable anions rather than chloride. (See",
"      <a class=\"local\" href=\"#H9060678\">",
"       'Nonreabsorbable anions'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Potassium wasting can also result from polyuria as seen, for example, in primary polydipsia. In this setting, the urine potassium concentration is appropriately low (less than 15",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      but cumulative potassium excretion may be greater than intake due to the marked increase in urine volume. (See",
"      <a class=\"local\" href=\"#H9060828\">",
"       'Polyuria'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, increases in both mineralocorticoid activity and distal flow are present concurrently (eg, diuretic therapy, primary aldosteronism).",
"    <strong>",
"     If only one parameter is increased, the other must be normal to permit excessive loss of potassium",
"    </strong>",
"    . This important concept is illustrated by the absence of hypokalemia in patients who have a compensatory increase in aldosterone due to volume depletion. In such cases, angiotensin II stimulates sodium reabsorption in the proximal and distal tubules, which reduces distal sodium and water delivery, and inhibits potassium secretory channels in the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/45,47,48\">",
"     45,47,48",
"    </a>",
"    ], thereby counterbalancing the stimulatory effect of aldosterone on potassium secretion.",
"   </p>",
"   <p>",
"    In response to hypokalemia due to increased but stable urinary losses, urinary potassium excretion eventually falls to a value equivalent to potassium intake. At this point, the serum potassium is low but will not fall further unless potassium wasting forces increase due, for example, to an increase in diuretic dose or in aldosterone secretion in primary aldosteronism.",
"   </p>",
"   <p>",
"    This adaptive response to hypokalemia results in part from reduction in the activity of the potassium secretory (eg, ROMK) channels in the luminal membrane of the cortical collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 4",
"    </a>",
"    ), an effect that is potentially mediated by increased angiotensin II activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/45,49,50\">",
"     45,49,50",
"    </a>",
"    ]. As an example, downregulation of luminal potassium channels will minimize the degree of hypokalemia seen in patients with primary aldosteronism and may explain why hypokalemia is an inconsistent finding in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features of primary aldosteronism\", section on 'Hypokalemia: an inconsistent finding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16897827\">",
"    <span class=\"h2\">",
"     Major causes of urinary potassium wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of hypokalemia due to urinary potassium losses include diuretic use, a primary increase in mineralocorticoid activity, increased distal delivery of nonreabsorbable anions, and loss of gastric secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27627359\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any diuretic that acts proximal to the potassium secretory site &mdash; carbonic anhydrase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ), loop diuretics, and thiazide-type diuretics &mdash; will both increase distal delivery and, via the induction of volume depletion, activate the renin-angiotensin-aldosterone system. As a result, urinary potassium excretion will increase, leading to hypokalemia if the urinary losses are greater than intake.",
"   </p>",
"   <p>",
"    The incidence and severity of hypokalemia are dose-dependent, occurring much less frequently with lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Thus, lower doses of thiazides (eg, 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) are now widely used in the treatment of hypertension because they are as effective in blood pressure reduction (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"UTD.htm?18/24/18829\">",
"     figure 5",
"    </a>",
"    ) with a lesser effect on electrolyte balance (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/53\">",
"     53",
"    </a>",
"    ]. In two large hypertension trials of low-dose chlorthalidone, hypokalemia requiring therapy occurred in 7 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In stable patients on a fixed diuretic dose, potassium loss, like other diuretic-induced fluid and electrolyte complications, occurs only during the first two weeks of therapy before a new steady state is established (",
"    <a class=\"graphic graphic_figure graphicRef74940 \" href=\"UTD.htm?15/33/15901\">",
"     figure 7",
"    </a>",
"    ). Thus, a stable patient with a normal serum potassium concentration at three weeks is not at risk of late hypokalemia unless the diuretic dose is increased, extrarenal potassium losses increase, or dietary potassium intake is reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a steady state is reached, further monitoring is not required, unless the diuretic dose is increased, extrarenal potassium losses increase, or dietary potassium intake is reduced. As an example, increased losses and decreased intake may be seen with gastroenteritis. In such patients, temporary cessation of diuretic therapy for a few days may be appropriate.",
"   </p>",
"   <p>",
"    In patients with hypertension who develop diuretic-induced hypokalemia, either another agent can be used, or the hypokalemia can be treated with a potassium-sparing diuretic or potassium supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820122#H3820122\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2791688\">",
"    <span class=\"h3\">",
"     Increased mineralocorticoid activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary potassium wasting is characteristic of any condition associated with primary hypersecretion of a mineralocorticoid, as with an aldosterone-producing adrenal adenoma. These patients are usually hypertensive, and the differential diagnosis includes diuretic therapy (which may be surreptitious) in a patient with underlying hypertension, and renovascular disease, in which increased secretion of renin leads to enhanced aldosterone release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased mineralocorticoid activity with suppressed circulating aldosterone concentrations (called apparent mineralocorticoid excess) is an uncommon condition due to autosomal recessive loss-of-function mutations in the 11&beta;-hydroxysteroid dehydrogenase-2 gene or to inhibition of this enzyme due to chronic licorice ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9060678\">",
"    <span class=\"h3\">",
"     Nonreabsorbable anions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lumen-negative electrical gradient created by sodium reabsorption in the cortical collecting tubule is partially attenuated by chloride reabsorption. There are, however, a number of clinical settings in which sodium is presented to the distal nephron with relatively large quantities of a nonreabsorbable anion, including bicarbonate with vomiting or proximal renal tubular acidosis, beta-hydroxybutyrate in diabetic ketoacidosis, hippurate following toluene use (glue-sniffing), or a penicillin derivative in patients receiving high-dose penicillin therapy. In these settings, more of the delivered sodium will be reabsorbed in exchange for potassium, leading to a potentially marked increase in potassium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. As an example, the serum potassium concentration is below 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in approximately one-fourth of patients with toluene-induced metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link&amp;anchor=H8#H8\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Toluene inhalation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of nonreabsorbable anions is likely to be most prominent when there is concurrent volume depletion. In this setting, the decrease in distal chloride delivery (thereby limiting the ability of chloride reabsorption to dissipate the lumen-negative gradient) and the enhanced secretion of aldosterone both promote potassium secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/57\">",
"     57",
"    </a>",
"    ]. In diabetic ketoacidosis, for example, increased distal sodium and water delivery (due to the glucose osmotic diuresis), hypovolemia-induced hyperaldosteronism, and beta-hydroxybutyrate acting as a nonreabsorbable anion all can contribute to potassium wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum potassium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9060979\">",
"    <span class=\"h3\">",
"     Loss of gastric secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which loss of gastric secretions leads to urinary potassium wasting is described above, in which there is an increase in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    delivery to the collecting tubule. This problem is usually apparent from the history. If, however, the history is not helpful, the differential diagnosis of a normotensive patient with hypokalemia, urinary potassium wasting, and metabolic alkalosis includes surreptitious vomiting, as well as diuretic use and Bartter syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link&amp;anchor=H16729862#H16729862\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\", section on 'Diagnostic approach in unexplained metabolic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16897841\">",
"    <span class=\"h2\">",
"     Less common causes of urinary potassium wasting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common causes of hypokalemia due to urinary losses include a variety of acquired and genetic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9060828\">",
"    <span class=\"h3\">",
"     Polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium depleted subjects can normally reduce the urine potassium concentration to a minimum of 5 to 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/1\">",
"     1",
"    </a>",
"    ]. If, however, the urine output is over 5 to 10",
"    <span class=\"nowrap\">",
"     L/day,",
"    </span>",
"    then obligatory potassium losses can exceed 50 to 100 meq per day. This problem is most likely to occur in primary (often psychogenic) polydipsia, in which the urine output may be elevated over a prolonged period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/59\">",
"     59",
"    </a>",
"    ]. An equivalent degree of polyuria can also occur in central diabetes insipidus, but patients with this disorder typically seek medical care soon after the polyuria has begun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium wasting can occur in both distal (type 1) and proximal (type 2) renal tubular acidosis. In each of these disorders, the degree of potassium depletion is masked by the tendency of acidemia to promote potassium movement out of the cells. Thus, the serum potassium concentration is higher than it should be in relation to the degree of potassium depletion. In some patients, the serum potassium concentration is normal or even elevated, although correction of the acidemia will uncover the true state of potassium balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to treatment with bicarbonate, patients with a proximal RTA usually demonstrate mild hypokalemia, due primarily to baseline hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/60\">",
"     60",
"    </a>",
"    ]. However, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to correct the acidemia increases distal tubular sodium and bicarbonate delivery, which can cause a marked increase in renal potassium wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25915937\">",
"    <span class=\"h3\">",
"     Hypomagnesemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia is present in up to 40 percent of patients with hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/61\">",
"     61",
"    </a>",
"    ]. In many cases, as with diuretic therapy, vomiting, diarrhea, or certain tubular toxins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and iphosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,62\">",
"     3,62",
"    </a>",
"    ], there are concurrent potassium and magnesium losses.",
"   </p>",
"   <p>",
"    However, hypomagnesemia can itself lead to increased urinary potassium losses via an uncertain mechanism, possibly involving an increase in the number of open potassium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/63\">",
"     63",
"    </a>",
"    ]. This mechanism, as well as the causes of hypomagnesemia, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link&amp;anchor=H3#H3\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Hypokalemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determining whether hypomagnesemia is present is important clinically because the hypokalemia often cannot be corrected until the magnesium deficit is reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia occurs in up to one-half of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/64\">",
"     64",
"    </a>",
"    ]. Amphotericin interacts with membrane sterols, leading to an increase in membrane permeability that can promote potassium secretion across the luminal membrane. Concurrent distal renal tubular acidosis may play a contributory role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16897924\">",
"    <span class=\"h3\">",
"     Salt-wasting nephropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal diseases associated with decreased proximal, loop, or distal sodium reabsorption can infrequently lead to hypokalemia via a mechanism similar to that induced by diuretics. This problem can be seen with Bartter or Gitelman syndrome, tubulointerstitial diseases (such as reflux nephropathy or interstitial nephritis due to Sj&ouml;gren's syndrome), hypercalcemia, tubular injury due to drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and tubular injury that may be induced by lysozyme in patients with leukemia, particularly acute monocytic or myelomonocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/3,25,65-67\">",
"     3,25,65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16897868\">",
"    <span class=\"h3\">",
"     Liddle's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autosomal dominant, gain-of-function mutation in subunits of the epithelial sodium channel (ENaC), in patients with Liddle&rsquo;s syndrome leads to hereditary hypokalemia and hypertension, mimicking the syndrome of apparent mineralocorticoid excess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Liddle's syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8326352\">",
"    <span class=\"h3\">",
"     Bartter and Gitelman syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in a variety of tubular transport proteins can mimic the effects of chronic therapy with loop diuretics (Bartter syndrome) or thiazide diuretics (Gitelman syndrome), resulting in hypokalemia and metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63249870\">",
"    <span class=\"h3\">",
"     Low calorie diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of low calorie diets (200 and 800",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    can result in hypokalemia, particularly in patients who do not consume supplementary potassium or who have an underlying predisposition to renal potassium wasting such as primary aldosteronism in which many patients are normokalemic at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. These diets, intended to produce rapid weight loss, are usually carbohydrate poor and protein rich, such as the Atkins diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H10#H10\">",
"     \"Dietary therapy for obesity\", section on 'Low-carbohydrate diets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of the hypokalemia in patients consuming low calorie diets is not completely understood. Urinary potassium wasting in thought to be important, since obese patients demonstrate a significant kaliuresis over the first two weeks of fasting or ingesting a low carbohydrate diet [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/71\">",
"     71",
"    </a>",
"    ]. The kaliuresis may be due at least in part to the ketogenesis that results from a decrease in carbohydrate intake. As noted above, increased urinary excretion of ketoacid anions can increase urinary potassium excretion (see",
"    <a class=\"local\" href=\"#H9060678\">",
"     'Nonreabsorbable anions'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25915988\">",
"    <span class=\"h1\">",
"     INCREASED SWEAT LOSSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily sweat losses are normally negligible, since the volume is low and the potassium concentration is only 5 to 10",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, individuals exercising in a hot climate can produce 10 L or more of sweat per day, leading to potassium depletion if these losses are not replaced [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/72\">",
"     72",
"    </a>",
"    ]. Significant loss of potassium in sweat can also occur in cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/73\">",
"     73",
"    </a>",
"    ]. Urinary potassium excretion may contribute to the hypokalemia associated with increased sweat loss, since aldosterone release is enhanced by exercise (via catecholamine-induced renin secretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/72,74\">",
"     72,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients with end-stage renal disease typically retain potassium and tend to be mildly hyperkalemic, hypokalemia can be induced in some patients by maintenance dialysis. As an example, dialysis potassium losses can reach 30 meq per day in patients on chronic peritoneal dialysis. This can become clinically important if intake is reduced or if there are concurrent gastrointestinal losses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/75\">",
"     75",
"    </a>",
"    ]. However, mild hypokalemia immediately following a session of hemodialysis is expected and should not be treated with potassium supplementation.",
"   </p>",
"   <p>",
"    A different mechanism may be operative in patients treated with hemodialysis who have underlying potassium depletion. In this setting, the metabolic acidosis induced by renal failure can result in a relatively normal predialysis serum potassium concentration due to potassium movement out of the cells. However, the high flows attained during hemodialysis can rapidly correct the acidemia, leading to potassium entry into cells and a potentially large reduction in the serum potassium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/17/5402/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PLASMAPHERESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis removes potassium in the same concentration as in the plasma. If, however, albumin is used as the replacement fluid, transient hypokalemia can be induced by dilution. This problem can be avoided by adding 4 meq of potassium to each liter of albumin solution given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link&amp;anchor=H12#H12\">",
"     \"Complications of therapeutic plasma exchange\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=see_link\">",
"       \"Patient information: Hypokalemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9061347\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia is a common clinical problem that can result from decreased intake, increased translocation into the cells, or, most often, increased losses of potassium from the gastrointestinal track or in the urine (",
"      <a class=\"graphic graphic_table graphicRef62892 \" href=\"UTD.htm?9/59/10172\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potassium intake is normally 40 to 120 meq per day. Since the kidney can reduce potassium excretion to 5 to 25 meq per day in the presence of potassium depletion, decreased intake alone rarely causes hypokalemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Decreased potassium intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Total body potassium is predominantly intracellular, a distribution maintained principally by the Na-K-ATPase pump. Increased activity of the Na-K-ATPase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alterations in other potassium transport pathways can result in hypokalemia due to increased potassium entry into cells. Common examples of this phenomenon include: (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Increased entry into cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased insulin action (see",
"      <a class=\"local\" href=\"#H17666515\">",
"       'Increased availability of insulin'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Elevated beta-adrenergic activity (see",
"      <a class=\"local\" href=\"#H17666854\">",
"       'Elevated beta-adrenergic activity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Elevated extracellular pH (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Elevation in extracellular pH'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of gastric or intestinal secretions from any cause (vomiting, diarrhea, laxatives, or tube drainage) is associated with potassium losses and possibly hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Upper gastrointestinal losses (eg, vomiting) lead to hypokalemia through urinary potassium wasting. This occurs because the metabolic alkalosis resulting from gastric acid loss increases the filtered bicarbonate load above its reabsorptive threshold. As a result, more",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      and water are delivered to the distal potassium secretory site. (See",
"      <a class=\"local\" href=\"#H17667289\">",
"       'Upper gastrointestinal losses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to gastric secretions, the potassium concentration in lower intestinal losses is relatively high. Hypokalemia due to lower gastrointestinal tract losses (usually from diarrhea) are typically associated with bicarbonate wasting and metabolic acidosis rather than the metabolic alkalosis observed with upper gastrointestinal losses. Hypokalemia from lower gastrointestinal losses is most common when the losses occur over a prolonged period. (See",
"      <a class=\"local\" href=\"#H17667296\">",
"       'Lower gastrointestinal losses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia from urinary potassium wasting usually requires either mineralocorticoid excess (often from an increase in aldosterone)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an increase in distal flow. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Increased urinary losses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major causes of urinary potassium wasting include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diuretics: any diuretic that acts proximal to the potassium secretory site will both increase distal delivery and, via the induction of volume depletion, activate the renin-angiotensin-aldosterone system. (See",
"      <a class=\"local\" href=\"#H27627359\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased mineralocorticoid activity: urinary potassium wasting is characteristic of any condition associated with primary hypersecretion of a mineralocorticoid, as with an aldosterone-producing adrenal adenoma. (See",
"      <a class=\"local\" href=\"#H2791688\">",
"       'Increased mineralocorticoid activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excretion of nonreabsorbable anions: when sodium is delivered to the distal nephron with relatively large quantities of a nonreabsorbable anion, such as bicarbonate or beta-hydroxybutyrate, more of the delivered sodium will be reabsorbed in exchange for potassium, leading to a potentially marked increase in potassium excretion. (See",
"      <a class=\"local\" href=\"#H9060678\">",
"       'Nonreabsorbable anions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia can occur in patients who sweat excessively, and in patients undergoing dialysis or plasmapheresis. (See",
"      <a class=\"local\" href=\"#H25915988\">",
"       'Increased sweat losses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Dialysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/1\">",
"      SQUIRES RD, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. J Clin Invest 1959; 38:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/2\">",
"      Gallen IW, Rosa RM, Esparaz DY, et al. On the mechanism of the effects of potassium restriction on blood pressure and renal sodium retention. Am J Kidney Dis 1998; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     Mount, DB, Zandi-Nejad, K. Disorders of Potassium Balance. In: Brenner and Rector's The Kidney, 8th ed, Brenner, BM (Ed), W.B. Saunders Co., Philadelphia 2008. p. 547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/4\">",
"      Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam Clin Pharmacol 2010; 24:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/5\">",
"      Adrogu&eacute; HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/6\">",
"      Bradberry SM, Vale JA. Disturbances of potassium homeostasis in poisoning. J Toxicol Clin Toxicol 1995; 33:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/7\">",
"      Fuentebella J, Kerner JA. Refeeding syndrome. Pediatr Clin North Am 2009; 56:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/8\">",
"      Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/9\">",
"      Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/10\">",
"      Gosmanov AR, Wong JA, Thomason DB. Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle. Am J Physiol Cell Physiol 2002; 283:C1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/11\">",
"      Schnack C, Podolsky A, Watzke H, et al. Effects of somatostatin and oral potassium administration on terbutaline-induced hypokalemia. Am Rev Respir Dis 1989; 139:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/12\">",
"      Williams ME, Gervino EV, Rosa RM, et al. Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 1985; 312:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/13\">",
"      T&oslash;nnesen E. Delirium tremens and hypokalemia. Lancet 1982; 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/14\">",
"      Morgan DB, Young RM. Acute transient hypokalaemia: new interpretation of a common event. Lancet 1982; 2:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/15\">",
"      Schaefer M, Link J, Hannemann L, Rudolph KH. Excessive hypokalemia and hyperkalemia following head injury. Intensive Care Med 1995; 21:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/16\">",
"      Shannon M, Lovejoy FH Jr. Hypokalemia after theophylline intoxication. The effects of acute vs chronic poisoning. Arch Intern Med 1989; 149:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/17\">",
"      Whyte KF, Reid C, Addis GJ, et al. Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline. Br J Clin Pharmacol 1988; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/18\">",
"      Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med 1989; 86:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/19\">",
"      Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/20\">",
"      Goldenberg IF, Olivari MT, Levine TB, Cohn JN. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol 1989; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/21\">",
"      Braden GL, von Oeyen PT, Germain MJ, et al. Ritodrine- and terbutaline-induced hypokalemia in preterm labor: mechanisms and consequences. Kidney Int 1997; 51:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/22\">",
"      de Wijkerslooth LR, Koch BC, Malingr&eacute; MM, et al. Life-threatening hypokalaemia and lactate accumulation after autointoxication with Stacker 2, a 'powerful slimming agent'. Br J Clin Pharmacol 2008; 66:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/23\">",
"      Struthers AD, Whitesmith R, Reid JL. Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia. Lancet 1983; 1:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/24\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. In: Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p. 836.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/26\">",
"      Adams PC, Woodhouse KW, Adela M, Parnham A. Exaggerated hypokalaemia in acute myeloid leukaemia. Br Med J (Clin Res Ed) 1981; 282:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/27\">",
"      Zydlewski AW, Hasbargen JA. Hypothermia-induced hypokalemia. Mil Med 1998; 163:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/28\">",
"      Schaller MD, Fischer AP, Perret CH. Hyperkalemia. A prognostic factor during acute severe hypothermia. JAMA 1990; 264:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/29\">",
"      Sigue G, Gamble L, Pelitere M, et al. From profound hypokalemia to life-threatening hyperkalemia: a case of barium sulfide poisoning. Arch Intern Med 2000; 160:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/30\">",
"      Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J 1999; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     Wells, JA, Wood, KE. Acute barium poisoning treated with hemodialysis. Am J Emerg Med 2001; 19:175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/32\">",
"      Melnikov P, Zanoni LZ. Clinical effects of cesium intake. Biol Trace Elem Res 2010; 135:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/33\">",
"      Gay LA, Stanfield PR. Cs(+) causes a voltage-dependent block of inward K currents in resting skeletal muscle fibres. Nature 1977; 267:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/34\">",
"      Malik AR, Wolf PK, Ravasia S. Hypokalemia from risperidone and quetiapine overdose. Can J Psychiatry 2005; 50:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/35\">",
"      Lin YC, Chen HZ, Chang TJ, Lane HY. Hypokalemia following rapid titration of quetiapine treatment. J Clin Psychiatry 2008; 69:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/36\">",
"      Older J, Older P, Colker J, Brown R. Secretory villous adenomas that cause depletion syndrome. Arch Intern Med 1999; 159:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/37\">",
"      Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/38\">",
"      Sitprija V. Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis. Nat Clin Pract Nephrol 2008; 4:91.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW. In: Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p. 333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/40\">",
"      Ho JM, Juurlink DN, Cavalcanti RB. Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. Ann Pharmacother 2010; 44:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/41\">",
"      Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/42\">",
"      Gonzalez JJ, Owens W, Ungaro PC, et al. Clay ingestion: a rare cause of hypokalemia. Ann Intern Med 1982; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/43\">",
"      Bennett A, Stryjewski G. Severe hypokalemia caused by oral and rectal administration of bentonite in a pediatric patient. Pediatr Emerg Care 2006; 22:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/44\">",
"      Ukaonu C, Hill DA, Christensen F. Hypokalemic myopathy in pregnancy caused by clay ingestion. Obstet Gynecol 2003; 102:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/45\">",
"      Wang WH, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/46\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/47\">",
"      Welling PA, Chang YP, Delpire E, Wade JB. Multigene kinase network, kidney transport, and salt in essential hypertension. Kidney Int 2010; 77:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/48\">",
"      Vallon V, Schroth J, Lang F, et al. Expression and phosphorylation of the Na+-Cl- cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. Am J Physiol Renal Physiol 2009; 297:F704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/49\">",
"      Wang ZJ, Sun P, Xing W, et al. Decrease in dietary K intake stimulates the generation of superoxide anions in the kidney and inhibits K secretory channels in the CCD. Am J Physiol Renal Physiol 2010; 298:F1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/50\">",
"      Babilonia E, Wei Y, Sterling H, et al. Superoxide anions are involved in mediating the effect of low K intake on c-Src expression and renal K secretion in the cortical collecting duct. J Biol Chem 2005; 280:10790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/51\">",
"      Papademetriou V. Diuretics, hypokalemia, and cardiac arrhythmia: a 20-year controversy. J Clin Hypertens (Greenwich) 2006; 8:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/52\">",
"      Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology 1994; 84 Suppl 2:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/53\">",
"      Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/54\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/55\">",
"      Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/56\">",
"      Mohr JA, Clark RM, Waack TC, Whang R. Nafcillin-associated hypokalemia. JAMA 1979; 242:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/57\">",
"      Carlisle EJ, Donnelly SM, Ethier JH, et al. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int 1991; 39:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/58\">",
"      Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol 1991; 1:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/59\">",
"      Hariprasad MK, Eisinger RP, Nadler IM, et al. Hyponatremia in psychogenic polydipsia. Arch Intern Med 1980; 140:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/60\">",
"      Sebastian A, McSherry E, Morris RC Jr. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest 1971; 50:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/61\">",
"      Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med 1992; 152:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/62\">",
"      Husband DJ, Watkin SW. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy. Lancet 1988; 1:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/63\">",
"      Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/64\">",
"      Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/65\">",
"      Perazella MA, Eisen RN, Frederick WG, Brown E. Renal failure and severe hypokalemia associated with acute myelomonocytic leukemia. Am J Kidney Dis 1993; 22:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/66\">",
"      Mir MA, Brabin B, Tang OT, et al. Hypokalaemia in acute myeloid leukaemia. Ann Intern Med 1975; 82:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/67\">",
"      Aldinger KA, Samaan NA. Hypokalemia with hypercalcemia. Prevalence and significance in treatment. Ann Intern Med 1977; 87:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/68\">",
"      Liu T, Nagami GT, Everett ML, Levine BS. Very low calorie diets and hypokalaemia: the importance of ammonium excretion. Nephrol Dial Transplant 2005; 20:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/69\">",
"      Singh BN, Gaarder TD, Kanegae T, et al. Liquid protein diets and torsade de pointes. JAMA 1978; 240:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/70\">",
"      Advani A, Taylor R. Life-threatening hypokalaemia on a low-carbohydrate diet associated with previously undiagnosed primary hyperaldosteronism [corrected]. Diabet Med 2005; 22:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/71\">",
"      Rabast U, Vornberger KH, Ehl M. Loss of weight, sodium and water in obese persons consuming a high- or low-carbohydrate diet. Ann Nutr Metab 1981; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/72\">",
"      Knochel JP, Dotin LN, Hamburger RJ. Pathophysiology of intense physical conditioning in a hot climate. I. Mechanisms of potassium depletion. J Clin Invest 1972; 51:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/73\">",
"      Dav&eacute; S, Honney S, Raymond J, Flume PA. An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis 2005; 45:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/74\">",
"      Kosunen KJ, Pakarinen AJ. Plasma renin, angiotensin II, and plasma and urinary aldosterone in running exercise. J Appl Physiol 1976; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/75\">",
"      Rostand SG. Profound hypokalemia in continuous ambulatory peritoneal dialysis. Arch Intern Med 1983; 143:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/17/5402/abstract/76\">",
"      Wiegand CF, Davin TD, Raij L, Kjellstrand CM. Severe hypokalemia induced by hemodialysis. Arch Intern Med 1981; 141:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2341 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5402=[""].join("\n");
var outline_f5_17_5402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9061347\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DECREASED POTASSIUM INTAKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCREASED ENTRY INTO CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17666515\">",
"      Increased availability of insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17666854\">",
"      Elevated beta-adrenergic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Elevation in extracellular pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased blood cell production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25915856\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25915863\">",
"      Barium intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59114396\">",
"      Cesium intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chloroquine intoxication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172581345\">",
"      Antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INCREASED GASTROINTESTINAL LOSSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17667289\">",
"      Upper gastrointestinal losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17667296\">",
"      Lower gastrointestinal losses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INCREASED URINARY LOSSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16897827\">",
"      Major causes of urinary potassium wasting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27627359\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2791688\">",
"      - Increased mineralocorticoid activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9060678\">",
"      - Nonreabsorbable anions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9060979\">",
"      - Loss of gastric secretions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16897841\">",
"      Less common causes of urinary potassium wasting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9060828\">",
"      - Polyuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25915937\">",
"      - Hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16897924\">",
"      - Salt-wasting nephropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16897868\">",
"      - Liddle's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8326352\">",
"      - Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63249870\">",
"      - Low calorie diets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25915988\">",
"      INCREASED SWEAT LOSSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PLASMAPHERESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9061347\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2341|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/12/26829\" title=\"figure 1\">",
"      Epinephrine and plasma K",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/51/30525\" title=\"figure 2\">",
"      Beta blocker and potassium load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/17/1309\" title=\"figure 3\">",
"      Plasma K and HCO3 reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 4\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18829\" title=\"figure 5\">",
"      Antihypertensive dose-response to thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 6\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15901\" title=\"figure 7\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/59/10172\" title=\"table 1\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/54/14177?source=related_link\">",
"      Patient information: Hypokalemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2021?source=related_link\">",
"      Treatment of hypertension in asthma and COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_17_5403="Corticosteroid coverage surgery";
var content_f5_17_5403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Corticosteroid coverage for surgery in patients taking exogenous corticosteroids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        For minor procedures or surgery under local anesthesia (eg, inguinal hernia repair) take usual morning steroid dose. No extra supplementation is necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For moderate surgical stress (eg, lower extremity revascularization, total joint replacement) take usual morning steroid dose. Give 50 mg hydrocortisone intravenously just before the procedure and 25 mg of hydrocortisone every 8 hours for 24 hours. Resume usual dose thereafter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For major surgical stress (eg, esophagogastrectomy, total proctocolectomy, open heart surgery) take usual&nbsp;morning steroid dose. Give 100 mg of intravenous hydrocortisone before induction of anesthesia, and 50 mg every 8 hours for 24 hours. Taper dose by half per day to maintenance level.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5403=[""].join("\n");
var outline_f5_17_5403=null;
var title_f5_17_5404="Characteristics of good candidates for psychodynamic therapy";
var content_f5_17_5404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F58113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F58113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychological characteristics that indicate a patient is a good candidate for psychodynamic psychotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Significant symptoms and suffering due to intrapsychic conflict centered upon competing wishes and urges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motivation to understand the unconscious patterns in one's life that lead to self-defeating behavior and hurting others that one doesn't wish to hurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to anticipate the consequences of one's actions (judgment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intact reality testing (ability to assess reality) that is not impaired by faulty judgment or grossly disturbed by psychosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Good impulse control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meaningful object relations, which is the ability to relate to significant others in a meaningful and consistent way, form intimate relationships, tolerate separation and loss, and maintain autonomy and independence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to sustain activity such as work or school despite setbacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to regress in the service of the ego, which involves using the irrational processes of the unconscious to develop alternative ways of thinking and feeling, and also involves activities that help one to recover from the stress of life, in order to continue to function well",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to tolerate frustration and intense affects associated with exploring unpleasant aspects of the self",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mentalizing capacity, which is the ability to see that internal, mental states explain behavior; and the ability to sense the mental state of another person and respond accordingly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capacity for insight (psychological mindedness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capacity to understand analogies and metaphors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reflective responses to the clinician's initial interpretations of transference and resistance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5404=[""].join("\n");
var outline_f5_17_5404=null;
var title_f5_17_5405="Protease inhibitors PI";
var content_f5_17_5405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protease inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing instructions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects &amp; interactions",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Atazanavir (Reyataz&reg;)",
"       </td>",
"       <td>",
"        Take with food, usually once per day",
"       </td>",
"       <td>",
"        Interacts with many medications. Avoid St. John's wort. Check with healthcare provider before taking with omeprazole (Prilosec&reg;), esomeprozole (Nexium&reg;), or lansoprazole (Prevacid&reg;). Other medicines that decrease stomach acid, like calcium (Tums&reg;), ranitidine (Zantac&reg;), or cimetidine (Tagamet&reg;), should be taken at a different time of the day than atazanavir.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Fosamprenavir (Lexiva&reg;)",
"       </td>",
"       <td>",
"        Tablet can be taken with or without food",
"       </td>",
"       <td>",
"        Tell your healthcare provider if you are allergic to sulfonamide (sulfa) medications",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Indinavir (Crixivan&reg;)",
"       </td>",
"       <td>",
"        <p>",
"         Take at least one hour before or two hours after eating a meal. You may take with a low-fat snack (eg, pretzels, skim milk).",
"        </p>",
"        <p>",
"         If taking with ritonavir, you may take indinavir with or without food.",
"        </p>",
"        Drink plenty of water (at least 48 ounces or 1.5 liters per day) to decrease the risk of developing kidney stones.",
"       </td>",
"       <td>",
"        May change location of fat in body. Interacts with many medications. Avoid St. John's wort and grapefruit juice. Infrequently used now due to availability of other drugs that are more convenient.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Lopinavir/ritonavir (Kaletra&reg;)",
"       </td>",
"       <td>",
"        Usually recommended twice daily. Should be taken with food.",
"       </td>",
"       <td>",
"        Can increase cholesterol and blood glucose levels, can change location of fat in body, nausea and vomiting can occur. Interacts with many medications. Avoid St. John's wort.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nelfinavir (Viracept&reg;)",
"       </td>",
"       <td>",
"        Take with food",
"       </td>",
"       <td>",
"        Diarrhea is a common side effect. Can change location of fat in body. Interacts with many medications.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Ritonavir (Norvir&reg;)",
"       </td>",
"       <td>",
"        Take with a meal",
"       </td>",
"       <td>",
"        Previous forms of the drug required refrigeration; newer forms do not. Can increase cholesterol and blood glucose levels, can change location of fat in body, nausea and vomiting can occur. Interacts with many medications. Avoid St. John's wort.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Saquinavir (Invirase&reg;)",
"       </td>",
"       <td>",
"        Take saquinavir with a full meal or within two hours after eating",
"       </td>",
"       <td>",
"        500 mg tablets available and may reduce the number of pills needed. Avoid direct sunlight. May change location of fat in body. Interacts with many medications. Avoid St. John's wort and garlic supplements. May cause heart rhythm disturbances.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Tipranavir (Aptivus)",
"       </td>",
"       <td>",
"        Take tipranavir (Aptivus 500 mg) with ritonavir (Norvir 200 mg) twice daily with meals",
"       </td>",
"       <td>",
"        May change location of fat in body. Interacts with many medications. Avoid St. John's wort. Store unopened bottles in the refrigerator. Tell your healthcare provider if you are allergic to sulfonamide (sulfa) medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Darunavir (Prezista&reg;, TMC 114)",
"       </td>",
"       <td>",
"        Take darunavir (Prezista&reg;) with ritonavir (Norvir&reg;) twice a day with food",
"       </td>",
"       <td>",
"        May change location of fat in body. Interacts with many medications. Avoid St. John's wort. Tell your healthcare provider if you are allergic to sulfonamide (sulfa) medications.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The information contained in this table is a supplement to the standard educational brochures your pharmacy provides. The information in these tables highlights a few issues but is not all-inclusive. Read the complete information provided to you by your pharmacy and/or healthcare provider.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5405=[""].join("\n");
var outline_f5_17_5405=null;
var title_f5_17_5406="Chest pain differentiation";
var content_f5_17_5406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiation of life-threatening causes of chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Historical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examination findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Electrocardiogram",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chest X-ray",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional important information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Acute coronary syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Substernal/left sided chest pressure or tightness is common",
"        </p>",
"        <p>",
"         &bull; Onset is gradual",
"        </p>",
"        <p>",
"         &bull; Pain radiating to shoulders or pain with exertion increases relative risk",
"        </p>",
"        <p>",
"         &bull; \"Atypical\" symptoms (eg, dyspnea, weakness) more common in elderly, women, diabetics",
"        </p>",
"        <p>",
"         &bull; Elderly can present with dyspnea, weakness, syncope, or &Delta;MS alone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Nonspecific",
"        </p>",
"        <p>",
"         &bull; May detect signs of HF",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; ST segment elevations, Q waves, new left bundle branch block are evidence of AMI",
"        </p>",
"        <p>",
"         &bull; Single ECG is not sensitive for ACS",
"        </p>",
"        <p>",
"         &bull; Prominent R waves with ST segment depressions in V",
"         <sub>",
"          1",
"         </sub>",
"         and V",
"         <sub>",
"          2",
"         </sub>",
"         strongly suggests posterior AMI",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Nonspecific",
"        </p>",
"        <p>",
"         &bull; May show evidence of HF",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Troponin and/or CK-MB elevations diagnose AMI",
"        </p>",
"        <p>",
"         &bull; Single set of biomarkers is not sufficiently sensitive to rule out AMI",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Assume symptoms of ACS within days or a few weeks of PCI or CABG is from an occluded artery or graft",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Aortic dissection",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Sudden onset of sharp, tearing, or ripping pain",
"        </p>",
"        <p>",
"         &bull; Maximal severity at onset",
"        </p>",
"        <p>",
"         &bull; Most often begins in chest, can begin in back",
"        </p>",
"        <p>",
"         &bull; Can mimic: stroke, ACS, mesenteric ischemia, kidney stone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Absent upper extremity or carotid pulse is suggestive",
"        </p>",
"        <p>",
"         &bull; Discrepancy in systolic BP &gt;20 mmHg between right and left upper extremity is suggestive",
"        </p>",
"        <p>",
"         &bull; Up to 30 percent with neurologic findings",
"        </p>",
"        <p>",
"         &bull; Findings vary with arteries affected",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Ischemic changes in 15 percent",
"        </p>",
"        <p>",
"         &bull; Nonspecific ST and T changes in 30 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Wide mediastinum or loss of normal aortic knob contour is common (up to 76 percent)",
"        </p>",
"        <p>",
"         &bull; 10 percent have normal CXR",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull; Can mimic many diseases depending on branch arteries involved (eg, AMI, stroke)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pulmonary embolism",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull;  Many possible presentations, including pleuritic pain and painless dyspnea",
"        </p>",
"        <p>",
"         &bull;  Often sudden onset",
"        </p>",
"        <p>",
"         &bull; Dyspnea often dominant feature",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; No finding is sensitive or specific",
"        </p>",
"        <p>",
"         &bull; Extremity exam generally normal",
"        </p>",
"        <p>",
"         &bull; Lung exam generally nonspecific; focal wheezing may be present; tachypnea is common",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Usually abnormal but nonspecific",
"        </p>",
"        <p>",
"         &bull; Signs of right heart strain suggestive (eg, RAD, RBBB, RAE)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Great majority are normal",
"        </p>",
"        <p>",
"         &bull; May show: atelectasis, elevated hemidiaphragm, pleural effusion",
"        </p>",
"       </td>",
"       <td>",
"        &bull; A high-sensitivity D-dimer is useful to rule out PE only when negative in low-risk patients",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tension pneumothorax",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Often sudden onset",
"        </p>",
"        <p>",
"         &bull; Initial pain often sharp and pleuritic",
"        </p>",
"        <p>",
"         &bull; Dyspnea often dominant feature",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Ipsilateral diminished or absent breath sounds",
"        </p>",
"        <p>",
"         &bull; Subcutaneous emphysema is uncommon",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull; Demonstrates air in pleural space",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pericardial tamponade",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Pain from pericarditis is most often sharp anterior chest pain made worse by inspiration or lying supine and relieved by sitting forward",
"        </p>",
"        <p>",
"         &bull; Dyspnea is common",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Severe tamponade creates obstructive shock, and causes jugular venous distension, pulsus paradoxus",
"        </p>",
"        <p>",
"         &bull; Pericardial effusion can cause friction rub",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Decreased voltage and electrical alternans can appear with significant effusions",
"        </p>",
"        <p>",
"         &bull; Diffuse PR segment depressions and/or ST segment elevations can appear with acute pericarditis",
"        </p>",
"       </td>",
"       <td>",
"        &bull; May reveal enlarged heart",
"       </td>",
"       <td>",
"        &bull; Ultrasound reveals pericardial effusion with tamponade",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mediastinitis (esophageal rupture)",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Forceful vomiting often precedes esophageal rupture",
"        </p>",
"        <p>",
"         &bull; Recent upper endoscopy or instrumentation increases risk of perforation",
"        </p>",
"        <p>",
"         &bull; Odontogenic infection is possible cause",
"        </p>",
"        <p>",
"         &bull; Coexistent respiratory and gastrointestinal complaints may occur",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Ill-appearing; shock, fever",
"        </p>",
"        <p>",
"         &bull; May hear (Hamman's) crunch over mediastinum",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull; Large majority have some abnormality: pneumomediastinum, pleural effusion, pneumothorax",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &Delta;MS: altered mental status; ACS: acute coronary syndrome; AMI: acute myocardial infarction; BP: blood pressure; CABG: coronary artery bypass graft; CK-MB: creatine kinase-MB; CXR: chest x-ray; ECG: electrocardiogram; HF: heart failure; PCI: percutaneous coronary intervention; PE: pulmonary embolism; RAD: right axis deviation; RAE: right atrial enlargement; RBBB: right bundle branch block.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5406=[""].join("\n");
var outline_f5_17_5406=null;
var title_f5_17_5407="Long axis view dilated CM";
var content_f5_17_5407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long axis echocardiogram in dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 227px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis echocardiogram from a patient with a dilated cardiomyopathy demonstrates spherical or globular dilation. The long and short axis dimensions now have a nearly 1:1 ratio (normal 2:1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_17_5407=[""].join("\n");
var outline_f5_17_5407=null;
